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Abstract 
Ghrelin is a 28 amino acid hormone involved in appetite stimulation, maintenance of 
energy balance, and a range of other neuroendocrine functions. Over the course of its expression 
and maturation, proghrelin (the prohormone of ghrelin) undergoes a unique posttranslational 
modification whereby a serine side chain is esterified with octanoic acid. Proghrelin then 
undergoes subsequent proteolysis to yield ghrelin. This octanoylation modification has been 
demonstrated to be required for ghrelin to activate its cognate receptor. Since acylated ghrelin 
has been linked with a variety of disease states, ghrelin signaling is a prime target for inhibition 
and inhibitor development. Biochemical and structural studies of the enzyme responsible for 
ghrelin octanoylation, ghrelin O-acyltransferase (GOAT), have identified features required for 
recognition of ghrelin by GOAT. A majority of these studies have utilized peptide mimetics of 
the N-terminal sequence of ghrelin. However, the impact of downstream elements in ghrelin and 
its 94 amino acid precursor proghrelin remains to be fully defined. To investigate this, we have 
developed bacterial expression systems to explore the role of both ghrelin and C-terminal ghrelin 
in proghrelin’s biological activity and maturation. The work presented in this dissertation is the 
first instance of expression and structural characterization of human proghrelin and C-ghrelin, as 
well as an unidentified self-cleavage behavior which has implications in hormone maturation. In 
complementary studies to characterize ghrelin binding to GOAT, ghrelin peptide mimetics 
incorporating an amine-substituted Dap residue at the site of acylation provided a superior 
system for exploring the molecular requirements for ghrelin recognition by GOAT. These studies 
have identified previously unidentified binding contacts and provides a comprehensive model of 
peptide binding in the hGOAT active site. The work utilizing Dap-substituted peptides provides 
a comprehensive peptide scaffold for future inhibitor design for targeting ghrelin signaling.  
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Chapter 1: Introduction 
 
Portions of this chapter have been previously published and reprinted with permission from the 
publisher, reference 46, Cleverdon, E. R.; McGovern-Gooch, K. R.; Hougland, J. L., The 
octanoylated energy regulating hormone ghrelin: An expanded view of ghrelin's biological 
interactions and avenues for controlling ghrelin signaling. Mol Membr Biol 2016, 33 (6-8), 111-
124.Copyright © 2016Taylor & Francis.
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1.1 Post-translational modifications  
After a gene is transcribed into RNA and translated into a protein by the ribosome, this 
polypeptide can be further modified using either co- or post-translational modification(s) through 
one of two mechanisms: the first is enzyme-catalyzed covalent attachment of chemical groups; 
and the second being through proteolytic or autocatalytic covalent cleavage of peptide 
backbones.
1
 Chemical modifications of proteins are wide-spread with more than 200 distinct 
types of chemical group attachment having been characterized.
1
 Common forms of post-
translational modifications that occur on a variety of protein substrates that include 
phosphorylation,
2
 acylation (acetylation,
3
 N-myristoylation,
4
 N/S-palmitoylation,
5-8
 
ubiquitylation,
9
 O-acylation
10
) (Figure 1.1), alkylation (S-Prenylation 
11-13
), glycosylation,
14-16
  
and oxidation,
17-18
 all of which are catalyzed by enzymes.
1, 12
 These small chemical 
modifications diversify the proteome and can cause changes in structure, localization, protein-
protein interactions, and recognition motifs in comparison to their unmodified forms.
1, 12
  
Lipidation is a specific class of modification which includes prenylation, palmitoylation 
and O-acylation among others (Figure 1.1).
19-20
 Prenylation is the attachment of 15 or 20 carbon 
long isoprenoid group to a C-terminal cysteine residue by protein farnesyltransferase and protein 
geranylgeranyltransferase types I and II, respectively, which serve as the first step in a 
modification pathway often leading to protein membrane localization.
11, 13
 This attachment 
establishes a thioether bond which is very stable and is not likely to hydrolyze in the cell.
11, 13
  
Palmitoylation most commonly involves the attachment of a 16-carbon chain to a cysteine, 
threonine or serine residue.
7-8, 21
 This attachment commonly occurs through formation of either 
an amide bond through N-terminal attachment of the carbon chain or through formation of a 
thioester linkage, although an ester linkage is possible with serine or threonine palmitoylation.
7-8, 
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21
 This modification has been demonstrated in a number of proteins and increases trafficking to 
intracellular membranes.
7, 12
 O-acylation occurs when a serine or threonine residue is modified 
with the attachment of a lipid moiety.
10, 22
 This type of acylation has been associated with 
intracellular trafficking, receptor binding and activation in both Wnt proteins and also ghrelin.
10, 
22-26
 This acylation forms an ester linkage and is more susceptible to hydrolysis than the other 
forms of lipidation.
7
  
4 
 
Figure 1.1. Different forms of protein acylation. Figure is reproduced with permission from 
Reference 20 (Appendix I). © 2015 Portland Printed Press.
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1.2 Ghrelin 
1.2.1 Discovery 
 
The peptide hormone ghrelin is one of several biological signaling molecules that require 
a lipidation modification for receptor recognition and biological function. Ghrelin was initially 
discovered in 1999 as a result of the search for the endogenous ligand for an orphan receptor, the 
growth hormone secretagogue receptor 1a (GHS-R1a). 
10, 27-28
 Through the use of a synthetic 
ghrelin compared to ghrelin extracted from the stomachs of rats, there was a difference in 
retention time using reverse phase HPLC (high performance liquid chromatography) which is 
indicative of a the presence of a large hydrophobic group.
10
 Further analysis using mass 
spectrometry indicated that this was an 8 carbon long (n-octanoyl) chain which was attached at 
the N-terminal S3 residue.
10
 This discovery presented the first instance of post-translational 
modification with an n-octanoyl group, and O-acylation of a serine residue is also exceedingly 
rare among characterized examples of protein modifications.
12
 
Ghrelin’s post-translational modification, octanoylation, has been demonstrated to be 
absolutely essential for GHS-R1a receptor recognition and activation.
26
 Desacyl ghrelin is unable 
to bind to and activate the GHS-R1a receptor even though both forms are freely circulating 
throughout the bloodstream and present in the same tissues.
26
 While there is evidence suggesting 
that the deacylated form of ghrelin is playing a physiological role, the exact nature of this 
signaling by desacyl ghrelin remains unclear.
29
 There is recent evidence suggesting that ghrelin 
can be reacylated extracellularly, which could provide another avenue of investigation into the 
biological role of desacyl ghrelin and the regulation between the two forms.
30-31
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1.2.2 Tissue distribution 
 
Ghrelin was originally found to be expressed by endocrine X/A cells in mice and rats 
(P/D cells in humans) in the gastric mucosa of the stomach and small intestine, 
10, 32-35
 with 
subsequent investigations demonstrating that ghrelin and its receptor (GHS-R1a) are expressed 
in various tissues such as pancreatic alpha cells, the pituitary gland and the hypothalamus. 
10, 32, 
36-37
 There is indication based on RT-PCR (reverse transcription polymerase chain reaction) 
studies of mRNA for ghrelin and its receptor in almost all tissue types in the body; however, this 
does not necessarily mean there is protein expression found in all of the identified tissue types.
38-
39
 This RT-PCR mRNA evidence is supported by a plethora of biochemical techniques 
including: in situ hybridization, immunohistochemistry monitored by optical microscopy, and 
immunostaining coupled with electron microscopy, which found that ghrelin and its receptor are 
present in a range of tissues through the body, including the kidney, lung, gall bladder, prostate 
and liver. 
10, 27, 32, 36, 40-41
 This expression pattern indicates that ghrelin expression is wide-spread 
throughout the body and could explain the multiple physiological effects attributed to ghrelin.  
1.2.3 Ghrelin processing 
 
Ghrelin must undergo a series of processing steps following translation to generate the 
mature peptide hormone found in circulation (Figure 1.2).
42-46
 Proghrelin is translated by the 
ribosome as a 117 amino acid protein, preproghrelin, which contains a signal sequence which 
directs the protein to the endoplasmic reticulum where the signal sequence is cleaved by signal 
peptidase.
44, 47
 The resulting prohormone, proghrelin, is post-translationally modified by the 
attachment of an n-octanoyl moiety in a reaction catalyzed by the integral membrane enzyme 
ghrelin O-acyltransferase (GOAT).
44, 48-49
After modification by GOAT, the acylated proghrelin 
7 
 
is trafficked to the Golgi apparatus and packaged into secretory vesicles where prohormone 
convertase 1/3 or furin cleaves amino acids 29-94 (C-ghrelin) from amino acids 1-28 (ghrelin).
44, 
47
 Subsequent cleavage of the C-terminal portion of proghrelin is proposed to generate the 
hormone obestatin (amino acids 53-76). The exact mechanism in which obestatin is processed 
from C-ghrelin is unknown but is hypothesized to involve processing by carboxypeptidase E and 
peptidyl glycine α-amidating monooxygenase (PAM) leading to C-terminal amidation.50 
Following this array of modifications, ghrelin and obestatin are released into the bloodstream in 
order to fulfill their biological signaling roles.  
8 
 
 
Figure 1.2. The processing of preproghrelin to ghrelin. Figure is reproduced with permission 
from Reference 46 (Appendix II). © 2016 Taylor and Francis. 
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1.2.4 Binding partners for ghrelin within the body 
 
After their release into the bloodstream, there are a variety of binding partners that 
desacyl and acylated ghrelin can interact with including lipoproteins, esterases, antibodies and 
the GHS-R1a receptor (Figure 1.3).  There are three major classes of lipoproteins in blood serum, 
VLDL (very low density lipoproteins, responsible for endogenous fat transport), HDL (high 
density lipoproteins, responsible for reverse cholesterol transport), and LDL (low density 
lipoproteins, major carrier of cholesterol in the blood) which are used to traffic proteins 
throughout the bloodstream.
51
 Cholesterol and triacylglycerols are transported in lipoprotein 
particles which consist of hydrophobic lipids surrounded by outer shells of more polar lipids and 
proteins (apoproteins), with these apoproteins  synthesized in the liver and the intestines.
51
 
Recent studies support that lipoproteins in the bloodstream act as ghrelin (acyl and desacyl) 
transporters.
52
 The level of cholesterol lipoproteins increase with the increased production of 
ghrelin, demonstrating a potential relationship between availability of lipoproteins and ghrelin in 
the body.
52
 Ghrelin and desacyl ghrelin show distinct binding preferences for different 
lipoproteins in circulation, with ghrelin binding VLDL, LDL and HDL equally, while desacyl 
ghrelin primarily associates with HDL lipoproteins.
53-54
 Since HDL particles contain esterases 
involved in reverse cholesterol transport,
53
 the preference for desacyl ghrelin to bind HDL is 
interesting since the HDL-associated esterase PON1 increases the deacylation and degradation of 
acylated ghrelin.
55
 This data suggests that HDLs can store ghrelin and effectively immobilize it 
within the bloodstream. 
52
 The same can be said of VLDL and LDL with acylated ghrelin, which 
protect the octanoyl group on acylated ghrelin from hydrolysis and serve to shield ghrelin from 
degradation in circulation.
52-54
 Further investigation into the interactions between ghrelin and 
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lipoproteins is needed to better understand its trafficking in the bloodstream leading to GHS-R1a 
activation and the ability of lipoproteins to affect acylated ghrelin’s half-life in the blood serum.  
Due to its hydrolytic susceptibility, the ester-linked acyl chain attached to ghrelin has a 
limited lifetime in circulation. This has been demonstrated in the collection of blood serum from 
both rodents and humans, with complete hydrolysis of the acylated ghrelin in 240 minutes in one 
study and another yielding an estimated half-life of 10 minutes, although these times have been 
shown to be variable between serum samples.
56
 Ester hydrolysis (cleavage of the octanoyl 
moiety) initially was demonstrated by adding blood serum to a synthetic acylated ghrelin (1-28) 
that resulted in complete conversion to its desacyl form.
56
 This esterase activity has complicated 
studies of ghrelin concentration in blood serum, with ester hydrolysis rendering accurate sample 
analysis problematic. Sample treatment with phenylmethylsulfonyl fluoride (PMSF) or other 
common protease inhibitors was shown to slow ghrelin hydrolysis in blood samples;
 56-57
 and 
addition of alkyl fluorophosphonate esterase inhibitors provide complete protection of ghrelin 
from esterase hydrolysis.
58
  
There has been discussion in the literature about which esterase is the “ghrelin” esterase, 
with a range of esterases that have been demonstrated to have ghrelin hydrolytic activity 
including: platelet activating factor (PAF), paraoxanase (PON), carboxypeptidase, 
butyrylcholinesterase, carboxylesterases, APT1, and alpha 2-macroglobulin.
53, 56, 59-61
 Among 
these enzymes, the strongest body of evidence supports butyrylcholinesterase (abbreviated BChE 
or BuChE) as the most likely esterase responsible for a majority of the ghrelin hydrolysis in 
circulation.
62-65
 Recombinantly expressed BChE has been shown to hydrolyze ghrelin when it 
was added externally to acylated ghrelin.
65-66
 There are also implications in BChE in ghrelin’s 
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biological role, with BChE deficient mice that were fed a high fat diet showing weight gain and 
were overall heavier than wild-type mice.
 63-65, 67
 The BChE deficient mice also demonstrated 
reduced insulin sensitivity compared to their wild-type counterparts (BChE present), both of 
these observed results could indicate that this esterase has implications in weight control and 
glucose metabolism via ghrelin hydrolysis.
63-65, 67
 There are also indications that BChE has other 
implications in ghrelin’s biological role, including its effects on aggressive behavior in mice.67 In 
resident/intruder testing (a provocation test) there was an increase in behavior consistent with 
stress and increased aggression in mice which had knockout BChE resulting in higher circulating 
acylated ghrelin levels compared to their wild-type counterparts.
64
 In contrast, mice in which 
there were higher BChE levels present and increased levels of circulating desacyl ghrelin 
displayed lower aggression levels (compared to wild-type mice).
64
  The above studies support 
BChE as a ghrelin esterase in circulation, however, in BChE deficient human populations there 
have been no adverse side-effects on their health as long as they do not eat a high-fat diet.
 68-69
 
This data suggests that there may be a compensation mechanism for ghrelin hydrolysis or there is 
a yet unidentified ghrelin esterase that is responsible for a major portion of ghrelin to desacyl 
ghrelin processing.
68-69
 
 In addition to lipoprotein complexes and esterases (Figure 1.3), ghrelin has also been 
found to interact with autoantibodies in circulation. Autoantibodies are antibodies that recognize 
self-antigens that are produced in germ-like B-cells as a part of native immunity.
70
 These 
antigens may be found in all cell types or be highly specific for a specific cell types or organs.
70
 
Ghrelin-reactive autoantibodies were initially discovered in blood serum in both humans and 
rodents.
71-72
 There is also evidence of desacyl ghrelin-reactive autoantibodies (Immunoglobulin 
G (IgG)) in the same species. 
71-73
 Ghrelin-reactive IgG was the first antibody detected revealing 
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that it may have a functional role in ghrelin signaling by protecting it from degradation in 
plasma.
71
 In the same study, it was shown that depletion of IgG from the plasma resulted in loss 
of acylated ghrelin while titration back into plasma resulted in recovery, indicating that ghrelin-
reactive autoantibodies also serve as a chaperone of ghrelin in a similar fashion to lipoproteins 
that protect ghrelin from hydrolysis.
71
 There has been investigation into the relative affinity of 
IgG in different populations, with IgG from obese individuals exhibiting higher affinity for the 
ghrelin-IgG complexes.
71
 This stronger interaction between ghrelin and its autoantibody extends 
the lifetime of ghrelin in circulation leading to higher acylated ghrelin concentrations and 
enhanced trafficking. 
71-72
 This observation is consistent with the finding that high levels of 
ghrelin-reactive antibodies lead to increased appetite and an elevated ability for ghrelin to signal 
hunger.
71-72, 74
 In contrast, patients with anorexia nervosa were shown to have lower ghrelin-IgG 
plasma levels  and lower affinity for ghrelin-IgG complex formation which leads to the opposite 
effect, less stable ghrelin and inefficient ghrelin signaling.
73
 The ghrelin-IgG complexes provide 
another area for exploration into ghrelin trafficking throughout circulation and its ability to serve 
its biological functions. 
The biological activity of ghrelin stems from its ability to bind and activate its GHS-R1a 
receptor.
10, 75
 Initial investigations of this receptor were through expression and cloning 
analysis.
27
 There was also investigation into ligand binding to the GHS-R1a to identify 
compounds or peptide sequences that would elevate growth hormone release from the anterior 
pituitary gland for disorders involving a lack of growth hormone release.
27, 76-77
 GHS-R1a was 
confirmed as a GPCR (G-protein coupled receptor) through homology modeling as well as 
antibody-binding studies.
27, 78
 The activation of signaling through GHS-R1a is indicated by 
increased intracellular calcium release, increased protein kinase C (PKC) activity, and inhibition 
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of GHS-R1a activity by guanosine triphosphate analogues.
27
 The GHS-R1a receptor requires the 
first five amino acids of ghrelin for recognition and activation with equal efficiency to full length 
ghrelin (amino acids 1-28), however the receptor will weakly bind the first four amino acids of 
ghrelin with similar receptor activation to full length ghrelin (amino acids 1-28).
26
 Receptor 
activation requires a lipid moiety at the S3 position for complete receptor activation which can 
be achieved using ligands bearing medium to long acyl chains (up to 16 carbons), however, there 
is a decreased affinity with acyl chains with less than 7 carbons.
26
 After recognition and 
activation of the receptor the signaling transduction pathway indicative of GPCRs is initiated and 
PKA (protein kinase A)/cAMP (cyclic adenosine monophosphate) pathway is the proposed 
mechanism for GH secretion.
79
 A majority of the studies investigating the effects of ghrelin on 
receptor activation have been based in pituitary cells; however, the result of activation can differ 
based upon the cell type. Hepatoma, hypothalamus, and colonic epithelial cells all induce 
varying cascades which are caused by GHS-R1a activation.
80-82
 The different roles and receptor 
activation behavior is one of the proposed sources for the diversity in ghrelin’s biological role.  
14 
 
 
 
Figure 1.3. Ghrelin interacts with multiple partners in circulation. Ghrelin and desacyl 
ghrelin can interact with multiple binding partners in the bloodstream (equilibrium arrows), with 
esterases converting ghrelin to desacyl ghrelin by serine ester hydrolysis (single arrows). In 
interaction with lipoproteins (VLDL, HDL, and LDL), desacyl ghrelin shows a preference for 
binding to HDL (bold). Figure is reproduced with permission from Reference 46 (Appendix II). 
© 2016 Taylor and Francis.  
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1.2.5 Physiological effects 
 
Since its discovery in 1999, ghrelin has been implicated in a variety of physiological 
processes and critical biological signaling pathways.
10
 The initial role identified for ghrelin was 
to signal the release of growth hormone, then subsequently ghrelin was shown to control appetite 
signaling and the hunger response.
10
 This diversified role increased the interest into ghrelin and 
ghrelin signaling, since the ability to control hunger is advantageous and critical for obesity 
therapeutics. Through additional investigations ghrelin has been implicated in food intake, 
reward-seeking behavior, body weight (adiposity), glucose homeostasis and insulin production, 
energy balance, and gastrointestinal mobility.
83-95
 Ghrelin’s effects are far-reaching with 
implications in learning and memory, psychological stress, mood and anxiety, depression, 
thymopoiesis (the production of thymocytes, which later become T cells), sleep/wake rhythm, 
and aging.
96-111
  
Circulating ghrelin levels also play a role in a number of pathological conditions. It has 
been established that ghrelin levels have positive correlation with cachexia associated with 
chronic obstructive lung disease (COPD) or chronic heart failure (CHF).
 112-114
  There is a 
negative correlation between ghrelin levels with insulin resistance which has implications in the 
formation and progression of diabetes.
112-114
 Ghrelin serum levels are low in obese patients and 
binge-eaters but very high in patients with Prader-Willi syndrome associated with hyperphagia, 
Hashimoto's Thyroiditis, or patients with anorexia nervosa and bulimia nervosa.
40, 113-118
 Body 
weight alone is not an indication of circulating ghrelin levels, since ghrelin levels are not 
elevated in obese patients with Bardet-Biedl syndrome, Cushing's disease, or HIV-
Lipodystrophy.
118-122
 In non-obesity related illnesses such as Parkinson’s disease, ghrelin has 
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been demonstrated to play a neuroprotective role.
104, 106
 The ability to better understand and to 
control ghrelin signaling could potentially treat the diseases mentioned above, as well as, other 
ghrelin-linked disorders. 
1.3 GOAT 
1.3.1 Discovery 
 
After the discovery of ghrelin in 1999, 
10
 there was a subsequent search for the acyl 
transferase that catalyzed the attachment of the 8 carbon chain lipid moiety to ghrelin. This 
enzyme, ghrelin O-acyltransferase (GOAT), was identified by two independent research groups 
in 2008.
48-49
 The search for GOAT focused on a family of O-acyltransferases given the 
designation MBOAT (membrane-bound O-acyltransferase).
24
 Proghrelin contains a signal 
sequence which traffics it to the endoplasmic reticulum, it was thought a membrane-bound 
enzyme such as a member of the MBOAT family (since members of this family are located in 
the membrane of the ER ) would be good a candidate for the ghrelin acyltransferase.
44
 There are 
sixteen members of the MBOAT family of enzymes, three of which (including GOAT) act upon 
protein substrates with the other family members acting upon small molecules.
24, 48-49
 Two 
examples of MBOATs in the family that modify non-protein substrates include ACATs which 
attach fatty acids to cholesterol and DGAT1 which acylates diacylglycerol.
24
 Genome database 
searches using criteria such as similarity to known MBOAT members sequences, presence of a 
human homolog, and a known primary sequence of the gene of interest were necessary metrics 
for the uncharacterized pool of candidates to investigate.
48-49
 Using mRNA silencing there was a 
candidate, MBOAT4, which when it was silenced lead to a lack of ghrelin acylation.
48
 In side-
by-side studies knockout comparisons in TT (thyroid carcinoma)
48
 and INS-1 (pancreatic 
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insulin-secreting) cells
49
 between MBOAT4 and other MBOAT family members demonstrated 
that this enzyme was required to acylate ghrelin.
48-49
 After exogenous expression in endocrine 
cell lines GOAT was able to acylate proghrelin which demonstrates the ubiquity of 
GOAT/ghrelin in different tissue types.
49
 There have also been two recent studies which indicate 
that there is ghrelin reacylation extracellularly in both the bone marrow and in the hippocampus 
which would indicate that GOAT is not necessarily located primarily in the ER membrane but 
also located in the plasma membrane.
30-31
 These findings also possibly indicate that there is a 
cyclical nature to ghrelin signaling with deacylation and then selective reacylation of ghrelin. 
30-
31
 
1.3.2 GOAT conservation across species 
 
GOAT is a topologically complex membrane bound protein containing the conserved 
residues asparagine-307 (N307) and histidine-338 (H338) which have been shown to be required 
for enzyme function.
48-49, 123
 MBOAT family members that modify protein substrates include 
GOAT, PORCN and Hhat.
24
 GOAT acylates using a medium chain fatty acid (8-carbon chain) 
instead of a long chain like PORCN and Hhat (16-carbon chain).
37, 123-126
 The other 
differentiating factor between these enzymes is PORCN and Hhat acylate a cysteine or threonine 
residue (PORCN has been shown to acylate at a serine residue, though preferentially a cysteine) 
when GOAT is demonstrated to acylate a serine residue (although GOAT has been observed to 
acylate a threonine residue in bullfrog ghrelin).
37, 123-128
 These protein-modifying MBOATs are 
ER integral membrane proteins which modify substrates within the ER lumen; however, the 
precise mechanism in which the acyl donor enters the ER lumen is still unclear. 
24, 123
 
Purification and solubilization of these membrane-bound enzymes in an active form has been a 
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challenge, with success reported only for Hhat and ACAT1 (known as SOAT1).
124, 126, 129-130
 
While there are no structural models available for any MBOAT family members, five MBOAT 
family members that have been topologically examined including human ACAT1 (Acyl-
CoA:cholesterol acyltransferase, also known as Sterol O-acyltransferase, SOAT), ACAT2, 
Ghrelin O-acyltransferase (GOAT), Hedgehog acyltransferase (Hhat) and yeast Gup1.
37, 123-124, 
131-132
 To determine the topology of GOAT, Taylor and coworkers applied topological mapping 
programs (MemBrain and MEMSAT-SVM), and cross-species conservation analysis, modeling, 
and hydropathy mapping to separate the primary sequence into sections (helical, nonhelical, loop 
domains) (Figure 1.4).
123
 Through the use of selective permeabilization and epitope tags, it was 
determined that GOAT contains 11 transmembrane domains and one re-entrant loop.
123
  The 
topology and mutational studies found that N307 and H338 are required for activity and located 
in the C-terminus of the enzyme which is consistent with other MBOAT family members.
123
 
Other than the described methodology, no other published data is available on the secondary 
(tertiary/quaternary) structure of this enzyme or how catalysis occurs to octanoylate ghrelin. The 
topology mapping is a good step in the right direction but does not provide enough information 
to model or locate the substrate binding site(s) or the active site.   
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Figure 1.4. The proposed membrane topology of GOAT. This is the current topological 
mapping of the structure of GOAT as published by Taylor and coworkers of the enzyme in the 
endoplasmic reticulum membrane. GOAT contains two conserved residues N307 and H338 
(starred) eleven transmembrane helices as well as one re-entrant loop. Figure reproduced with 
permission from Reference 123 (Appendix III). © 2013 American Society for Biochemistry and 
Molecular Biology. 
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1.4 GOAT inhibitors  
 
Ghrelin has implications in a variety of disease states such as diabetes, Prader-Willi 
Syndrome and obesity, so the ability to control or modulate ghrelin signaling is an opportunity to 
treat a variety of ghrelin-linked diseases.
117, 133-135
 Acylation of ghrelin by GOAT is a necessary 
step for GHS-R1a receptor activation, which makes this processing step an attractive target for 
inhibition.
26
 There is also the possibility that there will be reduced off-target effects when 
targeting ghrelin acylation since GOAT only has one predicted substrate, ghrelin.
136
 GOAT is a 
high-value target for controlling or modulating ghrelin signaling; however, there has been 
difficulty in inhibitor design since there has been no identification of the catalytic machinery or 
the residues that comprise the active site of GOAT.  
1.4.1 Ghrelin product mimetics as GOAT inhibitors 
 
The first reported class of GOAT inhibitors was peptide-based product mimetics of 
acylated ghrelin. There are four known inhibitors that contain a portion of ghrelin’s N-terminal 
sequence as well as an acyl chain derivative: [Dap
3
]octanoyl-ghrelin(1–5)-NH2, [Dap
3
]octanoyl-
ghrelin(1–28)-NH2, phenylalkyl triazole-linked acylated ghrelin and Go-CoA-Tat (Figure 1.5).
137-
139
 Of these inhibitors, Go-CoA-Tat has been shown to disrupt ghrelin signaling.
137
  
Initially, a pentapeptide mimetic of ghrelin containing an amidated C-terminus was used 
as a human GOAT (hGOAT) inhibitor.
138
 Through subsequent testing with attachment of an 
octanoyl group at the S3 position, this modification increased the inhibitory efficiency 50%.
138
 
The acyl chain length was also varied to find GOAT’s preference; attachment of a 14-carbon 
myristoyl or a 16-carbon palmitoyl in place of the 8-carbon octanoyl group abolished all 
inhibitory activity.
138
 The final resulting peptide inhibitor replaced the ester linkage of the acyl 
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group with an amide linkage to yield [Dap
3
]octanoyl-ghrelin(1–5)-NH2, which to date is one of 
the most potent peptide mimetic GOAT inhibitors reported in an in vitro enzyme assay to have 
an IC50 value of 1 μM.
138
 The longer full-length ghrelin mimetic, [Dap
3
]octanoyl-ghrelin(1–28)-
NH2 also acts as a potent GOAT inhibitor with a slightly lower measured in vitro IC50 of 0.2 μM. 
138
 These inhibitors are structurally similar to octanoylated ghrelin and so may have unintended 
GHS-R1a receptor activation since peptide length (first four residues) and the octanoyl group are 
recognized by the receptor.
26
  
In an effort to increase the low potency, biostability, and cell permeability of the current 
field of peptide mimetic inhibitors, a series of 1,2,3-triazole linked acylated peptides were 
designed (Figure 1.5).
139
 These peptides used GSSFL-NH2 as their starting peptide scaffold, 
replacing S3 with a Dap (2,3-diaminopropanoic acid, which is converted to an azide via a diazo 
transfer) residue which is the site of acylation in the parent peptide. The triazole linkage acts in a 
similar manner to an ester/amide bond, however, it increases the biostability and is more resistant 
to biological enzymatic degradation compared to [Dap
3
]octanoyl-ghrelin(1–5)-NH2.
139
 After 
copper-catalyzed cycloaddition the peptide then has an alkylated triazole in place of the octanoyl 
ester.
140
 A panel of triazole-linked side chains were incorporated including a range of aromatic 
groups to probe hGOAT tolerance instead of simple acyl chains.
139
 The most potent inhibitor, 
phenylpropyl triazole, has an in vitro measured IC50 of 0.7 μM.
139
 There was a defined 
relationship between the inhibitory activity and the length of the side chain, extending or 
shortening the length of the acyl chain from phenylpropyl resulted in loss of inhibitory 
activity.
139
 Like the above mentioned [Dap
3
]octanoyl-ghrelin(1–5)-NH2, the phenylalkyl triazole 
inhibitors are peptide mimetics containing the first five amino acids of ghrelin, the first four are 
required for receptor activation, and acyl chain stemming from the S3 position, so there is still 
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the possibility that these inhibitors would show low cell permeability and receptor activation as 
well.  
Since previous inhibitor studies have identified that GOAT discriminates substrate length 
as well as the length of the acyl chain, there was an effort to combine both of these 
considerations into one bi-substrate inhibitor GO-CoA-Tat (Figure 1.5).
137
 The first ten amino 
acids of ghrelin were selected in an effort to increase GOAT selectivity, octanoyl-CoA, and an 
11-mer HIV Tat-derived peptide sequence to enhance cell penetration.
137
 In cell studies using 
HeLa and HEK 293FT cell lines expressing mGOAT and preproghrelin, GO-CoA-Tat decreased 
acylated ghrelin levels with a measured IC50 of 5 μM in their assay and had no effect on levels of 
desacyl ghrelin.
137
 During cell studies there was delayed inhibition observed, with cells having to 
be incubated for 24 hours in the presence of Go-CoA-Tat, indicating a slow kinetic interaction.
137
 
In mice treated with GO-CoA-Tat, serum levels of acylated ghrelin decreased, they showed 
resistance to weight gain on a high fat diet and had a significant increase of insulin levels in a 
glucose challenge.
137
 In other rodents GO-CoA-Tat treatment decreased fasting-induced food 
foraging and hoarding in hamsters and reduced meal frequency in rats.
137, 141-142
 GO-CoA-Tat 
shows no evidence of cytotoxicity and when measured there was no observed GHS-R1a receptor 
activation.
137
 GO-CoA-Tat is the first instance of an inhibitor having therapeutic potential for 
GOAT and ghrelin acylation as a drug target.  
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Figure 1.5. Peptide mimetic inhibitors of GOAT. Figure is reproduced with permission from 
Reference 46 (Appendix II). © 2016 Taylor and Francis. 
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1.4.2 Small molecule GOAT inhibitors 
 
 The first reported investigation into small molecule inhibitors of GOAT was performed 
by Garner and Janda in 2010 and 2011.
143-144
 After a screen of small molecule library, a series of 
small molecule inhibitors containing small and medium acyl chains exhibited low micromolar 
IC50 values (Figure 1.6).
143-144
 The relative inhibitor effectiveness compared to acyl chain length 
is an indication that these small molecules might be targeting the octanoyl-CoA binding site. 
These lipidated small molecule inhibitors were the first step towards small molecule inhibitors; 
however, no cell or animal studies were conducted so their efficacy as therapeutics is unknown.  
The next step in small molecule inhibitor design was to try and mimic the transition state 
of the GOAT octanoylation reaction by using aromatic groups that model peptide side chains. 
These aromatic groups would theoretically mimic ghrelin’s N-terminal peptide side chain 
residues in the GOAT active site. In a series of reported inhibitors from Harran and coworkers, 
their small molecules mimic serine and phenylalanine residues which surround S3’s 
octanoylation site.
145
 However, their patented and most potent inhibitor BK1114 (Figure 1.6) 
does not contain those functionalities that were proposed to increase inhibitor affinity. 
145
 
In a more recent study, a screen of an NIH small molecule library identified two 
derivatives of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) as inhibitors of 
hGOAT in a microsomal enzyme assay with IC50 values in the low micromolar range (Figure 
1.6).
146
 The GOAT inhibitors provide information about the potential mechanism for GOAT-
catalyzed acylation, as structure activity relationship studies of these compounds demonstrate 
that compounds containing Michael addition electrophiles point to a covalent reversible 
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inhibition-based mechanism as their mechanism of action for GOAT inhibition.
146
 This 
conclusion implies that there might be a functionally essential cysteine in the GOAT active site.  
There are currently two industrial labs that are investigating possible small molecule 
inhibitors of GOAT for therapeutic use, Takeda Pharmaceuticals and Eli Lilly (Figure 1.6). 
Takeda has reported in the patent literature small molecule inhibitors containing a series of 
aromatic rings. 
147-148
 They have recently reported the most potent GOAT inhibitor to date using 
a screening of an internal small molecule library and from that lead compound, 4-chloro-6-{[2-
methyl-6-(trifluoromethyl)pyridin-3-yl]methoxy}-1-benzothiophen-3-yl)acetic acid was 
synthesized.
148
 In a microsomal enzyme assay, ELISA, and in vivo mouse studies this small 
molecule exhibited single nanomolar IC50 values and decreased the total amount of acylated 
ghrelin.
148
 The inhibitor still needs to be evaluated further in vitro and to investigate if there are 
possible off-target effects, however, there is indication from competition studies that this small 
molecule is targeting the octanoyl-CoA binding site. This is hypothesis supported by the use of 
the above mentioned small molecule inhibitor of GOAT (Figure 1.6, Takeda 2017 compound) in 
a lipid competition experiment.
148
 The amount of octanoyl-CoA was varied in comparison to the 
inhibitor compound, which showed a shift in its IC50 (higher) at increasing levels of octanoyl-
CoA, indicating it was octanoyl-CoA substrate competitive.
148
 The other pharmaceutical 
company with patented GOAT inhibitors, Eli Lilly, has reported two piperidyl-ethyl-pyrimidine 
derived GOAT inhibitors.
149-150
 The supporting information in their patent applications indicates 
that these compounds (Figure 1.6) have potency in enzyme-, cell-, and animal studies. The lead 
compound in this class was discovered using a high-throughput GOAT activity screening assay. 
Through compound optimization both inhibitors have mid-nanomolar range in in vitro GOAT 
activity assays.
149-150
 The published data on the Takeda GOAT inhibitors indicate that these 
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small molecules are targeting the octanoyl-CoA binding site within GOAT’s active site. Further 
inhibitor testing for unintended effects, receptor activation, as well as, positive effects of 
blocking ghrelin signaling (body weight, glucose levels, insulin secretion) still need to be 
evaluated.  
27 
 
 
Figure 1.6. Small molecule GOAT inhibitors. A) The current field of academic-derived 
inhibitors published in peer-reviewed publication and B) is the current field of industrial- derived 
inhibitors reported in patent applications or issued patents.  Figure was adapted with permission 
from Reference 46 (Appendix II). © 2016 Taylor and Francis. 
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1.5 GOAT recognition of ghrelin- the role of the N-terminal “GSSF” sequence and beyond 
 
The active site and catalytic mechanism of GOAT remains to be revealed, the functional 
and structural recognition elements for GOAT recognition within ghrelin and ghrelin mimetic 
substrates have been characterized. After GOAT’s initial discovery, Yang and coworkers utilized 
full-length proghrelin to evaluate GOAT’s sequence selectivity near the site of acylation.138 In 
these studies an [
3
H]octanoyl radiolabel-based assay was used to study mouse proghrelin 
acylation by mouse GOAT (mGOAT).
138
 Mutation of S3 to alanine, G1 to serine, F4 to alanine, 
and addition of a serine-alanine dipeptide at the N-terminus all resulted in no acylation, 
indicating the N-terminal region’s importance in GOAT recognition.138 There was no noticeable 
decrease in the efficiency of substrate acylation in the presence of an S2 alanine mutation.
138
 A 
less noticeable impact on proghrelin octanoylation was also observed when positions five 
through seven of proghrelin were mutated to alanine, indicating that the first five residues are of 
primary importance for recognition by GOAT.
123, 138
  
Further analysis using fluorescently labeled peptides with the sequence GSSFLCAcDan and 
a microsomal enzyme assay was used to define a broad structure-activity relationship of 
substrate requirements for GOAT reactivity to occur.
136, 151
 These studies indicated that the N-
terminal glycine is important for recognition, with any loss of the N-terminal amine abrogating 
all catalysis.
151
 There is a broad sequence tolerance at the S2 position with alanine, threonine, 
valine and phenylalanine all accepted.
136, 151
 The mouse and human isoforms of GOAT can 
accept an amine substitution at S3 which reduces but does not eliminate acylation activity.
136, 152
 
The bullfrog form of ghrelin contains a threonine at the acylation site and has been demonstrated 
to be acylacted, which supports the evidence that there can be substitution at this position 
29 
 
without loss of catalytic activity. 
127-128
 There was also broad tolerance at the F4 position with a 
variety of amino acid substitutions.
136, 151
 These studies determined that the G1 position is 
absolutely necessary for acylation, as is a hydroxyl residue (serine or threonine) at the S3 
position, with the S2 and F4 having broad tolerance for a variety of chemical group substitutions. 
Since the active site and catalytic residues of GOAT are still unknown, these structure-activity 
relationship studies helped to identify ghrelin substrate requirements which are necessary for 
GOAT catalysis to occur.  
To determine if intermediate sequence lengths between full-length proghrelin (1-94) and 
small N-terminal peptides (1-5), there was an interest if longer sequences could bind and be 
efficiently bind to GOAT. Peptides with the sequences of ghrelin (1-5), (1-10), (1-18), and (1-28) 
were evaluated.
136
 Their IC50 values were measured in microsomal enzyme assay leading to the 
observation that there was tighter binding affinity (lower IC50) with the longer the ghrelin 
sequence, with a discrepancy with (1-10) exhibiting a higher IC50 value than the other 
sequences.
136
 There were also studies using Dap-incorporated peptides with longer ghrelin 
sequences, ghrelin (1-10) and (1-27), which also showed that the longer sequence had a tighter 
binding affinity than the shorter sequence.
152
 These data indicate that there are possible substrate 
interactions occurring outside conventional ghrelin (1-5) sequence and is advantageous for 
GOAT binding. 
1.6 Obestatin  
 
In 2005, bioinformatic analysis of the sequence of preproghrelin identified a conserved 
region that was surrounded by potential enzymatic cleavage sites that could result in cleavage 
and formation of a new peptide hormone (other than ghrelin).
153
 This 23 amino acid peptide, 
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named obestatin, is derived from the C-terminus of proghrelin and contains a C-terminal 
amidated glycine residue.
153
 The complete processing pathway of obestatin is unknown, 
including the enzyme(s) that cleave obestatin from proghrelin.
50
 Obestatin is found in the same 
cell types as ghrelin, specifically several endocrine cell types.
153-162 
The initial study describing 
obestatin reported that intraperitoneal/intracerebroventricular injection of obestatin decreased 
food intake and also reduced body weight in mice as well as inhibiting gastrointestinal 
mobility.
153, 163-169
 Since this initial study, only a minority of other studies (25%) have replicated 
these findings such as evidence of an anorexigenic effect upon obestatin administration.
170-185
 
The large number of conflicting findings may be the result of differences in in vitro and in vivo 
methodology as well as the relatively short half-life and stability of the obestatin peptide.
186-187
 
Due to the varying experimental results, the exact role obestatin is involved in are undefined or 
at least ambiguous. 
Since ghrelin activates the GHS-R1a receptor, it was thought that obestatin also acts as a 
receptor ligand. When measured in crude plasma membrane preparation of rat jejunum (the part 
of the small intestine between the duodenum and ileum), obestatin was found to bind jejunum 
with high affinity indicating it was binding to a receptor in the membrane.
153
 It was hypothesized 
that obestatin was binding to an orphan GPCR (akin to GHS-R1a), with the receptor identified as 
GPR39.
153, 167
 In CHO (chinese hamster ovary) cells expressing the GPR39 receptor, there was 
observed receptor activation in the presence of obestatin.
153
 Subsequent studies failed to 
reproduce these initial findings, and the current consensus holds that obestatin is not an 
endogenous ligand for GPR39.
171, 174-175
 Apart from GPR39, some studies have found that 
obestatin binds the GLP-1R and CRF receptors, although the reproducibility of these studies 
remains to be established.
154, 185, 188-189
  There are still unanswered questions as to the processing 
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and biological role of obestatin; including what is the mechanism of cleavage from C-ghrelin, is 
obestatin activating a receptor and is it actually a hormone?  
1.7 Aims of this work 
 
There are three main aims of this work described in this thesis. The first was to create an 
expression system for proghrelin to enable purification to homogeneity, allowing investigation of 
the secondary structure of the protein. This led to the second aim of my doctoral studies, 
investigating unique processing behavior of proghrelin and C-ghrelin that was observed during 
proghrelin purification. The final aim was to develop a structure activity relationship of small 
substrate mimetics of ghrelin with unnatural amino acid incorporation. There has been little 
investigation into the structure of proghrelin and its recognition as a substrate for GOAT-
catalyzed octanoylation beyond the initial study by Yang and coworkers. In order to understand 
the effects of the C-terminus of proghrelin on enzymatic catalysis as well as any interactions that 
the enzyme has with proghrelin outside the active site, proghrelin needs to be further evaluated. 
The approach taken was to investigate secondary structural motifs present in proghrelin and the 
contribution of ghrelin and C-ghrelin to identify potential recognition elements for proghrelin-
GOAT interactions. There was a unique cleavage behavior seen while purifying recombinantly 
expressed proghrelin which could indicate that under biological conditions proghrelin processes 
obestatin in the absence of an unknown proposed enzyme. In the same vein of understanding 
GOAT’s acylation of proghrelin, small peptide mimetics were designed utilizing an unnatural 
amino acid at the S3 position in order to study purely binding instead of binding and catalysis of 
the enzyme. These unnatural amino acid incorporated peptides were designed to make a model 
peptide for future therapeutic development. The study of the biological substrate and trying to 
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understand the implications of its structural and processing behavior is fundamental to 
understanding the GOAT system and the eventual effects ghrelin has on the body.  
33 
 
1.8 References  
 
1. Walsh, C. T.; Garneau-Tsodikova, S.; Gatto, G. J., Jr., Protein posttranslational modifications: 
the chemistry of proteome diversifications. Angew Chem Int Ed Engl 2005, 44 (45), 7342-72. 
2. Woodgett, J. R.; Hunter, T., Regulation of protein kinase C by activators, Ca2+, and 
phosphorylation. Prog Clin Biol Res 1987, 249, 237-47. 
3. Zhang, K.; Williams, K. E.; Huang, L.; Yau, P.; Siino, J. S.; Bradbury, E. M.; Jones, P. R.; 
Minch, M. J.; Burlingame, A. L., Histone acetylation and deacetylation: identification of 
acetylation and methylation sites of HeLa histone H4 by mass spectrometry. Mol Cell 
Proteomics 2002, 1 (7), 500-8. 
4. Johnson, D. R.; Bhatnagar, R. S.; Knoll, L. J.; Gordon, J. I., Genetic and biochemical studies 
of protein N-myristoylation. Annu Rev Biochem 1994, 63, 869-914. 
5. Bijlmakers, M. J.; Marsh, M., The on-off story of protein palmitoylation. Trends Cell Biol 
2003, 13 (1), 32-42. 
6. Buglino, J. A.; Resh, M. D., Palmitoylation of Hedgehog proteins. Vitam Horm 2012, 88, 229-
52. 
7. Linder, M. E.; Deschenes, R. J., New insights into the mechanisms of protein palmitoylation. 
Biochemistry 2003, 42 (15), 4311-20. 
8. Pepinsky, R. B.; Zeng, C.; Wen, D.; Rayhorn, P.; Baker, D. P.; Williams, K. P.; Bixler, S. A.; 
Ambrose, C. M.; Garber, E. A.; Miatkowski, K.; Taylor, F. R.; Wang, E. A.; Galdes, A., 
Identification of a palmitic acid-modified form of human Sonic hedgehog. J Biol Chem 1998, 
273 (22), 14037-45. 
9. Pickart, C. M., Ubiquitin enters the new millennium. Mol Cell 2001, 8 (3), 499-504. 
34 
 
10. Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K., Ghrelin is a 
growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402 (6762), 656-60. 
11. Casey, P. J.; Seabra, M. C., Protein prenyltransferases. J Biol Chem 1996, 271 (10), 5289-92. 
12. Jiang, H.; Zhang, X.; Chen, X.; Aramsangtienchai, P.; Tong, Z.; Lin, H., Protein Lipidation: 
Occurrence, Mechanisms, Biological Functions, and Enabling Technologies. Chem Rev 2018, 
118 (3), 919-988. 
13. Zhang, F. L.; Casey, P. J., Protein prenylation: molecular mechanisms and functional 
consequences. Annu Rev Biochem 1996, 65, 241-69. 
14. Furmanek, A.; Hofsteenge, J., Protein C-mannosylation: facts and questions. Acta Biochim 
Pol 2000, 47 (3), 781-9. 
15. Mechref, Y.; Novotny, M. V., Structural investigations of glycoconjugates at high sensitivity. 
Chem Rev 2002, 102 (2), 321-69. 
16. Wells, L.; Vosseller, K.; Cole, R. N.; Cronshaw, J. M.; Matunis, M. J.; Hart, G. W., Mapping 
sites of O-GlcNAc modification using affinity tags for serine and threonine post-translational 
modifications. Mol Cell Proteomics 2002, 1 (10), 791-804. 
17. Giles, N. M.; Watts, A. B.; Giles, G. I.; Fry, F. H.; Littlechild, J. A.; Jacob, C., Metal and 
redox modulation of cysteine protein function. Chem Biol 2003, 10 (8), 677-93. 
18. Jacob, C.; Giles, G. I.; Giles, N. M.; Sies, H., Sulfur and selenium: the role of oxidation state 
in protein structure and function. Angew Chem Int Ed Engl 2003, 42 (39), 4742-58. 
19. Nadolski, M. J.; Linder, M. E., Protein lipidation. FEBS J 2007, 274 (20), 5202-10. 
20. Thinon, E.; Hang, H. C., Chemical reporters for exploring protein acylation. Biochem Soc 
Trans 2015, 43 (2), 253-61. 
35 
 
21. Towler, D. A.; Gordon, J. I.; Adams, S. P.; Glaser, L., The biology and enzymology of 
eukaryotic protein acylation. Annu Rev Biochem 1988, 57, 69-99. 
22. Takada, R.; Satomi, Y.; Kurata, T.; Ueno, N.; Norioka, S.; Kondoh, H.; Takao, T.; Takada, 
S., Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. Dev Cell 
2006, 11 (6), 791-801. 
23. Doubravska, L.; Krausova, M.; Gradl, D.; Vojtechova, M.; Tumova, L.; Lukas, J.; Valenta, 
T.; Pospichalova, V.; Fafilek, B.; Plachy, J.; Sebesta, O.; Korinek, V., Fatty acid modification of 
Wnt1 and Wnt3a at serine is prerequisite for lipidation at cysteine and is essential for Wnt 
signalling. Cell Signal 2011, 23 (5), 837-48. 
24. Hofmann, K., A superfamily of membrane-bound O-acyltransferases with implications for 
wnt signaling. Trends Biochem Sci 2000, 25 (3), 111-2. 
25. Avau, B.; Carbone, F.; Tack, J.; Depoortere, I., Ghrelin signaling in the gut, its physiological 
properties, and therapeutic potential. Neurogastroenterol Motil 2013, 25 (9), 720-32. 
26. Bednarek, M. A.; Feighner, S. D.; Pong, S. S.; McKee, K. K.; Hreniuk, D. L.; Silva, M. V.; 
Warren, V. A.; Howard, A. D.; Van Der Ploeg, L. H.; Heck, J. V., Structure-function studies on 
the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for 
activation of growth hormone secretagogue receptor 1a. J Med Chem 2000, 43 (23), 4370-6. 
27. Howard, A. D.; Feighner, S. D.; Cully, D. F.; Arena, J. P.; Liberator, P. A.; Rosenblum, C. I.; 
Hamelin, M.; Hreniuk, D. L.; Palyha, O. C.; Anderson, J.; Paress, P. S.; Diaz, C.; Chou, M.; Liu, 
K. K.; McKee, K. K.; Pong, S. S.; Chaung, L. Y.; Elbrecht, A.; Dashkevicz, M.; Heavens, R.; 
Rigby, M.; Sirinathsinghji, D. J.; Dean, D. C.; Melillo, D. G.; Patchett, A. A.; Nargund, R.; 
Griffin, P. R.; DeMartino, J. A.; Gupta, S. K.; Schaeffer, J. M.; Smith, R. G.; Van der Ploeg, L. 
36 
 
H., A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 
1996, 273 (5277), 974-7. 
28. Callaghan, B.; Furness, J. B., Novel and conventional receptors for ghrelin, desacyl-ghrelin, 
and pharmacologically related compounds. Pharmacol Rev 2014, 66 (4), 984-1001. 
29. Delhanty, P. J.; Sun, Y.; Visser, J. A.; van Kerkwijk, A.; Huisman, M.; van Ijcken, W. F.; 
Swagemakers, S.; Smith, R. G.; Themmen, A. P.; van der Lely, A. J., Unacylated ghrelin rapidly 
modulates lipogenic and insulin signaling pathway gene expression in metabolically active 
tissues of GHSR deleted mice. PLoS One 2010, 5 (7), e11749. 
30. Hopkins, A. L.; Nelson, T. A.; Guschina, I. A.; Parsons, L. C.; Lewis, C. L.; Brown, R. C.; 
Christian, H. C.; Davies, J. S.; Wells, T., Unacylated ghrelin promotes adipogenesis in rodent 
bone marrow via ghrelin O-acyl transferase and GHS-R1a activity: evidence for target cell-
induced acylation. Sci Rep 2017, 7, 45541. 
31. Murtuza, M. I.; Isokawa, M., Endogenous ghrelin-O-acyltransferase (GOAT) acylates local 
ghrelin in the hippocampus. J Neurochem 2018, 144 (1), 58-67. 
32. Date, Y.; Kojima, M.; Hosoda, H.; Sawaguchi, A.; Mondal, M. S.; Suganuma, T.; Matsukura, 
S.; Kangawa, K.; Nakazato, M., Ghrelin, a novel growth hormone-releasing acylated peptide, is 
synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. 
Endocrinology 2000, 141 (11), 4255-61. 
33. Stengel, A.; Tache, Y., Ghrelin - a pleiotropic hormone secreted from endocrine x/a-like cells 
of the stomach. Front Neurosci 2012, 6, 24. 
34. Mizutani, M.; Atsuchi, K.; Asakawa, A.; Matsuda, N.; Fujimura, M.; Inui, A.; Kato, I.; 
Fujimiya, M., Localization of acyl ghrelin- and des-acyl ghrelin-immunoreactive cells in the rat 
37 
 
stomach and their responses to intragastric pH. Am J Physiol Gastrointest Liver Physiol 2009, 
297 (5), G974-80. 
35. Rindi, G.; Necchi, V.; Savio, A.; Torsello, A.; Zoli, M.; Locatelli, V.; Raimondo, F.; Cocchi, 
D.; Solcia, E., Characterisation of gastric ghrelin cells in man and other mammals: studies in 
adult and fetal tissues. Histochem Cell Biol 2002, 117 (6), 511-9. 
36. Date, Y.; Nakazato, M.; Hashiguchi, S.; Dezaki, K.; Mondal, M. S.; Hosoda, H.; Kojima, M.; 
Kangawa, K.; Arima, T.; Matsuo, H.; Yada, T.; Matsukura, S., Ghrelin is present in pancreatic 
alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 2002, 51 (1), 124-9. 
37. Konitsiotis, A. D.; Jovanovic, B.; Ciepla, P.; Spitaler, M.; Lanyon-Hogg, T.; Tate, E. W.; 
Magee, A. I., Topological analysis of Hedgehog acyltransferase, a multipalmitoylated 
transmembrane protein. J Biol Chem 2015, 290 (6), 3293-307. 
38. Koussounadis, A.; Langdon, S. P.; Um, I. H.; Harrison, D. J.; Smith, V. A., Relationship 
between differentially expressed mRNA and mRNA-protein correlations in a xenograft model 
system. Sci Rep 2015, 5, 10775. 
39. McManus, J.; Cheng, Z.; Vogel, C., Next-generation analysis of gene expression regulation--
comparing the roles of synthesis and degradation. Mol Biosyst 2015, 11 (10), 2680-9. 
40. Korbonits, M.; Bustin, S. A.; Kojima, M.; Jordan, S.; Adams, E. F.; Lowe, D. G.; Kangawa, 
K.; Grossman, A. B., The expression of the growth hormone secretagogue receptor ligand 
ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin 
Endocrinol Metab 2001, 86 (2), 881-7. 
41. Gnanapavan, S.; Kola, B.; Bustin, S. A.; Morris, D. G.; McGee, P.; Fairclough, P.; 
Bhattacharya, S.; Carpenter, R.; Grossman, A. B.; Korbonits, M., The tissue distribution of the 
38 
 
mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 
2002, 87 (6), 2988. 
42. Chen, C. Y.; Fujimiya, M.; Asakawa, A.; Chang, F. Y.; Cheng, J. T.; Lee, S. D.; Inui, A., At 
the cutting edge: ghrelin gene products in food intake and gut motility. Neuroendocrinology 
2009, 89 (1), 9-17. 
43. Takahashi, T.; Ida, T.; Sato, T.; Nakashima, Y.; Nakamura, Y.; Tsuji, A.; Kojima, M., 
Production of n-octanoyl-modified ghrelin in cultured cells requires prohormone processing 
protease and ghrelin O-acyltransferase, as well as n-octanoic acid. J Biochem 2009, 146 (5), 675-
82. 
44. Zhu, X.; Cao, Y.; Voogd, K.; Steiner, D. F., On the processing of proghrelin to ghrelin. J Biol 
Chem 2006, 281 (50), 38867-70. 
45. Romero, A.; Kirchner, H.; Heppner, K.; Pfluger, P. T.; Tschop, M. H.; Nogueiras, R., 
GOAT: the master switch for the ghrelin system? Eur J Endocrinol 2010, 163 (1), 1-8. 
46. Cleverdon, E. R.; McGovern-Gooch, K. R.; Hougland, J. L., The octanoylated energy 
regulating hormone ghrelin: An expanded view of ghrelin's biological interactions and avenues 
for controlling ghrelin signaling. Mol Membr Biol 2016, 33 (6-8), 111-124. 
47. Zhou, A.; Webb, G.; Zhu, X.; Steiner, D. F., Proteolytic processing in the secretory pathway. 
J Biol Chem 1999, 274 (30), 20745-8. 
48. Gutierrez, J. A.; Solenberg, P. J.; Perkins, D. R.; Willency, J. A.; Knierman, M. D.; Jin, Z.; 
Witcher, D. R.; Luo, S.; Onyia, J. E.; Hale, J. E., Ghrelin octanoylation mediated by an orphan 
lipid transferase. Proc Natl Acad Sci U S A 2008, 105 (17), 6320-5. 
39 
 
49. Yang, J.; Brown, M. S.; Liang, G.; Grishin, N. V.; Goldstein, J. L., Identification of the 
acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008, 
132 (3), 387-96. 
50. Garg, A., The ongoing saga of obestatin: is it a hormone? J Clin Endocrinol Metab 2007, 92 
(9), 3396-8. 
51. Berg, J. M.; Tymoczko, J. L.; Stryer, L.; Stryer, L., Biochemistry. 6th ed.; W.H. Freeman: 
New York, 2007. 
52. Purnell, J. Q.; Weigle, D. S.; Breen, P.; Cummings, D. E., Ghrelin levels correlate with 
insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, 
menopausal status, or cortisol levels in humans. J Clin Endocrinol Metab 2003, 88 (12), 5747-
52. 
53. De Vriese, C.; Hacquebard, M.; Gregoire, F.; Carpentier, Y.; Delporte, C., Ghrelin interacts 
with human plasma lipoproteins. Endocrinology 2007, 148 (5), 2355-62. 
54. Holmes, E.; Davies, I.; Lowe, G.; Ranganath, L. R., Circulating ghrelin exists in both 
lipoprotein bound and free forms. Ann Clin Biochem 2009, 46 (Pt 6), 514-6. 
55. Beaumont, N. J.; Skinner, V. O.; Tan, T. M.; Ramesh, B. S.; Byrne, D. J.; MacColl, G. S.; 
Keen, J. N.; Bouloux, P. M.; Mikhailidis, D. P.; Bruckdorfer, K. R.; Vanderpump, M. P.; Srai, K. 
S., Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase. J Biol 
Chem 2003, 278 (11), 8877-80. 
56. De Vriese, C.; Gregoire, F.; Lema-Kisoka, R.; Waelbroeck, M.; Robberecht, P.; Delporte, C., 
Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites. 
Endocrinology 2004, 145 (11), 4997-5005. 
40 
 
57. Delhanty, P. J.; Huisman, M.; Julien, M.; Mouchain, K.; Brune, P.; Themmen, A. P.; Abribat, 
T.; van der Lely, A. J., The acylated (AG) to unacylated (UAG) ghrelin ratio in esterase 
inhibitor-treated blood is higher than previously described. Clin Endocrinol (Oxf) 2015, 82 (1), 
142-6. 
58. McGovern-Gooch, K. R.; Rodrigues, T.; Darling, J. E.; Sieburg, M. A.; Abizaid, A.; 
Hougland, J. L., Ghrelin Octanoylation Is Completely Stabilized in Biological Samples by Alkyl 
Fluorophosphonates. Endocrinology 2016, 157 (11), 4330-4338. 
59. Dantas, V. G.; Furtado-Alle, L.; Souza, R. L.; Chautard-Freire-Maia, E. A., Obesity and 
variants of the GHRL (ghrelin) and BCHE (butyrylcholinesterase) genes. Genet Mol Biol 2011, 
34 (2), 205-7. 
60. Eubanks, L. M.; Stowe, G. N.; De Lamo Marin, S.; Mayorov, A. V.; Hixon, M. S.; Janda, K. 
D., Identification of alpha2 macroglobulin as a major serum ghrelin esterase. Angew Chem Int 
Ed Engl 2011, 50 (45), 10699-702. 
61. Satou, M.; Nishi, Y.; Yoh, J.; Hattori, Y.; Sugimoto, H., Identification and characterization of 
acyl-protein thioesterase 1/lysophospholipase I as a ghrelin deacylation/lysophospholipid 
hydrolyzing enzyme in fetal bovine serum and conditioned medium. Endocrinology 2010, 151 
(10), 4765-75. 
62. Brimijoin, S.; Chen, V. P.; Pang, Y. P.; Geng, L.; Gao, Y., Physiological roles for 
butyrylcholinesterase: A BChE-ghrelin axis. Chem Biol Interact 2016, 259 (Pt B), 271-275. 
63. Chen, V. P.; Gao, Y.; Geng, L.; Brimijoin, S., Butyrylcholinesterase regulates central ghrelin 
signaling and has an impact on food intake and glucose homeostasis. Int J Obes (Lond) 2017. 
41 
 
64. Chen, V. P.; Gao, Y.; Geng, L.; Parks, R. J.; Pang, Y. P.; Brimijoin, S., Plasma 
butyrylcholinesterase regulates ghrelin to control aggression. Proc Natl Acad Sci U S A 2015, 
112 (7), 2251-6. 
65. Schopfer, L. M.; Lockridge, O.; Brimijoin, S., Pure human butyrylcholinesterase hydrolyzes 
octanoyl ghrelin to desacyl ghrelin. Gen Comp Endocrinol 2015, 224, 61-8. 
66. Yao, J.; Yuan, Y.; Zheng, F.; Zhan, C. G., Unexpected Reaction Pathway for 
butyrylcholinesterase-catalyzed inactivation of "hunger hormone" ghrelin. Sci Rep 2016, 6, 
22322. 
67. Li, B.; Duysen, E. G.; Lockridge, O., The butyrylcholinesterase knockout mouse is obese on 
a high-fat diet. Chem Biol Interact 2008, 175 (1-3), 88-91. 
68. Manoharan, I.; Boopathy, R.; Darvesh, S.; Lockridge, O., A medical health report on 
individuals with silent butyrylcholinesterase in the Vysya community of India. Clin Chim Acta 
2007, 378 (1-2), 128-35. 
69. Manoharan, I.; Wieseler, S.; Layer, P. G.; Lockridge, O.; Boopathy, R., Naturally occurring 
mutation Leu307Pro of human butyrylcholinesterase in the Vysya community of India. 
Pharmacogenet Genomics 2006, 16 (7), 461-8. 
70. Elkon, K.; Casali, P., Nature and functions of autoantibodies. Nat Clin Pract Rheumatol 
2008, 4 (9), 491-8. 
71. Takagi, K.; Legrand, R.; Asakawa, A.; Amitani, H.; Francois, M.; Tennoune, N.; Coeffier, 
M.; Claeyssens, S.; do Rego, J. C.; Dechelotte, P.; Inui, A.; Fetissov, S. O., Anti-ghrelin 
immunoglobulins modulate ghrelin stability and its orexigenic effect in obese mice and humans. 
Nat Commun 2013, 4, 2685. 
42 
 
72. Francois, M.; Takagi, K.; Legrand, R.; Lucas, N.; Beutheu, S.; Bole-Feysot, C.; Cravezic, A.; 
Tennoune, N.; do Rego, J. C.; Coeffier, M.; Inui, A.; Dechelotte, P.; Fetissov, S. O., Increased 
Ghrelin but Low Ghrelin-Reactive Immunoglobulins in a Rat Model of Methotrexate 
Chemotherapy-Induced Anorexia. Front Nutr 2016, 3, 23. 
73. Terashi, M.; Asakawa, A.; Harada, T.; Ushikai, M.; Coquerel, Q.; Sinno, M. H.; Dechelotte, 
P.; Inui, A.; Fetissov, S. O., Ghrelin reactive autoantibodies in restrictive anorexia nervosa. 
Nutrition 2011, 27 (4), 407-13. 
74. Francois, M.; Barde, S.; Legrand, R.; Lucas, N.; Azhar, S.; el Dhaybi, M.; Guerin, C.; 
Hokfelt, T.; Dechelotte, P.; Coeffier, M.; Fetissov, S. O., High-fat diet increases ghrelin-
expressing cells in stomach, contributing to obesity. Nutrition 2016, 32 (6), 709-715. 
75. Kojima, M.; Hosoda, H.; Matsuo, H.; Kangawa, K., Ghrelin: discovery of the natural 
endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 
2001, 12 (3), 118-22. 
76. Bowers, C. Y.; Reynolds, G. A.; Chang, D.; Hong, A.; Chang, K.; Momany, F., A study on 
the regulation of growth hormone release from the pituitaries of rats in vitro. Endocrinology 
1981, 108 (3), 1071-80. 
77. Bowers, C. Y.; Sartor, A. O.; Reynolds, G. A.; Badger, T. M., On the actions of the growth 
hormone-releasing hexapeptide, GHRP. Endocrinology 1991, 128 (4), 2027-35. 
78. Pedretti, A.; Villa, M.; Pallavicini, M.; Valoti, E.; Vistoli, G., Construction of human ghrelin 
receptor (hGHS-R1a) model using a fragmental prediction approach and validation through 
docking analysis. J Med Chem 2006, 49 (11), 3077-85. 
79. Root, A. W.; Root, M. J., Clinical pharmacology of human growth hormone and its 
secretagogues. Curr Drug Targets Immune Endocr Metabol Disord 2002, 2 (1), 27-52. 
43 
 
80. Murata, M.; Okimura, Y.; Iida, K.; Matsumoto, M.; Sowa, H.; Kaji, H.; Kojima, M.; 
Kangawa, K.; Chihara, K., Ghrelin modulates the downstream molecules of insulin signaling in 
hepatoma cells. J Biol Chem 2002, 277 (7), 5667-74. 
81. Kohno, D.; Gao, H. Z.; Muroya, S.; Kikuyama, S.; Yada, T., Ghrelin directly interacts with 
neuropeptide-Y-containing neurons in the rat arcuate nucleus: Ca2+ signaling via protein kinase 
A and N-type channel-dependent mechanisms and cross-talk with leptin and orexin. Diabetes 
2003, 52 (4), 948-56. 
82. Mousseaux, D.; Le Gallic, L.; Ryan, J.; Oiry, C.; Gagne, D.; Fehrentz, J. A.; Galleyrand, J. 
C.; Martinez, J., Regulation of ERK1/2 activity by ghrelin-activated growth hormone 
secretagogue receptor 1A involves a PLC/PKCvarepsilon pathway. Br J Pharmacol 2006, 148 
(3), 350-65. 
83. Tschop, M.; Smiley, D. L.; Heiman, M. L., Ghrelin induces adiposity in rodents. Nature 
2000, 407 (6806), 908-13. 
84. Cowley, M. A.; Smith, R. G.; Diano, S.; Tschop, M.; Pronchuk, N.; Grove, K. L.; 
Strasburger, C. J.; Bidlingmaier, M.; Esterman, M.; Heiman, M. L.; Garcia-Segura, L. M.; Nillni, 
E. A.; Mendez, P.; Low, M. J.; Sotonyi, P.; Friedman, J. M.; Liu, H.; Pinto, S.; Colmers, W. F.; 
Cone, R. D.; Horvath, T. L., The distribution and mechanism of action of ghrelin in the CNS 
demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003, 37 (4), 
649-61. 
85. Cummings, D. E., Ghrelin and the short- and long-term regulation of appetite and body 
weight. Physiol Behav 2006, 89 (1), 71-84. 
44 
 
86. Cummings, D. E.; Frayo, R. S.; Marmonier, C.; Aubert, R.; Chapelot, D., Plasma ghrelin 
levels and hunger scores in humans initiating meals voluntarily without time- and food-related 
cues. Am J Physiol Endocrinol Metab 2004, 287 (2), E297-304. 
87. Cummings, D. E.; Purnell, J. Q.; Frayo, R. S.; Schmidova, K.; Wisse, B. E.; Weigle, D. S., A 
preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 
2001, 50 (8), 1714-9. 
88. Wortley, K. E.; del Rincon, J. P.; Murray, J. D.; Garcia, K.; Iida, K.; Thorner, M. O.; 
Sleeman, M. W., Absence of ghrelin protects against early-onset obesity. J Clin Invest 2005, 115 
(12), 3573-8. 
89. Sun, Y.; Asnicar, M.; Saha, P. K.; Chan, L.; Smith, R. G., Ablation of ghrelin improves the 
diabetic but not obese phenotype of ob/ob mice. Cell Metab 2006, 3 (5), 379-86. 
90. Broglio, F.; Arvat, E.; Benso, A.; Gottero, C.; Muccioli, G.; Papotti, M.; van der Lely, A. J.; 
Deghenghi, R.; Ghigo, E., Ghrelin, a natural GH secretagogue produced by the stomach, induces 
hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001, 86 (10), 
5083-6. 
91. Broglio, F.; Gottero, C.; Benso, A.; Prodam, F.; Destefanis, S.; Gauna, C.; Maccario, M.; 
Deghenghi, R.; van der Lely, A. J.; Ghigo, E., Effects of ghrelin on the insulin and glycemic 
responses to glucose, arginine, or free fatty acids load in humans. J Clin Endocrinol Metab 2003, 
88 (9), 4268-72. 
92. Egido, E. M.; Rodriguez-Gallardo, J.; Silvestre, R. A.; Marco, J., Inhibitory effect of ghrelin 
on insulin and pancreatic somatostatin secretion. Eur J Endocrinol 2002, 146 (2), 241-4. 
45 
 
93. Falken, Y.; Hellstrom, P. M.; Sanger, G. J.; Dewit, O.; Dukes, G.; Gryback, P.; Holst, J. J.; 
Naslund, E., Actions of prolonged ghrelin infusion on gastrointestinal transit and glucose 
homeostasis in humans. Neurogastroenterol Motil 2010, 22 (6), e192-200. 
94. Murray, C. D.; Martin, N. M.; Patterson, M.; Taylor, S. A.; Ghatei, M. A.; Kamm, M. A.; 
Johnston, C.; Bloom, S. R.; Emmanuel, A. V., Ghrelin enhances gastric emptying in diabetic 
gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005, 54 (12), 1693-8. 
95. Tack, J.; Depoortere, I.; Bisschops, R.; Delporte, C.; Coulie, B.; Meulemans, A.; Janssens, J.; 
Peeters, T., Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 2006, 
55 (3), 327-33. 
96. Chuang, J. C.; Zigman, J. M., Ghrelin's Roles in Stress, Mood, and Anxiety Regulation. Int J 
Pept 2010, 2010. 
97. Diano, S.; Farr, S. A.; Benoit, S. C.; McNay, E. C.; da Silva, I.; Horvath, B.; Gaskin, F. S.; 
Nonaka, N.; Jaeger, L. B.; Banks, W. A.; Morley, J. E.; Pinto, S.; Sherwin, R. S.; Xu, L.; 
Yamada, K. A.; Sleeman, M. W.; Tschop, M. H.; Horvath, T. L., Ghrelin controls hippocampal 
spine synapse density and memory performance. Nat Neurosci 2006, 9 (3), 381-8. 
98. Spencer, S. J.; Emmerzaal, T. L.; Kozicz, T.; Andrews, Z. B., Ghrelin's Role in the 
Hypothalamic-Pituitary-Adrenal Axis Stress Response: Implications for Mood Disorders. Biol 
Psychiatry 2015, 78 (1), 19-27. 
99. Kanoski, S. E.; Fortin, S. M.; Ricks, K. M.; Grill, H. J., Ghrelin signaling in the ventral 
hippocampus stimulates learned and motivational aspects of feeding via PI3K-Akt signaling. 
Biol Psychiatry 2013, 73 (9), 915-23. 
46 
 
100. Kanoski, S. E.; Hayes, M. R.; Greenwald, H. S.; Fortin, S. M.; Gianessi, C. A.; Gilbert, J. 
R.; Grill, H. J., Hippocampal leptin signaling reduces food intake and modulates food-related 
memory processing. Neuropsychopharmacology 2011, 36 (9), 1859-70. 
101. Lutter, M.; Sakata, I.; Osborne-Lawrence, S.; Rovinsky, S. A.; Anderson, J. G.; Jung, S.; 
Birnbaum, S.; Yanagisawa, M.; Elmquist, J. K.; Nestler, E. J.; Zigman, J. M., The orexigenic 
hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci 2008, 11 
(7), 752-3. 
102. Barim, A. O.; Aydin, S.; Colak, R.; Dag, E.; Deniz, O.; Sahin, I., Ghrelin, paraoxonase and 
arylesterase levels in depressive patients before and after citalopram treatment. Clin Biochem 
2009, 42 (10-11), 1076-81. 
103. Kurt, E.; Guler, O.; Serteser, M.; Cansel, N.; Ozbulut, O.; Altinbas, K.; Alatas, G.; Savas, 
H.; Gecici, O., The effects of electroconvulsive therapy on ghrelin, leptin and cholesterol levels 
in patients with mood disorders. Neurosci Lett 2007, 426 (1), 49-53. 
104. Andrews, Z. B.; Erion, D.; Beiler, R.; Liu, Z. W.; Abizaid, A.; Zigman, J.; Elsworth, J. D.; 
Savitt, J. M.; DiMarchi, R.; Tschoep, M.; Roth, R. H.; Gao, X. B.; Horvath, T. L., Ghrelin 
promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial 
mechanism. J Neurosci 2009, 29 (45), 14057-65. 
105. Dixit, V. D.; Yang, H.; Sun, Y.; Weeraratna, A. T.; Youm, Y. H.; Smith, R. G.; Taub, D. D., 
Ghrelin promotes thymopoiesis during aging. J Clin Invest 2007, 117 (10), 2778-90. 
106. Moon, M.; Kim, H. G.; Hwang, L.; Seo, J. H.; Kim, S.; Hwang, S.; Kim, S.; Lee, D.; 
Chung, H.; Oh, M. S.; Lee, K. T.; Park, S., Neuroprotective effect of ghrelin in the 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial 
activation. Neurotox Res 2009, 15 (4), 332-47. 
47 
 
107. Szentirmai, E.; Kapas, L.; Krueger, J. M., Ghrelin microinjection into forebrain sites 
induces wakefulness and feeding in rats. Am J Physiol Regul Integr Comp Physiol 2007, 292 (1), 
R575-85. 
108. Szentirmai, E.; Kapas, L.; Sun, Y.; Smith, R. G.; Krueger, J. M., Spontaneous sleep and 
homeostatic sleep regulation in ghrelin knockout mice. Am J Physiol Regul Integr Comp Physiol 
2007, 293 (1), R510-7. 
109. Szentirmai, E.; Hajdu, I.; Obal, F., Jr.; Krueger, J. M., Ghrelin-induced sleep responses in 
ad libitum fed and food-restricted rats. Brain Res 2006, 1088 (1), 131-40. 
110. Tolle, V.; Bassant, M. H.; Zizzari, P.; Poindessous-Jazat, F.; Tomasetto, C.; Epelbaum, J.; 
Bluet-Pajot, M. T., Ultradian rhythmicity of ghrelin secretion in relation with GH, feeding 
behavior, and sleep-wake patterns in rats. Endocrinology 2002, 143 (4), 1353-61. 
111. Weikel, J. C.; Wichniak, A.; Ising, M.; Brunner, H.; Friess, E.; Held, K.; Mathias, S.; 
Schmid, D. A.; Uhr, M.; Steiger, A., Ghrelin promotes slow-wave sleep in humans. Am J Physiol 
Endocrinol Metab 2003, 284 (2), E407-15. 
112. Nagaya, N.; Kojima, M.; Uematsu, M.; Yamagishi, M.; Hosoda, H.; Oya, H.; Hayashi, Y.; 
Kangawa, K., Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J 
Physiol Regul Integr Comp Physiol 2001, 280 (5), R1483-7. 
113. Cummings, D. E.; Weigle, D. S.; Frayo, R. S.; Breen, P. A.; Ma, M. K.; Dellinger, E. P.; 
Purnell, J. Q., Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N 
Engl J Med 2002, 346 (21), 1623-30. 
114. Muller, T. D.; Perez-Tilve, D.; Tong, J.; Pfluger, P. T.; Tschop, M. H., Ghrelin and its 
potential in the treatment of eating/wasting disorders and cachexia. J Cachexia Sarcopenia 
Muscle 2010, 1 (2), 159-167. 
48 
 
115. Shiiya, T.; Nakazato, M.; Mizuta, M.; Date, Y.; Mondal, M. S.; Tanaka, M.; Nozoe, S.; 
Hosoda, H.; Kangawa, K.; Matsukura, S., Plasma ghrelin levels in lean and obese humans and 
the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002, 87 (1), 240-4. 
116. Geliebter, A.; Gluck, M. E.; Hashim, S. A., Plasma ghrelin concentrations are lower in 
binge-eating disorder. J Nutr 2005, 135 (5), 1326-30. 
117. DelParigi, A.; Tschop, M.; Heiman, M. L.; Salbe, A. D.; Vozarova, B.; Sell, S. M.; Bunt, J. 
C.; Tataranni, P. A., High circulating ghrelin: a potential cause for hyperphagia and obesity in 
prader-willi syndrome. J Clin Endocrinol Metab 2002, 87 (12), 5461-4. 
118. Malandrino, N.; Miceli, A.; Leggio, L.; Mingrone, G.; Capristo, E., High ghrelin levels in 
post-treatment euthyroid patients with Hashimoto's thyroiditis: a case-control preliminary study. 
Exp Clin Endocrinol Diabetes 2014, 122 (9), 540-3. 
119. Buscher, A. K.; Cetiner, M.; Buscher, R.; Wingen, A. M.; Hauffa, B. P.; Hoyer, P. F., 
Obesity in patients with Bardet-Biedl syndrome: influence of appetite-regulating hormones. 
Pediatr Nephrol 2012, 27 (11), 2065-2071. 
120. Giordano, R.; Picu, A.; Pagotto, U.; De Iasio, R.; Bonelli, L.; Prodam, F.; Broglio, F.; 
Marafetti, L.; Pasquali, R.; Maccario, M.; Ghigo, E.; Arvat, E., The negative association between 
total ghrelin levels, body mass and insulin secretion is lost in hypercortisolemic patients with 
Cushing's disease. Eur J Endocrinol 2005, 153 (4), 535-43. 
121. Koutkia, P.; Meininger, G.; Canavan, B.; Breu, J.; Grinspoon, S., Metabolic regulation of 
growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am J 
Physiol Endocrinol Metab 2004, 286 (2), E296-303. 
122. Libe, R.; Morpurgo, P. S.; Cappiello, V.; Maffini, A.; Bondioni, S.; Locatelli, M.; 
Zavanone, M.; Beck-Peccoz, P.; Spada, A., Ghrelin and adiponectin in patients with Cushing's 
49 
 
disease before and after successful transsphenoidal surgery. Clin Endocrinol (Oxf) 2005, 62 (1), 
30-6. 
123. Taylor, M. S.; Ruch, T. R.; Hsiao, P. Y.; Hwang, Y.; Zhang, P.; Dai, L.; Huang, C. R.; 
Berndsen, C. E.; Kim, M. S.; Pandey, A.; Wolberger, C.; Marmorstein, R.; Machamer, C.; 
Boeke, J. D.; Cole, P. A., Architectural organization of the metabolic regulatory enzyme ghrelin 
O-acyltransferase. J Biol Chem 2013, 288 (45), 32211-28. 
124. Matevossian, A.; Resh, M. D., Membrane topology of hedgehog acyltransferase. J Biol 
Chem 2015, 290 (4), 2235-43. 
125. Gao, X.; Hannoush, R. N., Single-cell imaging of Wnt palmitoylation by the acyltransferase 
porcupine. Nat Chem Biol 2014, 10 (1), 61-8. 
126. Buglino, J. A.; Resh, M. D., Hhat is a palmitoylacyltransferase with specificity for N-
palmitoylation of Sonic Hedgehog. J Biol Chem 2008, 283 (32), 22076-88. 
127. Kaiya, H.; Kojima, M.; Hosoda, H.; Koda, A.; Yamamoto, K.; Kitajima, Y.; Matsumoto, 
M.; Minamitake, Y.; Kikuyama, S.; Kangawa, K., Bullfrog ghrelin is modified by n-octanoic 
acid at its third threonine residue. J Biol Chem 2001, 276 (44), 40441-8. 
128. Kaiya, H.; Sakata, I.; Yamamoto, K.; Koda, A.; Sakai, T.; Kangawa, K.; Kikuyama, S., 
Identification of immunoreactive plasma and stomach ghrelin, and expression of stomach ghrelin 
mRNA in the bullfrog, Rana catesbeiana. Gen Comp Endocrinol 2006, 148 (2), 236-44. 
129. Chang, S. C.; Magee, A. I., Acyltransferases for secreted signalling proteins (Review). Mol 
Membr Biol 2009, 26 (1), 104-13. 
130. Buglino, J. A.; Resh, M. D., Identification of conserved regions and residues within 
Hedgehog acyltransferase critical for palmitoylation of Sonic Hedgehog. PLoS One 2010, 5 (6), 
e11195. 
50 
 
131. Chen, M. H.; Li, Y. J.; Kawakami, T.; Xu, S. M.; Chuang, P. T., Palmitoylation is required 
for the production of a soluble multimeric Hedgehog protein complex and long-range signaling 
in vertebrates. Genes Dev 2004, 18 (6), 641-59. 
132. Guo, Z. Y.; Lin, S.; Heinen, J. A.; Chang, C. C.; Chang, T. Y., The active site His-460 of 
human acyl-coenzyme A:cholesterol acyltransferase 1 resides in a hitherto undisclosed 
transmembrane domain. J Biol Chem 2005, 280 (45), 37814-26. 
133. Delhanty, P. J.; Huisman, M.; Baldeon-Rojas, L. Y.; van den Berge, I.; Grefhorst, A.; 
Abribat, T.; Leenen, P. J.; Themmen, A. P.; van der Lely, A. J., Des-acyl ghrelin analogs prevent 
high-fat-diet-induced dysregulation of glucose homeostasis. FASEB J 2013, 27 (4), 1690-700. 
134. Francois, M.; Barde, S.; Legrand, R.; Lucas, N.; Azhar, S.; El Dhaybi, M.; Guerin, C.; 
Hokfelt, T.; Dechelotte, P.; Coeffier, M.; Fetissov, S. O., High-fat diet increases ghrelin-
expressing cells in stomach, contributing to obesity. Nutrition 2016, 32 (6), 709-15. 
135. Heppner, K. M.; Muller, T. D.; Tong, J.; Tschop, M. H., Ghrelin in the control of energy, 
lipid, and glucose metabolism. Methods Enzymol 2012, 514, 249-60. 
136. Darling, J. E.; Zhao, F.; Loftus, R. J.; Patton, L. M.; Gibbs, R. A.; Hougland, J. L., 
Structure-activity analysis of human ghrelin O-acyltransferase reveals chemical determinants of 
ghrelin selectivity and acyl group recognition. Biochemistry 2015, 54 (4), 1100-10. 
137. Barnett, B. P.; Hwang, Y.; Taylor, M. S.; Kirchner, H.; Pfluger, P. T.; Bernard, V.; Lin, Y. 
Y.; Bowers, E. M.; Mukherjee, C.; Song, W. J.; Longo, P. A.; Leahy, D. J.; Hussain, M. A.; 
Tschop, M. H.; Boeke, J. D.; Cole, P. A., Glucose and weight control in mice with a designed 
ghrelin O-acyltransferase inhibitor. Science 2010, 330 (6011), 1689-92. 
138. Yang, J.; Zhao, T. J.; Goldstein, J. L.; Brown, M. S., Inhibition of ghrelin O-acyltransferase 
(GOAT) by octanoylated pentapeptides. Proc Natl Acad Sci U S A 2008, 105 (31), 10750-5. 
51 
 
139. Zhao, F.; Darling, J. E.; Gibbs, R. A.; Hougland, J. L., A new class of ghrelin O-
acyltransferase inhibitors incorporating triazole-linked lipid mimetic groups. Bioorg Med Chem 
Lett 2015, 25 (14), 2800-3. 
140. Holub, J. M.; Kirshenbaum, K., Tricks with clicks: modification of peptidomimetic 
oligomers via copper-catalyzed azide-alkyne [3+2] cycloaddition. Chem Soc Rev 2010, 39 (4), 
1325-1337. 
141. Teubner, B. J.; Garretson, J. T.; Hwang, Y.; Cole, P. A.; Bartness, T. J., Inhibition of 
ghrelin O-acyltransferase attenuates food deprivation-induced increases in ingestive behavior. 
Horm Behav 2013, 63 (4), 667-73. 
142. Teuffel, P.; Wang, L.; Prinz, P.; Goebel-Stengel, M.; Scharner, S.; Kobelt, P.; Hofmann, T.; 
Rose, M.; Klapp, B. F.; Reeve, J. R., Jr.; Stengel, A., Treatment with the ghrelin-O-
acyltransferase (GOAT) inhibitor GO-CoA-Tat reduces food intake by reducing meal frequency 
in rats. J Physiol Pharmacol 2015, 66 (4), 493-503. 
143. Garner, A. L.; Janda, K. D., cat-ELCCA: a robust method to monitor the fatty acid 
acyltransferase activity of ghrelin O-acyltransferase (GOAT). Angew Chem Int Ed Engl 2010, 49 
(50), 9630-4. 
144. Garner, A. L.; Janda, K. D., A small molecule antagonist of ghrelin O-acyltransferase 
(GOAT). Chem Commun (Camb) 2011, 47 (26), 7512-4. 
145. Harran, P. G.; Brown, M. S.; Goldstein, J. L.; Yang, J.; Zhao, T. J., Small Molecule 
Inhibitors of Ghrelin O-Acyltransferase. Google Patents: 2010. 
146. McGovern-Gooch, K. R.; Mahajani, N. S.; Garagozzo, A.; Schramm, A. J.; Hannah, L. G.; 
Sieburg, M. A.; Chisholm, J. D.; Hougland, J. L., Synthetic Triterpenoid Inhibition of Human 
52 
 
Ghrelin O-Acyltransferase: The Involvement of a Functionally Required Cysteine Provides 
Mechanistic Insight into Ghrelin Acylation. Biochemistry 2017, 56 (7), 919-931. 
147. Takakura, N.; Banno, Y.; Terao, Y.; OCHIDA, A.; Morimoto, S.; Kitamura, S.; Tomata, Y.; 
Yasuma, T.; IKOMA, M.; Masuda, K., Aromatic ring compound. Google Patents: 2013. 
148. Yoneyama-Hirozane, M.; Deguchi, K.; Hirakawa, T.; Ishii, T.; Odani, T.; Matsui, J.; 
Nakano, Y.; Imahashi, K.; Takakura, N.; Chisaki, I.; Takekawa, S.; Sakamoto, J., Identification 
and Characterization of a New Series of Ghrelin O-Acyl Transferase Inhibitors. SLAS Discov 
2017, 2472555217727097. 
149. Galka, C. S.; Hembre, E. J.; Honigschmidt, N. A.; Martinez-Grau, M. A.; PLAZA, G. R.; 
RUBIO, A., Ghrelin o-acyl transferase inhibitors. Google Patents: 2016. 
150. Martinez-Grau, M. A., Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase 
inhibitor. Google Patents: 2015. 
151. Darling, J. E.; Prybolsky, E. P.; Sieburg, M.; Hougland, J. L., A fluorescent peptide 
substrate facilitates investigation of ghrelin recognition and acylation by ghrelin O-
acyltransferase. Anal Biochem 2013, 437 (1), 68-76. 
152. Taylor, M. S.; Dempsey, D. R.; Hwang, Y.; Chen, Z.; Chu, N.; Boeke, J. D.; Cole, P. A., 
Mechanistic analysis of ghrelin-O-acyltransferase using substrate analogs. Bioorg Chem 2015, 
62, 64-73. 
153. Zhang, J. V.; Ren, P. G.; Avsian-Kretchmer, O.; Luo, C. W.; Rauch, R.; Klein, C.; Hsueh, 
A. J., Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. 
Science 2005, 310 (5750), 996-9. 
154. Granata, R.; Settanni, F.; Gallo, D.; Trovato, L.; Biancone, L.; Cantaluppi, V.; Nano, R.; 
Annunziata, M.; Campiglia, P.; Arnoletti, E.; Ghe, C.; Volante, M.; Papotti, M.; Muccioli, G.; 
53 
 
Ghigo, E., Obestatin promotes survival of pancreatic beta-cells and human islets and induces 
expression of genes involved in the regulation of beta-cell mass and function. Diabetes 2008, 57 
(4), 967-79. 
155. Gronberg, M.; Tsolakis, A. V.; Magnusson, L.; Janson, E. T.; Saras, J., Distribution of 
obestatin and ghrelin in human tissues: immunoreactive cells in the gastrointestinal tract, 
pancreas, and mammary glands. J Histochem Cytochem 2008, 56 (9), 793-801. 
156. Guo, Z. F.; Ren, A. J.; Zheng, X.; Qin, Y. W.; Cheng, F.; Zhang, J.; Wu, H.; Yuan, W. J.; 
Zou, L., Different responses of circulating ghrelin, obestatin levels to fasting, re-feeding and 
different food compositions, and their local expressions in rats. Peptides 2008, 29 (7), 1247-54. 
157. Kellokoski, E.; Kunnari, A.; Jokela, M.; Makela, S.; Kesaniemi, Y. A.; Horkko, S., Ghrelin 
and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion 
and oxidized low-density lipoprotein binding. Metabolism 2009, 58 (11), 1572-80. 
158. Pradhan, G.; Wu, C. S.; Han Lee, J.; Kanikarla, P.; Guo, S.; Yechoor, V. K.; Samson, S. L.; 
Sun, Y., Obestatin stimulates glucose-induced insulin secretion through ghrelin receptor GHS-R. 
Sci Rep 2017, 7 (1), 979. 
159. Tsolakis, A. V.; Grimelius, L.; Stridsberg, M.; Falkmer, S. E.; Waldum, H. L.; Saras, J.; 
Janson, E. T., Obestatin/ghrelin cells in normal mucosa and endocrine tumours of the stomach. 
Eur J Endocrinol 2009, 160 (6), 941-9. 
160. Volante, M.; Rosas, R.; Ceppi, P.; Rapa, I.; Cassoni, P.; Wiedenmann, B.; Settanni, F.; 
Granata, R.; Papotti, M., Obestatin in human neuroendocrine tissues and tumours: expression 
and effect on tumour growth. J Pathol 2009, 218 (4), 458-66. 
54 
 
161. Zhao, C. M.; Furnes, M. W.; Stenstrom, B.; Kulseng, B.; Chen, D., Characterization of 
obestatin- and ghrelin-producing cells in the gastrointestinal tract and pancreas of rats: an 
immunohistochemical and electron-microscopic study. Cell Tissue Res 2008, 331 (3), 575-87. 
162. Morash, M. G.; Gagnon, J.; Nelson, S.; Anini, Y., Tissue distribution and effects of fasting 
and obesity on the ghrelin axis in mice. Regul Pept 2010, 163 (1-3), 62-73. 
163. Bresciani, E.; Rapetti, D.; Dona, F.; Bulgarelli, I.; Tamiazzo, L.; Locatelli, V.; Torsello, A., 
Obestatin inhibits feeding but does not modulate GH and corticosterone secretion in the rat. J 
Endocrinol Invest 2006, 29 (8), RC16-8. 
164. Green, B. D.; Irwin, N.; Flatt, P. R., Direct and indirect effects of obestatin peptides on food 
intake and the regulation of glucose homeostasis and insulin secretion in mice. Peptides 2007, 28 
(5), 981-7. 
165. Nagaraj, S.; Peddha, M. S.; Manjappara, U. V., Fragments of obestatin as modulators of 
feed intake, circulating lipids, and stored fat. Biochem Biophys Res Commun 2008, 366 (3), 731-
7. 
166. Nagaraj, S.; Peddha, M. S.; Manjappara, U. V., Fragment analogs as better mimics of 
obestatin. Regul Pept 2009, 158 (1-3), 143-8. 
167. Zhang, J. V.; Jahr, H.; Luo, C. W.; Klein, C.; Van Kolen, K.; Ver Donck, L.; De, A.; Baart, 
E.; Li, J.; Moechars, D.; Hsueh, A. J., Obestatin induction of early-response gene expression in 
gastrointestinal and adipose tissues and the mediatory role of G protein-coupled receptor, 
GPR39. Mol Endocrinol 2008, 22 (6), 1464-75. 
168. Brunetti, L.; Leone, S.; Orlando, G.; Recinella, L.; Ferrante, C.; Chiavaroli, A.; Di Nisio, 
C.; Di Michele, P.; Vacca, M., Effects of obestatin on feeding and body weight after standard or 
cafeteria diet in the rat. Peptides 2009, 30 (7), 1323-7. 
55 
 
169. Brunetti, L.; Di Nisio, C.; Recinella, L.; Orlando, G.; Ferrante, C.; Chiavaroli, A.; Leone, 
S.; Di Michele, P.; Shohreh, R.; Vacca, M., Obestatin inhibits dopamine release in rat 
hypothalamus. Eur J Pharmacol 2010, 641 (2-3), 142-7. 
170. Bassil, A. K.; Haglund, Y.; Brown, J.; Rudholm, T.; Hellstrom, P. M.; Naslund, E.; Lee, K.; 
Sanger, G. J., Little or no ability of obestatin to interact with ghrelin or modify motility in the rat 
gastrointestinal tract. Br J Pharmacol 2007, 150 (1), 58-64. 
171. Chartrel, N.; Alvear-Perez, R.; Leprince, J.; Iturrioz, X.; Reaux-Le Goazigo, A.; Audinot, 
V.; Chomarat, P.; Coge, F.; Nosjean, O.; Rodriguez, M.; Galizzi, J. P.; Boutin, J. A.; Vaudry, H.; 
Llorens-Cortes, C., Comment on "Obestatin, a peptide encoded by the ghrelin gene, opposes 
ghrelin's effects on food intake". Science 2007, 315 (5813), 766; author reply 766. 
172. De Smet, D.; Jochmans, K.; Neyns, B., Development of thrombotic thrombocytopenic 
purpura after a single dose of gemcitabine. Ann Hematol 2008, 87 (6), 495-6. 
173. Gourcerol, G.; Million, M.; Adelson, D. W.; Wang, Y.; Wang, L.; Rivier, J.; St-Pierre, D. 
H.; Tache, Y., Lack of interaction between peripheral injection of CCK and obestatin in the 
regulation of gastric satiety signaling in rodents. Peptides 2006, 27 (11), 2811-9. 
174. Holst, B.; Egerod, K. L.; Schild, E.; Vickers, S. P.; Cheetham, S.; Gerlach, L. O.; 
Storjohann, L.; Stidsen, C. E.; Jones, R.; Beck-Sickinger, A. G.; Schwartz, T. W., GPR39 
signaling is stimulated by zinc ions but not by obestatin. Endocrinology 2007, 148 (1), 13-20. 
175. Lauwers, E.; Landuyt, B.; Arckens, L.; Schoofs, L.; Luyten, W., Obestatin does not activate 
orphan G protein-coupled receptor GPR39. Biochem Biophys Res Commun 2006, 351 (1), 21-5. 
176. Nogueiras, R.; Pfluger, P.; Tovar, S.; Arnold, M.; Mitchell, S.; Morris, A.; Perez-Tilve, D.; 
Vazquez, M. J.; Wiedmer, P.; Castaneda, T. R.; DiMarchi, R.; Tschop, M.; Schurmann, A.; 
56 
 
Joost, H. G.; Williams, L. M.; Langhans, W.; Dieguez, C., Effects of obestatin on energy balance 
and growth hormone secretion in rodents. Endocrinology 2007, 148 (1), 21-6. 
177. Samson, W. K.; White, M. M.; Price, C.; Ferguson, A. V., Obestatin acts in brain to inhibit 
thirst. Am J Physiol Regul Integr Comp Physiol 2007, 292 (1), R637-43. 
178. Sibilia, V.; Bresciani, E.; Lattuada, N.; Rapetti, D.; Locatelli, V.; De Luca, V.; Dona, F.; 
Netti, C.; Torsello, A.; Guidobono, F., Intracerebroventricular acute and chronic administration 
of obestatin minimally affect food intake but not weight gain in the rat. J Endocrinol Invest 2006, 
29 (11), RC31-4. 
179. Tremblay, F.; Perreault, M.; Klaman, L. D.; Tobin, J. F.; Smith, E.; Gimeno, R. E., Normal 
food intake and body weight in mice lacking the G protein-coupled receptor GPR39. 
Endocrinology 2007, 148 (2), 501-6. 
180. Van Dijck, A.; Van Dam, D.; Vergote, V.; De Spiegeleer, B.; Luyten, W.; Schoofs, L.; De 
Deyn, P. P., Central administration of obestatin fails to show inhibitory effects on food and water 
intake in mice. Regul Pept 2009, 156 (1-3), 77-82. 
181. Yamamoto, D.; Ikeshita, N.; Daito, R.; Herningtyas, E. H.; Toda, K.; Takahashi, K.; Iida, 
K.; Takahashi, Y.; Kaji, H.; Chihara, K.; Okimura, Y., Neither intravenous nor 
intracerebroventricular administration of obestatin affects the secretion of GH, PRL, TSH and 
ACTH in rats. Regul Pept 2007, 138 (2-3), 141-4. 
182. Zizzari, P.; Longchamps, R.; Epelbaum, J.; Bluet-Pajot, M. T., Obestatin partially affects 
ghrelin stimulation of food intake and growth hormone secretion in rodents. Endocrinology 
2007, 148 (4), 1648-53. 
57 
 
183. Kobelt, P.; Wisser, A. S.; Stengel, A.; Goebel, M.; Bannert, N.; Gourcerol, G.; Inhoff, T.; 
Noetzel, S.; Wiedenmann, B.; Klapp, B. F.; Tache, Y.; Monnikes, H., Peripheral obestatin has no 
effect on feeding behavior and brain Fos expression in rodents. Peptides 2008, 29 (6), 1018-27. 
184. Mondal, M. S.; Toshinai, K.; Ueno, H.; Koshinaka, K.; Nakazato, M., Characterization of 
obestatin in rat and human stomach and plasma, and its lack of acute effect on feeding behavior 
in rodents. J Endocrinol 2008, 198 (2), 339-46. 
185. Unniappan, S.; Speck, M.; Kieffer, T. J., Metabolic effects of chronic obestatin infusion in 
rats. Peptides 2008, 29 (8), 1354-61. 
186. Gao, X. Y.; Kuang, H. Y.; Liu, X. M.; Ma, Z. B.; Nie, H. J.; Guo, H., Plasma obestatin 
levels in men with chronic atrophic gastritis. Peptides 2008, 29 (10), 1749-54. 
187. Seim, I.; Walpole, C.; Amorim, L.; Josh, P.; Herington, A.; Chopin, L., The expanding roles 
of the ghrelin-gene derived peptide obestatin in health and disease. Mol Cell Endocrinol 2011, 
340 (1), 111-7. 
188. Ataka, K.; Inui, A.; Asakawa, A.; Kato, I.; Fujimiya, M., Obestatin inhibits motor activity in 
the antrum and duodenum in the fed state of conscious rats. Am J Physiol Gastrointest Liver 
Physiol 2008, 294 (5), G1210-8. 
189. Fujimiya, M.; Asakawa, A.; Ataka, K.; Kato, I.; Inui, A., Different effects of ghrelin, des-
acyl ghrelin and obestatin on gastroduodenal motility in conscious rats. World J Gastroenterol 
2008, 14 (41), 6318-26. 
 
 
58 
 
Chapter 2: Proghrelin and C-ghrelin: Expression, purification and 
structural analysis 
 
The work presented in this chapter is unpublished. In this chapter, there was experimental 
contribution from Carlos A. Castañeda (Syracuse University), performed the nuclear magnetic 
resonance analysis and interpretation for structural characterization of proghrelin.  
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2.1 Introduction 
 
Following the initial discovery of GOAT and its role in ghrelin maturation,
 1-2
 there was 
interest in the mechanism by which this enzyme modifies its biological substrate proghrelin.
3
 In 
a second study from the Brown and Goldstein laboratory following their initial discovery of 
GOAT,
 2
 recombinantly expressed mouse proghrelin-His8 was utilized for GOAT octanoylation 
assays. They used a GST-TEV-mouse-proghrelin-His8 fusion construct to express the gene in E. 
coli.
 3
 It was purified using glutathione-agarose beads and proghrelin-His8 was liberated using a 
TEV protease. After the TEV cleavage; nickel affinity chromatography, dialysis, and 
concentration were all used to yield purified proghrelin-His8.
3
 Their substrate selectivity studies 
used proghrelin-His8 to study GOAT octanoylation by incubating recombinantly expressed 
proghrelin-His8 with mouse GOAT (mGOAT)-containing membrane fraction in the presence of 
[
3
H]octanoyl-CoA.
3
 Following the octanoylation reaction, the proghrelin-His8 was isolated 
utilizing nickel-coated beads and octanoylation was detected by liquid scintillation counting.
3
 
This study was the first instance of recombinant expression and purification of mouse proghrelin. 
This investigation also focused on the N-terminal region and alanine mutations and looked at no 
other factors influencing proghrelin GOAT interactions.
3
 Subsequent studies used small peptides 
to investigate GOAT octanoylation, with the longest sequence being full-length ghrelin (1-28), 
with the first five N-terminal amino acids to be the predominant motif for GOAT recognition.
4-7
 
In contrast, the C-terminal sequence of proghrelin or the full-length protein has not been 
extensively studied.  
Moving forward from biochemical and functional studies, there has been no investigation 
into the structure of full-length proghrelin but a small number into the hormones produced from 
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proghrelin, ghrelin and obestatin.
8-10
 After the initial discovery of ghrelin, there was investigation 
into the necessary recognition motifs of acylated ghrelin to its cognate receptor GHS-R1a.
11
 
Knowing the requirements for receptor binding was of interest since GHS-R1a recognition is 
necessary for ghrelin’s biological effects.11-14 There have been two studies using molecular 
dynamics to investigate ghrelin’s structure in relation to its receptor. 15-16 Their studies indicated 
that ghrelin (acylated) has secondary structural in the form of an alpha helix from residues P7 to 
E17 and a backwards folding loop from E17 to K20. This helix was present in either simply 
water or when a lipid membrane was introduced.
15-16
 There was also a conclusion that the 
octanoylated S3 and residue F4 form a rigid structure that acts as an anchor in the plasma 
membrane.
15-16
 To study the environment of the GHS-R1a located in the plasma membrane and 
its relation to ghrelin structure, further structural studies employing circular dichroism (CD) used 
the addition of sodium dodecyl sulfate (SDS) micelles and trifluoroethanol (TFE) which act to 
induce structure in proteins.
15
 For both desacyl and acylated ghrelin, the presence of SDS or TFE 
lead to the formation of an alpha helix from P7 to S18.
17
 There has also been investigation into 
the secondary structure of desacyl and acylated ghrelin using 
1
H NMR (nuclear magnetic 
resonance) to identify structural features.
17-20
 Using CD and NMR there was a similar structure 
found in previous studies, in which they concluded that there is formation of a small alpha helix 
between P7 and Q14 only if SDS (40-80 mM, CMC for SDS is 7-10 mM) or a structure-
stabilizing agent such as hexafluoroacetone (HFA) (25-80% v/v) was present.
18
 There was no 
concentration dependence of SDS in relation to ghrelin structure but there was concentration 
dependency in relation with HFA addition.
18
 Based upon these analytical methods and structural 
modeling, there was a conclusion that there is a small helical core in ghrelin in the presence of 
lipids (structural agents) but it is a mostly flexible peptide that goes through multiple 
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conformations.
20
 In juxtaposition to the previously reported studies which used the addition of 
structuring agents, CD spectra were measured for both acylated ghrelin (1-28) and acylated 
ghrelin (1-5), in a purely aqueous environment. Both ghrelin sequences exhibited features 
consistent with random coil conformation and lack of a defined secondary structure.
19
 This data 
was supported by 
1
H NMR studies indicating a lack of structure present in acylated ghrelin. 
Further analysis using 2D NMR, TOCSY (total correlation spectroscopy) and NOESY (nuclear 
Overhauser effect spectroscopy), demonstrated that the chemical shifts were not greatly 
dispersed which indicates that both desacyl and acylated ghrelin are mostly random coil and 
unstructured.
19
 These studies were all non-buffered and in an aqueous solution in the absence of 
any lipids or detergent. The sample environment could impact any potential structural elements 
and is probably why these results are different from other published results. The structural 
investigation including the use of molecular dynamics, CD, and NMR conclude that ghrelin has a 
flexible structure that is random coil in an aqueous solution. This conformation changes when a 
membrane-like domain is present (including SDS) or a fluorinated structuring agent such as TFE 
or HFA. There was no indication that ghrelin’s structure impacted binding to its receptor but 
simulations with GOAT or implication to GOAT-ghrelin binding was not evaluated in any study.  
The interest in obestatin and the initial evidence that it plays a role in human health 
motivated structural studies of this peptide.
21-23
 Similar to ghrelin, CD spectra of obestatin in 
pure water indicates that is little secondary structure is present.
23
 When TFE, up to 70%, was 
added there was some formation of helical characteristics.
23
 NMR analysis of obestatin using the 
fingerprint region of NOESY (correlations between backbone NH signals and backbone CHa 
signals) in the presence of 33% TFE showed secondary structure, mainly single turn helix 
conformation between residues P4 and Q15 and H19 and A22 respectively.
23
 The majority of the 
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secondary structural elements were mapped in the C-terminal half of this 23 amino acid peptide 
from peak shifts during NMR analysis, with the first 10 residues having no structural 
characteristics.  Other studies of obestatin (or obestatin (11-23)) structure included lipids solution 
with obestatin based on the hypothesis that contact with a membrane or membrane-like 
lipid/detergent aggregate was essential for obestatin structure formation.
21-22, 24
 This model was 
supported by circular dichroism studies with detection of secondary structure (alpha helix) in the 
presence of SDS that was not observed in buffer alone.
21-22
 In NMR studies, inclusion of lipids 
resulted in peak dispersion reflecting the presence of stable secondary structure (alpha helix) 
with both TOCSY and NOESY.
21
 Chemical shift values from this study agree with previously 
mentioned ones that indicated that a majority of peaks associated with secondary structure were 
present in the C-terminal region of obestatin.   
In contrast to ghrelin and obestatin as described above, there has been a limited effort to 
further explore the potential for proghrelin structure to impact proghrelin recognition, binding 
and modification by GOAT. The study of human proghrelin and human GOAT has more 
therapeutic and biological relevancy since the goal of any work is to relate it to human subjects. 
The only characterization of GOAT’s substrate has been in its mouse form. Sequence alignment 
between mouse and human proghrelin showed that they share 86% conservation and 100% 
similarity (Figure 2.1), differences mainly arriving from differences in their C-terminal portions. 
Characterizing the structure of human proghrelin is crucial to understanding the enzyme-
substrate relationship between proghrelin and GOAT, which will inform inhibitor design and aid 
in the identification of potential substrate-enzyme contact points outside of the active site.  
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Figure 2.1. Human and mouse proghrelin (1-94) protein sequence alignment. Sequence 
alignment was done using Clustal W. Stars under the sequences indicate the residue is conserved 
across the two species, gaps indicate that the residue is not conserved. 
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2.2 Results  
2.2.1 Human proghrelin expression system 
 
To facilitate structural and functional investigations of human proghrelin, a bacterial 
expression system was designed for expressing proghrelin in the context of a fusion protein 
construct. The proghrelin gene was designed to include an N-terminal Glutathione S-transferase 
tag (GST-tag) to improve solubility and provide the capability for GST affinity purification, a 
TEV protease site for removal of GST from proghrelin, and a C-terminal His6 tag for affinity 
purification and Western blotting.
25
 This gene design mirrors the proghrelin expression system 
that Yang and coworkers used to express mouse proghrelin in their studies.
2-3
 The complete 
fusion protein encoded by the GThPH (GST-TEV-human Proghrelin-His6) gene would be 328 
amino acids (38.02 kDa), with TEV cleavage liberating the 100- amino acid proghrelin-His6 
(11.3 kDa). The gene insert was synthesized commercially (Genewiz) and provided in a pUC57 
vector, with the GThPH insert then subcloned into the pET23a plasmid for protein expression 
using BL21 (DE3) E. coli.
26
 In a similar effort to explore the impact of the processing products 
of proghrelin, a gene construct for the C-terminal portion of proghrelin, which remains following 
ghrelin excision (C-ghrelin), was designed with the same affinity tags as proghrelin.  This gene 
used the same parent plasmid, GThPH, with an enzymatic restriction site inserted so C-ghrelin 
could be inserted and ligated. The GThCgH (GST-TEV-human C-ghrelin-His6) gene would be 
303 amino acids (35.1 kDa), with TEV cleavage liberating a 74 amino acid (including 2 extra 
amino acids added during HINDIII restriction site insertion) C-ghrelin-His6 (8.3 kDa).  
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2.2.2 Induction method optimization for proghrelin-His6 
 
The classical method for protein expression using the T7-lac induction system uses a 
lactose analog, isopropyl β-D-1-thiogalactopyranoside (IPTG), to induce gene expression.27 
When IPTG induction (0.4 mM) was used to express GThPH (Figure 2.1A) there was protein 
detected during lysis only in the presence of a denaturing lysis buffer (3XSB, 3X SDS sample 
buffer, which shows full protein content of the cell) instead of in the non-denaturing lysis buffer 
(BPER (Thermo scientific), bacterial protein extraction reagent, which extracts only soluble 
protein during lysis). This result indicated that insoluble inclusion bodies had formed which 
often reflects protein misfolding and aggregation (Figure 2.2A). In light of insoluble GThPH 
expression with IPTG induction, protein expression using autoinduction media was explored to 
attempt to increase the production of soluble protein. Autoinduction media, which contains a 
mixture of glucose, glycerol and lactose, results in a more gradual induction of recombinant 
protein expression.
28
 When GThPH was expressed using this method in BL21 (DE3) E. coli, the 
fusion protein expressed was observed in the soluble protein fraction of the bacterial lysate 
(Figure 2.2B). Expression of GThPH was further confirmed with both Anti-GST and Anti-His 
Western blotting (Figure 2.3 A-B). There was the appearance of lower molecular weight proteins 
between 25-35 kDa which were GST-tagged, based upon the Anti-GST western blot (Figure 
2.3B). This behavior is likely the result of protein cleavage and is discussed in detail in Chapter 
3.  Optimization of the growth conditions including time, temperature and culture size all 
contributed to the level of protein expression observed.  
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Figure 2.2. Expression analysis of recombinantly expressed GThPH. A) Expression analysis 
of IPTG-induced GThPH. 1mL bacterial pellets from two growths were lysed using BPER 
reagent or 3XSB. The gel is 12% polyacrylamide. Lane 1, protein ladder (Thermo scientific); 
Lane 3, BPER lysis; Lane 5, BPER lysis of growth 2; Lane, 7 3XSB lysis; Lane 9, 3XSB lysis of 
growth 2. B) Autoinduction expression analysis of GThPH. 1mL bacterial pellets were lysed 
using BPER reagent or 3XSB from one growth. The gel is 12% polyacrylamide. Lane 1, pET23a 
lysed with B-PER; Lane 2, GThPH lysed with B-PER; Lane 3, protein ladder (Thermo 
scientific); Lane 4, GThPH lysed with 3XSB; Lane5, pET23a lysed with 3XSB.   
 
 
 
 
 
 
GThPH 
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Figure 2.3. Western blot analysis of recombinantly expressed GThPH.  A) Anti-His western 
of the autoinduction expression of GThPH. The membrane was blotted with Anti-His-HRP 
conjugated antibody. The gel is 12% polyacrylamide. Molecular weight marker is to the left of 
lane 1. Lane 1, BPER lysis 1x; Lane 2, BPER lysis 1/10x; Lane 3, BPER lysis 1/50x; Lane 4, 
BPER lysis 1/100x; Lane 6, 3X sample buffer lysis 1x; Lane 7, 3X sample buffer lysis 1/10x; 
Lane 8, 3X sample buffer 1/50x; Lane 9, 3X sample buffer lysis 1/100x.  B) Anti-GST western 
of the autoinduction expression of GThPH. The membrane was blotted with Anti-GST-HRP 
conjugated antibody. The gel is 12% polyacrylamide. Molecular weight marker is to the left of 
Lane 1. Lane 1, BPER lysis 1x; Lane 2, BPER lysis 1/10x; Lane 3, BPER lysis 1/50x; Lane 4, 
BPER lysis 1/100x; Lane 5, Space; Lane 6, 3XSB lysis 1x; Lane 7, 3XSB lysis 1/10x; Lane 8, 
3XSB 1/50x; Lane 9, 3XSB lysis 1/100x.   
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2.2.3 C-ghrelin insolubility utilizing autoinduction 
 
The efforts to induce GThCgH in the same manner as proghrelin (GThPH) did not yield 
soluble protein. When GThCgH was expressed using autoinduction media, very little soluble 
protein expression was observed with the majority of protein present in the insoluble fraction 
(Figure 2.4A). Further analysis of the cell pellet remaining after non-denaturing bacterial lysis 
indicated that the majority of GThCgH was in inclusion bodies (Figure 2.4B). This loss of 
soluble expression for GThCgH compared to the proghrelin construct GThPH was unexpected 
and potentially reflects differences in protein structure and an increase in instability between 
proghrelin and C-ghrelin.  Attempts to increase GThCgH solubility by autoinduction expression 
at a lower temperature were unsuccessful.  
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Figure 2.4. GThCgH autoinduction expression analysis. A) GThCgH autoinduction 
expression. 1mL bacterial pellets are lysed using BPER and 3X sample buffer, parental proteins 
are boxed in red. The gel is 12% polyacrylamide. Lane 1, protein ladder (Thermo scientific); 
Lane 2, pET23a BPER lysis; Lane 3, pET23a 3XSB lysis; Lane 4, GThPH BPER lysis; Lane 5, 
GThPH 3XSB lysis; Lane 6, GThCgH BPER lysis; Lane 7, GThCgH 3XSB lysis. B) GThCgH 
insoluble expression characterized. Bacterial pellets lysed using BPER reagent, the supernatant 
removed, and the pellet was subsequently lysed using 3XSB; to confirm insoluble behavior 
another pellet was lysed using only 3XSB. The gel is 12% polyacrylamide. Lane 1, protein 
ladder (Thermo scientific); Lane 2, GThCgH BPER lysed pellet; Lane 3, BPER’d pellet lysed 
using 3XSB; Lane 4, GThCgH 3XSB lysis; Lane 5, GThCgH BPER lysis vortex then 3X SDS 
sample buffer was added; Lane 7, GThPH BPER lysis.  
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2.2.4 C-ghrelin expression optimization 
 
As autoinduction methods were not efficient in producing soluble GThCgH (Figure 2.5), 
IPTG-based induction (0.4 mM IPTG) was explored for GThCgH expression using a 
temperature range used from 16-28 ⁰ C. A low but detectable level of soluble C-ghrelin 
expression was observed at 16 ⁰ C. To attempt to further increase the expression of soluble 
GThCgH, the expression host was changed from BL21 (DE3) E. coli to LEMO-21 E. coli, which 
have been shown to facilitate expression of insoluble proteins through concurrent induction of 
lysozyme expression using rhamnose induction.
29
 This change to another cell line as well as the 
optimization of time, temperature, and the concentration of rhamnose (1 mM was optimal) 
during protein induction lead to an increase in the yield of GThCgH expression.  
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Figure 2.5. IPTG induction of GThCgH expression. A) GThCgH expression analysis. 
Bacterial pellets of IPTG-induced cultures (0.4 mM IPTG) were lysed using BPER and 3XSB. 
The gel is 12% polyacrylamide. Lane 1, protein ladder (Thermo scientific); Lane 2, GThCgH 
3XSB lysis; Lane 3, GThCgH BPER lysis; Lane 5, pET23a 3XSB lysis; Lane 6, pET23a BPER 
lysis. B) Expression analysis Anti-GST western blot. Bacterial proteins were detected using an 
Anti-GST-HRP conjugated antibody. The gel is 12% polyacrylamide. Molecular weight marker 
is to the left of Lane 1.  Lane 1, GThCgH 3XSB lysis; Lane 2, GThCgH BPER lysis. C) 
Expression analysis Anti-His western blot. Bacterial proteins were detected using an Anti-His-
HRP conjugated antibody. Molecular weight marker is to the left of Lane 1.  The gel is 12% 
polyacrylamide. Molecular weight marker is to the left of Lane 1. Lane 1, GThCgH 3XSB lysis; 
Lane 2, GThCgH BPER lysis.   
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2.2.5 Purification method for proghrelin-His6 
2.2.5.1 Ni
2+
-Sepharose Purifications  
 
To obtain purified proghrelin-His6, an initial proposed scheme was to affinity purify 
GThPH from bacterial lysate, perform a TEV protease digestion, to cleave GST from GThPH, 
and affinity purify proghrelin-His6 away from GST and the TEV protease. The first method 
attempted to purify GThPH from bacterial lysate utilized the His6 tag present in the C-terminus 
of the protein. Following preparative-scale GThPH expression, the bacterial pellet was lysed by 
sonication and GThPH was purified from the bacterial lysate utilizing a HisTrap Fast Flow (FF) 
Ni
2+
-Sepharose High Performance column (GE). Purifications utilized two different elution 
methods, stepwise elution in which the elution starts at 20 mM imidazole and then directly 
increases to 250 mM imidazole and a gradient elution in which the elution starts at 20 mM 
imidazole and gradually increases over a given volume to 250 mM imidazole. The length of the 
gradient was modified from a short to a longer time course; however, none of these efforts 
improved the purity directly out of the lysate (Figure 2.6A). The stepwise elution resulted in 
better purity than the gradient elution, but there were still contaminant proteins that persisted 
throughout the initial Ni
2+
-IMAC purification. In the first attempts at purifying GThPH from 
bacterial lysate there were appearances of lower molecular weight proteins (proteins between 35-
25 kDa) in the sample which impeded homogeneity.  
Since there were a plethora of impurities present in the eluted fractions after Ni
2+
-
Sepharose column, another IMAC column was substituted to investigate whether it would 
improve purity. The Co
2+
-HiTrap TALON crude column (GE) yielded no improvement in 
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purification of GThPH using stepwise elution. In both cases, Ni
2+
-Sepharose and Co
2+
-Agarose 
based columns produced the same result heterogeneity in eluted fractions (Figure 2.6B).  
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Figure 2.6. FPLC purification of GThPH from bacterial lysate. A) Ni
2+
-IMAC FPLC 
purification. Bacterial lysate after sonciation was loaded onto a HisTrap FF column. Eluted 
fractions were collected from under the A280 peak using a Step-wise elution method. The gel is 
12% polyacrylamide. Lane1, protein ladder (Thermo scientific); Lane 2, Loaded crude lysate of 
GThPH; Lane 3, flow-through; Lane 4, wash with lysis buffer; Lane 5, fraction #10; Lane 6, 
fraction # 12; Lane 7, fraction #14; Lane 8, fraction #16; Lane 9, fraction #17; Lane 10, fraction 
#18;  Lane 11, fraction #20; Lane 12, fraction #22; Lane 13, fraction #24; Lane 14, fraction #26; 
Lane 15, fraction #30.  B) Co
2+
-HiTrap TALON (IMAC) FPLC purification. Bacterial lysate 
after sonication was loaded onto a Co
2+
-TALON column. Eluted fractions were collected from 
under the A280 peak using a Step-wise elution method. The gel is 12% polyacrylamide. Lane1, 
protein ladder (Thermo scientific); Lane 2, Loaded crude lysate of GThPH; Lane 3, flow-
through; Lane 4, wash with lysis buffer; Lane 5, fraction #24; Lane 6, fraction #25; Lane 7, 
fraction #26; Lane 8, fraction #27; Lane 9, fraction #28; Lane 10, fraction #29; Lane 11, fraction 
#30; Lane 12, fraction #31; Lane 13, fraction #32; Lane 14, fraction #33; Lane 15, fraction #34.  
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 The next step in the proghrelin-His6 purification was a TEV digestion using TEV-His6 
protease (prepared from bacterial lysate using a HisTrap FF Ni
2+
-Sepharose High Performance 
column (GE)) which cleaves the GST tag from GThPH yielding proghrelin-His6. Cleavage by 
TEV-His6 protease is observable via the loss of the parental GThPH band and the appearance of 
a 25 kDa band equivalent to GST and an approximately 12 kDa band which is proghrelin-His6 
(Figure 2.7A). The most efficient GThPH: TEV-His6 ratio was determined to be 2000:1, which 
was observed to digest completely over 48 hours (Figure 2.7B). However, a ratio of 
200:1(GThPH: TEV-His6 protease) was used throughout purifications since this ratio digested 
GThPH in a shorter time compared to a 2000:1 ratio and resulted in reduced lower molecular 
weight impurities. Western blot analysis confirmed TEV-His6 cleavage with production of 
cleavage products at the appropriate molecular weights, confirmation of the fragment containing 
the GST tag using an Anti-GST antibody and proghrelin-His6 and TEV-His6 detected using an 
Anti-His antibody. There was also a number of lower molecular weight protein bands observed 
in the digestion reaction which were not bound by either Anti-GST or Anti-His antibodies.  
Purification of the TEV digestion reaction utilizing a Ni
2+
-IMAC column should afford 
the two His6-tagged proteins in the reaction, proghrelin-His6 and TEV-His6. However, this 
second Ni
2+
-IMAC purification proved ineffective for generating the desired level of proghrelin-
His6 purity with the presence of lower molecular weight protein impurities (Figure 2.8).  
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Figure 2.7. TEV digestion analysis of GThPH A) TEV digestion of GThPH. GThPH after a 
Ni
2+
-IMAC purification was incubated with TEV-His6 protease and the digestion was analyzed. 
The 38 kDa band is GThPH, 26 kDa band is GST, and 12 kDa band is proghrelin-His6. The gel is 
12% polyacrylamide. Lane 1, protein ladder (Thermo scientific); Lane 3, GThPH without TEV 
protease; Lane 5, TEV protease; Lane 7, GThPH with TEV protease. B) TEV protease 
digestion of GThPH with varying reaction conditions. GThPH after a Ni
2+
-IMAC purification 
was incubated with TEV-His6 protease under varying conditions, GThPH: TEV ratio and time 
(hrs), rxn indicates reaction. The 38 kDa band is GThPH, 26 kDa band is GST, and 12 kDa band 
is proghrelin-His6. The gel is 12% polyacrylamide. Lane 1, protein ladder (Thermo scientific); 
Lane 2, GThPH without TEV; Lane 3, 200:1 rxn 24hrs (positive control); Lane 4, 400:1 rxn; 
24hrs; Lane 5, 400:1 rxn 72hrs; Lane 6, 600:1 rxn 72 hrs; Lane 7, 1000:1 48 hrs; Lane 8, 1000:1 
rxn 72hrs; Lane 9, 2000:1 rxn 48hrs; Lane 10, 2000:1 rxn 72hrs.  
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Figure 2.8. Ni
2+
-IMAC purification following TEV digestion of GThPH. The fusion protein 
GThPH (193 mg) was digested using TEV-His6 protease (1930 μg). After digestion the GThPH 
mixture was purified using Ni
2+
-IMAC column and fractions were collected from the second 
A280 peak using a step-wise elution method. The gel is 15% polyacrylamide. Lane 1, protein 
ladder (Thermo scientific); Lane 2, Fraction # 17; Lane 3 Fraction #18; Lane 4, Fraction #19; 
Lane 5, Fraction #20; Lane 6, Fraction #21; Lane 7, Fraction #22; Lane 8, Fraction #23; Lane 9, 
Fraction #24; Lane 10, Fraction #25; Lane 11, Fraction # 26; Lane 12, Fraction #27; Lane 13, 
Fraction # 28.  
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2.2.5.2 Proghrelin purity improved after GST-Sepharose added to purification 
 
In light of this lack of homogeneity, the purification procedure for GThPH and 
proghrelin-His6 was redesigned by introducing a GST affinity purification step using a GSTrap 
FF (fast flow) High Performance GST-Sepharose affinity column (GE) into the purification, as 
well as the introduction of a GST-tagged TEV-His6 protease provided as a gift by Dr. Michael 
Cosgrove (SUNY Upstate Medical University). 
For GST affinity purification of GThPH, the same lysis procedure was used for GThPH 
from BL21 (DE3) E. coli  as was described above, followed by purification using a GST-
Sepharose column which utilizes the attraction of the GST-tag to immobilized glutathione. The 
GThPH fusion protein was effectively enriched from the cell lysate using the GST-Sepharose 
column (Figure 2.9A).  This method was optimized using a gradient-based elution and 
glutathione as the competitor, with flow rate is much lower compared to a HisTrap FF column 
(0.5 mL/min compared to 5 mL/min) and sample/volume size are markedly larger since the 
binding kinetics appeared slower with GST-Sepharose compared to Ni
2+
-Sepharose resin. 
Compared to purification using the His6 tag, GST affinity purification as the first step of the 
purification method markedly increased the purity of the protein sample from bacterial lysate. 
Following the GSTrap purification, TEV protease digestion was performed using a GST-TEV-
His6 protease which allows for removal of both the cleaved GST tag and GST-TEV-His6 
protease by another GST-Sepharose column. However, this second GST-Sepharose column was 
inefficient in depleting sufficient GST-containing from the digestion reaction to allow the desired 
level of purification of proghrelin-His6.  
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With tandem GST affinity purifications proving ineffective, the His6 affinity tag of 
proghrelin-His6 provides an orthogonal affinity purification option for post-digestion purification 
of proghrelin-His6. The GST-TEV-His6 protease, as well as, the GST cleavage products all lack a 
metal affinity tag making it was less likely that these proteins would be retained on the Ni
2+
-
IMAC column. After digestion with the GST-TEV-His6 protease, the digestion reaction was 
purified using a Ni
2+
-IMAC column. The eluted fractions containing proghrelin-His6 were 
depleted of GST-containing proteins and an overall improvement in proteins purity was obtained 
compared to previous approaches (Figure 2.9B). However, the small molecular weight protein 
impurities persisted through the Ni
2+
-IMAC purification. The molecular weight differences 
between the protein impurities and proghrelin-His6 suggest that size exclusion chromatography 
would serve as an appropriate final purification step. Size exclusion chromatography (SEC) was 
integrated into the procedure to obtain purified proghrelin-His6. 
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Figure 2.9. GThPH purification using tandem GST and His6 affinity purifications. A) 
FPLC fractions from gradient purification of GThPH using a GSTrap FF column. Bacterial 
pellet was lysed using sonication and loaded onto a GSTrap FF column. Fractions were collected 
from the A280 peak using a gradient elution method. The gel is 12% polyacrylamide. Lane1, 
protein ladder (Thermo scientific); Lane 2, crude lysate of GThPH; Lane 3, flow-through;  Lane 
4, fraction #12; Lane 5 fraction #13; Lane 6, fraction #17; Lane 7, fraction # 18; Lane 8, fraction 
#19; Lane 9, fraction #20 Lane 10, fraction #22; Lane 11, fraction #24; Lane 12, fraction #25; 
Lane 13 fraction #26; Lane 14, fraction #30; Lane 15, fraction #40. B) FPLC fractions from 
gradient purification of GThPH TEV digestion using a HisTrap FF column following TEV 
digestion. The TEV digestion was loaded onto a HisTrap FF column. Fractions were collected 
from the A280 peak using a step-wise elution method. The gel is 15% polyacrylamide. Lane1, 
protein ladder (Thermo scientific); Lane 2, TEV digest of GThPH; Lane 3,column flow-through; 
Lane 4, fraction #2; Lane 5, fraction #4; Lane 6, fraction #6;  Lane 7, fraction # 7; Lane 8, 
fraction # 8; Lane 9, fraction # 9; Lane 10, fraction #10; Lane 11, fraction # 12; Lane 12, fraction 
# 14; Lane 13, fraction # 15; Lane 14, fraction # 16; Lane 15, fraction # 17.  
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2.2.5.3 Size exclusion chromatography affords purified proghrelin-His6 
 
Incorporation of size exclusion chromatography (SEC) using either a HiLoad 16/60 
Superdex 75 or a HiPrep 16/60 Sephacryl S-100 HR size exclusion column (GE) dramatically 
improved the purity of proghrelin-His6 and yielded homogeneous proghrelin-His6 (Figure 2.10). 
To maximize proghrelin-His6 yield and minimize degradation/cleavage leading to lower 
molecular weight impurities, the complete purification protocol (bacterial cell lysis, GST-
Sepharose column, TEV digestion, Ni
2+
-IMAC column, size exclusion chromatography, 
proghrelin-His6 concentration) was completed in the minimal time possible (roughly 26-30 
hours). Delays in completing the purification protocol were found to increase the amount of 
lower-molecular weight bands which impacted the efficiency of the SEC purification. Over 
several purifications, it was also found that avoiding free-thaw cycles during and after the 
purification, concentrating the samples quickly, and protein lyophilization as soon as possible 
reduced the appearance of the lower molecular weight impurities.  
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Figure 2.10. Size exclusion chromatography purification of proghelin-His6 using a 
HiLoad16/60 Superdex 75pg size exclusion column. Fractions from the HisTrap FF column in 
Figure 2.9B were pooled and loaded onto a HiLoad16/60 Superdex 75pg size exclusion column. 
Fractions were collected from the A280 peak(s). The gel is 15% polyacrylamide. Lane 1, protein 
ladder (Thermo scientific); Lane 2, Loaded nickel column concentrate; Lane 3, Fraction #7; Lane 
4, Fraction #10; Lane 5, Fraction #12; Lane 6, Fraction #14; Lane 7, Fraction #16; Lane 8, 
Fraction #18; Lane 9, Fraction #20; Lane 10, Fraction #22; Lane 11, Fraction #24; Lane 12, 
Fraction #25; Lane 13, Fraction #26; Lane 14, Fraction #29; Lane 15, Fraction #30.  
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2.2.6 Purification approaches for C-ghrelin 
2.2.6.1 Ni
2+
-Sepharose based purifications 
 
As mentioned previously, C-ghrelin in the construct GThCgH initially expressed as an 
insoluble protein but with expression optimization soluble expression of this protein was 
improved. Prior to exploring IPTG-based induction, GThCgH from expression in autoinduction 
media was purified under denaturing conditions using Ni
2+
-IMAC resin by batch purification 
rather than flow purification described for GThPH. This purification method uses the presence of 
urea and guanidine hydrochloride (GuHCl) throughout the purification to increase the solubility 
of protein that express as insoluble aggregates. The purification of GThCgH under these 
conditions led to protein enrichment from bacterial lysate with little appearance of other 
impurities. However, during refolding following purification where the concentration of GuHCl 
is lowered, the GThCgH protein denatured and formed an insoluble aggregate in solution with 
less than 500 mM GuHCl present. A variety of approaches for protein refolding were attempted, 
including gradient elution with stepping down of denaturant concentration and step-wise dialysis, 
but none of these approaches improved the production of soluble GThCgH. Given these 
limitations, we investigated the efficiency of TEV digestion in the presence of sufficient GuHCl 
to allow GThCgH solubilization, but TEV digestion was not able to proceed under these 
conditions with little to no evidence of GST cleavage (similar to Figure 2.12). Since, GThCgH 
was unable to be purified successfully and solublely using this method, it was abandoned when 
the final expression optimization using LEMO-21 E. coli cells were used. 
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2.2.6.2 C-ghrelin purification using established GThPH protocol 
 
GThCgH was expressed under conditions described above using IPTG-based induction 
(0.4 mM IPTG) in LEMO-21 E. coli and then initially purified in the exact same manner as 
GThCgH using GST-Sepharose FPLC purification. In the analysis of the eluted fractions from 
this purification, the banding pattern mirrored what was observed during GThPH purification but 
with the corresponding mass differences (Figure 2.11). This was both encouraging and also 
interesting, as this indicates that both proteins show the same cleavage/banding pattern after lysis 
and column purification with their similarity located in the C-terminal ghrelin sequence. 
Following GST affinity purification, GThCgH was subjected to TEV protease digestion using 
the same procedure as with GThPH. However, the GST-TEV-His6 protease was unable to cleave 
GST from GThCgH (Figure 2.12). The lack of cleavage using TEV protease blocks the 
generation and purification of C-ghrelin-His6, and subsequent studies of C-ghrelin utilized the 
non-proteolyzed GThCgH fusion protein.  
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Figure 2.11. GST-Sepharose FPLC purification of GThCgH. A bacterial pellet was lysed 
using sonciation and was loaded onto a GSTrap FF column. Fractions were collected under the 
A280 peak from gradient elution method. The gel is 12% polyacrylamide.  Lane1, protein ladder 
(Thermo scientific); Lane 2, crude lysate of GThCgH; Lane 3, column flow-through; Lane 4, 
fraction #12; Lane 5, fraction #14; Lane 6, fraction #17; Lane 7, fraction #18; Lane 8, fraction 
#19; Lane 9, fraction #20; Lane 10, fraction #22; Lane 11, fraction #23; Lane 12, fraction #24; 
Lane 13, fraction #22; Lane 14, fraction #26; Lane 15, fraction #40.  
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Figure 2.12 TEV protease is unable to cleave C-ghrelin from GThCgH. The eluted fractions 
from Figure 2.11 were pooled and GST-TEV-His6 protease was added and the digestion was 
allowed to proceed. The digestion was then loaded onto a HisTrap FF column. Fractions were 
collected from the A280 peak using a step-wise elution method. Compare lanes 2 and 3 to see the 
inability of the TEV protease to digest GThCgH. The gel is 12% polyacrylamide. Lane1, protein 
ladder (Thermo scientific); Lane 2, GThCgH in absence of GST-TEV-His6 protease ; Lane 3, 
GThCgH in presence of GST-TEV-His6 protease; Lane 4, fraction #4; Lane 5, fraction #5; Lane 
6, fraction # 6; Lane 7, fraction #7; Lane 8, fraction #8; Lane 9, fraction #9; Lane 10, fraction 
#10; Lane 11, fraction #11; Lane 12, fraction #12; Lane 13, fraction #13; Lane 14, fraction #14; 
Lane 15, fraction #15. 
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2.2.7 Analysis of purified proghrelin-His6 
 
The product of purification of GThPH, proghrelin-His6, was confirmed with by a variety 
of methods. Anti-His Western blot analysis confirm the presence of the C-terminal His6 tag on a 
protein of appropriate molecular weight (Figure 2.13). Analysis of purified proghrelin-His6 by 
gel electrophoresis followed by both Coomassie and silver staining confirmed purification to 
>95% purity (Figure 2.14).
30
 The mass of purified proghrelin-His6 was verified by mass 
spectrometry with a Thermo LTQ Orbitrap mass spectrometer spectrum as representative data 
(Figure 2.15 and 2.16). All analytical data are consistent with purification of proghrelin-His6 to 
homogeneity.  
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Figure 2.13. Anti-His Western Blot of purified proghrelin-His6. After size exclusion 
chromatography fractions were pooled and concentrated. A purified sample of proghrelin-His6 
was run on an SDS-PAGE gel and detected using an Anti-His-HRP conjugated antibody. The gel is 
15% polyacrylamide. The molecular weight marker is indicated to the left of lane 1. Lane 2 
contains the proghrelin-His6 sample. 
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Figure 2.14. Verification of proghrelin-His6 using silver staining of purified proghrelin. 
After size exclusion chromatography eluted fractions were pooled and concentrated, and diluted 
to either 1:5 or 1:10 for gel loading. A 15% polyacrylamide gel, the gel was subjected to gel 
electrophoresis and then silver stained using manufacturer’s specifications (Bio Rad). Lane 1, 
protein ladder (Thermo scientific); Lane 2, proghrelin-His6; Lane 4, proghrelin-His6 1:5 dilution; 
Lane 6, proghrelin-His6 1:10 dilution.
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Figure 2.15. Verification of proghrelin-His6 mass by ESI-MS (monoisotopic). The spectrum 
was obtained utilizing Monoisotopic analysis using a Thermo LTQ Orbitrap mass spectrometer. 
Monoisotopic spectrum for proghrelin-His6.  
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Figure 2.16. Verification of proghrelin-His6 mass by ESI-MS (isotopic envelope). The 
spectrum was obtained utilizing Extracted Isotopic Envelope analysis using a Thermo LTQ 
Orbitrap mass spectrometer. Extracted isotopic envelope spectrum for proghrelin-His6. 
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2.2.8 Circular dichroism analysis of proghrelin-His6  
 
Circular dichroism (CD) of obestatin and ghrelin peptides has been used to study their 
structure in aqueous buffers and also in micelle and detergent solutions.
15-21, 23-24
 To commence 
the investigation of potential secondary structure within human proghrelin, the circular dichroism 
spectrum of proghrelin was measured under a variety of conditions including different buffers 
and detergents.  
2.2.8.1 pH and buffer effects on proghrelin CD spectrum 
 
Initial investigations of the proghrelin CD included buffer pH and buffer composition 
optimization. There was no observed effect of pH in 25 mM phosphate buffer (ranging from pH 
of 5.5 to 7.3) on the secondary structure of proghrelin structure as monitored by CD (Figure 
2.17). Two other buffers were explored for CD measurements, 25 mM Tris-HCl (2-amino-2-
(hydroxymethyl)propane-1,3-diol) and 50 mM HEPES ((4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid)), with buffer pH maintained at 7.3. Compared to phosphate 
buffer, 25 mM Tris-HCl (pH 7.3) enhanced formation of secondary structure (alpha helix) 
compared to either 25 mM phosphate buffer or 50 mM HEPES as reflected by a ~2-3-fold 
enhancement of ellipticity at 222 nm (Figure 2.19A). Increased background signal and an 
associated decrease in signal to noise ratio in the presence of 50 mM HEPES buffer rendered this 
buffer non-useful for further CD studies. The proghrelin concentration dependence was also 
determined, with 20 and 40 μM proghrelin providing similar CD spectra (Figure 2.18). 
Accordingly, 20 μM proghrelin was used in subsequent analyses. 
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Figure 2.17. pH dependence of proghrelin-His6 CD spectrum in 25 mM phosphate buffer. 
Proghrelin samples (40 μM) were prepared in 300 μL of 25 mM Na2HPO4/NaH2PO4 containing 1 
mM EDTA. Spectra were collected over the range 200-260 nm. Pathlength of the quartz cuvette 
was 0.1 cm and three accumulations were collected for each spectrum. 
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Figure 2.18. Concentration dependence of proghrelin-His6 CD spectrum in 25 mM 
phosphate buffer. Starting proghrelin sample (50 μM) were prepared in 300 μL of 25 mM 
Na2HPO4/NaH2PO4 then subsequently diluted for 40 and 20 μM. Spectra were collected over the 
range 200-260 nm. Pathlength of the quartz cuvette was 0.1 cm and three accumulations were 
collected for each spectrum. 
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2.2.8.2 Proghrelin secondary structure enhancement with detergents  
 
CD spectra of proghrelin suggest the presence of alpha helical structure in buffer alone. 
Based on literature reports that detergents such as SDS can enhance secondary structure in 
obestatin and ghrelin, 
15-16, 18, 20-21
 the CD spectra of proghrelin was examined in the presence of 
detergents to determine if similar enhancement of secondary structure is observed. A titration of 
SDS in either 25 mM phosphate or 25 mM Tris-HCl buffer led to an increase in helical character 
as reflected by increased ellipticity at 222 nm (Figure 2.19B). The increase in ellipticity reaches 
a maximum concentration at 2 mM SDS in 25 mM phosphate buffer and 1 mM SDS in 25 mM 
Tris-HCl, which compares favorably to the concentration of 2.8 mM SDS used in studies on 
obestatin
21
 and lies below the critical micelle concentration for SDS (7-10 mM). This behavior 
indicates that the detergent is stabilizing formation of secondary structure within proghrelin. A 
number of non-ionic detergents ((3-((3-cholamidopropyl) dimethylammonio)-1-
propanesulfonate) (CHAPS), octa-β-D –glucopyranoside (OBD), n-decyl-β-D-maltoside (DM), 
Tergitol and Triton X-100) were also examined for their ability to enhance the secondary 
structure of proghrelin as well as investigate more physiological detergents. All of these 
detergents were added at 0.1 and 1 mM, modeled from the SDS titration (Figure 2.20). Of the 
non-ionic detergents, Triton X-100 exhibited the largest increase in proghrelin secondary 
structure. In comparison between Triton X-100 and SDS, SDS was the better choice to aide in 
the secondary structure in both 25 mM phosphate buffer and Tris-HCl.  
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Figure 2.19. Impact of SDS on the CD spectrum of proghrelin-His6. Proghrelin-His6 samples 
(20 μM) were prepared in 300 μL of 25 mM Na2HPO4/NaH2PO4 or 25mM Tris-HCl. A) CD 
spectra spectra of proghrelin-His6 in 25 mM phosphate and 25 mM Tris-HCl buffer in the 
absence and presence of 1 mM SDS. B) The dependence of ellipticity at 222 nm on SDS 
concentration (0, 0.1, 0.5, 1, 2, and 3 mM SDS) in 25 mM phosphate and Tris-HCl buffer. 
Spectra were collected over the range 200-260 nm. Pathlength of the quartz cuvette was 0.1 cm 
and three accumulations were collected for each spectrum. 
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Figure 2.20. Impact of detergents on the CD spectra of proghrelin-His6. Proghrelin-His6 
samples (40 μM) were prepared in 300 μL of 25 mM Na2HPO4/NaH2PO4. The signals were 
buffer corrected and then delta ellipticity was calculated by subtracting the 0 mM detergent point 
signal at 222 nm from either the 0.1 or 1 mM detergent signal at 222 nm. A positive delta 
ellipticity indicates that there is more secondary structure present. Spectra were collected over 
the range 200-260 nm. Pathlength of the quartz cuvette was 0.1 cm and three accumulations were 
collected for each spectrum. 
 
98 
 
 
2.2.8.3 Comparison of ghrelin and proghrelin isolates the secondary structure contribution 
of C-ghrelin 
 
Ghrelin structural studies indicate that ghrelin is very flexible and there is little to no 
secondary structure present, 
19-20
 suggesting that the secondary structure observed in proghrelin 
can be localized to the C-terminal region of the ghrelin precursor. The relative contribution of C-
ghrelin, not just obestatin, compared to ghrelin is important to identify the residues involved in 
alpha helix formation. A circular dichroism spectrum of ghrelin shows no evidence for secondary 
structure which is consistent with the previously reported data (Figure 2.21).
19-20
 However, when 
comparison of ellipticity per residue for proghrelin and ghrelin indicates that the mean residue 
ellipticity is nearly identical between these two proteins (Figure 2.21B). This is consistent with 
the secondary structure within proghrelin not spread equally across the protein and instead 
involving a small number of residues, most likely in the C-terminus of proghrelin.  
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Figure 2.21. Comparison of CD spectra between ghrelin and proghrelin in aqueous 
environment. Ghrelin and proghrelin samples (20 μM) were prepared in 300 μL of 25 mM 
Na2HPO4/NaH2PO4 (proghrelin) or water (ghrelin). A) CD spectra of proghrelin (black) and 
ghrelin (purple) overlayed. B) Mean residue ellipticity comparison. Signal at 222 nm (absolute 
value) divided by the total number of amino acid residues (100 aa for proghrelin-His6, 28 aa for 
ghrelin). Spectra were collected over the range 200-260 nm. Pathlength of the quartz cuvet was 
0.1 cm and three accumulations were collected for each spectrum.  
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2.2.9 Nuclear magnetic resonance studies of proghrelin-His6 
 
The NMR analysis detailed below is with the assistance of Carlos A. Castañeda who ran 
the NMR experiments and helped to interpret the data obtained. Upon purification of proghrelin-
His6 a preliminary nuclear magnetic resonance study was completed using natural abundance 
1
H-
15
N SOFAST-HMQC to evaluate the potential for structural elements within proghrelin (Figure 
2.22). The NMR spectrum from this study showed multiple dispersed peaks suggesting the 
presence of folded secondary structure in proghrelin. To facilitate further NMR characterization 
of proghrelin structure,
 15N
 labeled proghrelin-His6 was expressed and purified. 
15
N labeled 
proghrelin-His6 was purified by the same protocol as unlabeled proghrelin-His6 (a GST-
Sepharose Fast Flow column, digestion using a GST- tagged TEV-His6 protease, a HisTrap Ni-
Sepharose High Performance column, and SEC using a HiLoad 16/60 Superdex 75 pg size 
exclusion column). Eluted proghrelin-His6 fractions were pooled and concentrated to a minimum 
concentration of 250-300 M for NMR studies. Initial NMR experiments included a pH-
dependence study at pH 7.3 and pH 5.5, with the lower pH slowing the hydrogen-deuterium 
exchange in the sample leading to enhancement of the NMR spectrum (Figure 2.23). 
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Figure 2.22. Natural abundance NMR of proghrelin-His6. Purified proghrelin (
14N) 300μM in 
20 mM NaH2PO4, 50mM Na Cl, 1mM TCEP and 1mM EDTA containing 5% D2O. The 
SOFAST experiment identifies interactions with 
1
H-
15
N backbone amides. The NMR experiment 
lasted 12-hours with 1024 scans and was run on an 800 MHz NMR. 
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pH 7.3 
pH 5.5 
Figure 2.23. pH dependence of proghrelin-His6 NMR spectrum. An HSQC spectrum was 
collected for 250 μM proghrelin in 20 mM NaH2PO4, 50 mM NaCl, 1mM TCEP and 1 mM 
EDTA containing 5% D2O at pH 7.3 (500 μL total volume), followed addition of 10 μL of 1 M 
HCl to drop the pH from 7.3 to 5.5.  The spectrum in green is pH 7.3, a spectrum in blue is pH 
5.5., and samples were analyzed on the 800 MHz NMR.   
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Subsequent efforts to pursue additional 2-D NMR analyses such as COSY and NOESY 
scans were handicapped by low levels of proghrelin-His6 expression. The amount of protein 
produced from 
15
N-labeling is decreased due to the minimal media used in these expressions to 
ensure that expressed protein is exclusively transcribed with 
15
N-containing amino acids. 
31
 
Extensive attempts to improve the expression of 
15
N-labeled GThPH, including changing culture 
volumes and 
15
NH4Cl concentration, were unsuccessful. Furthermore, this low level of 
proghrelin expression appeared to lead to a higher fraction of lower molecular weight impurities 
and consequently a lower amount of purified proghrelin. While these initial NMR studies of 
proghrelin are promising and supported the presence of secondary structure within proghrelin, 
the residues involved and overall molecular architecture remain to be determined.  
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2.3 Conclusions 
 
The expression and purification of GThPH and GThCgH resulted in varying patterns of 
protein expression, with GThPH exhibiting a high level of soluble expression while GThCgH 
required complete optimization in order to obtain a small quantity of soluble protein. In terms of 
expression and purification, these two fusion protein constructs exhibit very little similarity. This 
behavior is very interesting since the only difference between them consists of the 28 amino 
acids residues of the ghrelin sequence. Both constructs exhibited cleavage behavior during 
expression and purification, which will be explored in more detail in Chapter 3.  
Purification of proghrelin-His6 from the GThPH fusion protein was accomplished using a 
four-step purification process including two affinity purifications, a protease digestion, and a 
final size-exclusion purification step. However, subsequent to purification to homogeneity, the 
lower molecular weight impurities observed during purification of proghrelin reappear in 
purified fractions following incubation in solution. Since these lower molecular weight proteins 
were a constant partner to proghrelin-His6 from lysis through multiple column purifications, 
these proteins may result of self-cleavage or degradation of proghrelin itself. This behavior is 
unusual for proteins, but is intriguing and makes a possible case for C-terminal ghrelin 
processing. This cleavage behavior is discussed further in Chapter 3. To avoid formation of these 
lower molecular weight impurities, based on observations during repeated proghrelin 
purifications proghrelin was aliquoted to avoid freeze-thaw cycles, concentrated occurred 
directly after size exclusion chromatography, and the concentration of protein samples were kept 
below 100 M to avoid appearance of cleaved proghrelin-His6.  
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Studies of purified proghrelin-His6 using circular dichroism support the presence of alpha 
helical secondary structure in this small protein. Inclusion of detergents to proghrelin, 
specifically SDS, increases the secondary structure of the protein which is consistent with the 
literature.
15, 17, 20-21
 It was determined that detergents (especially SDS) enhance the secondary 
structure of proghrelin. The behavior demonstrated by this protein is of interest since proghrelin 
is located in the ER, is modified by an enzyme located in the ER membrane and then is 
trafficked and excreted via endosomes.
10
 This protein is in contact with lipids throughout its 
residence inside the cell and during processing, which could be necessary for secondary structure 
formation. Such structure formation could impact proghrelin recognition and acylation by GOAT 
through enzyme substrate interactions outside the N-terminal sequence of ghrelin that so far has 
been shown to be essential for modification by GOAT.
3, 5-6
  
The secondary structure within proghrelin appears to be localized within the C-terminal 
sequence of proghrelin by comparison of CD spectra for ghrelin and proghrelin. Investigations of 
ghrelin and obestatin’s secondary structure in the literature also supports this model, with ghrelin 
was shown to be mostly random coil but obestatin possessing more defined alpha helical 
character.
19-21
 It remains to be determined if the secondary structure in proghrelin is localized to 
the obestatin sequence or extends to other residues. 
NMR analysis of unlabeled proghrelin supports the presence of secondary structure 
suggested by circular dichroism. While these initial NMR experiments support further 
investigation into proghrelin structure, the yield of 
15
N proghrelin was not a high enough to 
support further NMR analysis. The low yielding expression also lead to higher appearance of 
lower molecular weight impurities and thus less homogeneous size exclusion chromatography 
fractions. All of these data are encouraging and interesting as to the secondary structure of 
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proghrelin and its implications in GOAT acylation and proghrelin processing. However, the 
exact residues and secondary structure of proghrelin has yet to be determined and is a future goal 
of this research.  
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2.4 Materials and Methods 
 
2.4.1 Transformation of pET23a/24a and pUC57-GST-TEV-proghrelin-His6 into DH5a E. 
coli. 200 ng of DNA was added to 100 μL of Z-competent DH5a E. coli and incubated for 30 
min on ice. The transformation mixture was then plated on prewarmed LB agar plates containing 
either ampicillin (100 μg/mL) or and kanamycin (50 μg/mL) as appropriate and incubated at 37 
ᵒC overnight (~17 hr). Two colonies were picked from each plate and inoculated into 5 mL 
cultures containing 1X LB (5 mL) and either ampicillin (100 μg/mL, pET23a) or kanamycin (50 
μg/mL, pET24a, pUC57). Cultures were incubated with shaking (225 rpm) at 37 ᵒC for 17 hr. 
Cultures were pelleted and purified using manufacturer’s specifications of EZ 10 spin column 
plasmid DNA gel extraction kit (Bio Basic Inc.).  
2.4.2 Analytical gel procedure. The uncut vector controls were performed under the following 
conditions: pUC57 (20 μL total volume), pUC57 (400 ng), NEB 10x Buffer 4 (2 μL), and 
ultrapure H2O; pET23a (20 μL total volume), pET23a (400 ng), NEB 10x Buffer 4 (2 μL), and 
ultrapure H2O. The single digest was performed under the following conditions: pUC57 (20 μL 
total volume), pUC57 (400 ng), NotI (0.5 μL, 10,000 units/mL) or NdeI (0.5 μL, 10,000 
units/mL), NEB 10x Buffer 4 (2 μL), and ultrapure H2O; pET23a (20 μL total volume), pET23a 
(400 ng), NotI (0.5 μL, 10,000 units/mL) or NdeI (.0.5 μL, 10,000 units/mL), NEB 10x Buffer 4 
(2 μL), and ultrapure H2O; pET24a (20 μL total volume ), pUC57 (400 ng), NotI (0.5 μL, 10,000 
units/mL) or NdeI (0.5 μL, 10,000 units/mL), NEB 10x Buffer 4 (2 μL), and ultrapure H2O. The 
double digest was performed under the following conditions: pUC57 (20 μL total volume ), 
pUC57 (400 ng), NotI (0.5 μL, 10,000 units/mL), NdeI (0.5 μL, 10,000 units/mL), NEB 10x 
Buffer 4 (2 μL), and ultrapure H2O; pET23a (20 μL total volume), pET23a (400 ng), NotI (0.5 
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μL, 10,000 units/mL), NdeI (0.5 μL, 10,000 units/mL), NEB 10x Buffer 4 (2 μL), and ultrapure 
H2O; pET24a (20 μL total volume ), pUC57 (400 ng), NotI (0.5 μL, 10,000 units/mL), NdeI (0.5 
μL, 10,000 units/mL), NEB 10x Buffer 4 (2 μL), and ultrapure H2O. Reactions were incubated 
for 2 hr at 37 ᵒC, followed by analysis and purification of the vector digestion by agarose gel 
electrophoresis (0.8% agarose, 1X TAE buffer); the size of the insert and linearized vector were 
verified by comparison to a DNA standards ladder (1kB PLUS ladder, GoldBio). 
2.4.3 Double digest procedure. pUC57 and pET vectors were digested with NotI and NdeI prior 
to ligation. The double digest reactions were performed under the following conditions: pUC57 
(30 μL total volume), pUC57 (2 μg), NotI (1 μL, 10,000 units/mL), NdeI (1 μL, 10,000 
units/mL), 100x BSA (0.3 μL), NEB 10x Buffer 4 (3 μL), and ultrapure H2O (14.7 μL); pET23a 
(60 μL total volume), pET23a (2 μg), NotI (1 μL, 10,000 units/mL), NdeI (1 μL, 10,000 
units/mL), 100x BSA (0.4 μL), NEB 10x Buffer 4 (4 μL), and ultrapure H2O (7.6 μL); pET24a 
(60 μL total volume), pET24a (2 μg), NotI (1 μL, 10,000 units/mL), NdeI (1 μL, 10,000 
units/mL), 100x BSA (0.4 μL), NEB 10x Buffer 4 (4 μL), and ultrapure H2O (4.6 μL). Reactions 
were incubated for 2 hr at 37 ᵒC, followed by analysis and purification of the vector digestion by 
agarose gel electrophoresis (0.8% agarose, 1X TAE buffer); the size of the insert and linearized 
vector were verified by comparison to a DNA standards ladder.  
2.4.4 Ligation of GST-TEV-proghrelin-His6 into pET24a and pET23a. Ligations were 
performed using a 1:3 molar ratio of vector to insert. Ligation reactions were performed under 
the following conditions: pET23a GThPH (21 μL total volume), NotI-NdeI double digested 
pET23a (50 ng), NotI-NdeI double digested pUC57 (41.9 ng), ultrapure H2O (6 μL), 2x Quick 
Ligase buffer (10 μL), and T4 Quick Ligase (New England Biolabs, 1 μL). Following addition of 
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Quick Ligase, reactions were incubated at room temperature for 5 min. Ligation mixtures (5 μL) 
were then transformed into a 50 μL aliquot of chemically competent Z-competent DH5α E.coli 
(Zymo Research) followed by incubation on ice for 30 min. Transformed bacteria were spread 
on a LB-ampicillin plate (100 μg/mL) for pET23a ligation and incubated at 37 ⁰ C overnight. 
Following overnight incubation at 37 ᵒC, single colonies were inoculated into LB media (5 mL) 
containing appropriate antibiotic in sterile culture tubes. These cultures were incubated overnight 
at 37 ᵒC with shaking (225 rpm). Following overnight growth, plasmids were purified from the 
saturated cultures using EZ-10 Spin Column Plasmid DNA kit (Bio Basic Inc.) per 
manufacturer’s instructions. Ligation was verified by double digestion with NotI and NdeI to 
excise the ligated insert followed by agarose gel electrophoresis and DNA sequencing (Genewiz 
Inc.).  
2.4.5 Transformation of ligated GThPH into Z-competent BL21(DE3) E. coli. Plasmid of 
pET23a GThPH was transformed into Z-competent BL21 (DE3) E. coli. Plasmids (100 ng) were 
transformed into a 100 μL aliquot of chemically competent Z-competent BL21 (DE3) cells 
(Zymo Research) followed by incubation on ice for 30 min. Transformed bacteria were spread 
on LB-ampicillin plates (100 μg/mL) and incubated at 37 ᵒC overnight.  
Following overnight incubation, single colonies were used plucked and a 5mL culture of 
LB media was grown for 4 hr at 37ᵒC then this was used to inoculate cultures of autoinduction 
media (1% tryptone, 0.5% yeast extract, 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 
mM Na2SO4, 2 mM MgSO4, 0.5% glycerol, 0.05% glucose, 0.2% α-D-lactose, and 100 μg/mL 
ampicillin). The shaken for 24 hr at 400 rpm at 28 °C. Following growth, bacteria were harvested 
by centrifugation (6000 x g, 15 min) and the supernatant removed. The bacterial pellet was 
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resuspended in B-PER lysis reagent (Thermo Scientific, 100 μL), vortexed on high for 1 min, 
and cell debris was removed by centrifugation (15,000 x g, 5 min). Proteins in the resulting 
supernatant were then analyzed 12% acrylamide gel electrophoresis and Coomassie staining.  
2.4.6 Auto-Induction media conditions. pET23a GThPH or pET23a GThCgH was transformed 
into Z-competent BL21 (DE3) E. coli cells. Plasmids (100 ng) were transformed into a 50 μL 
aliquot of chemically competent Z-competent BL21 (DE3) cells (Zymo Research) followed by 
incubation on ice for 30 min. Transformed bacteria were spread on LB-ampicillin plates (100 
μg/mL) and incubated at 37ᵒC overnight.  
Following overnight incubation, single colony was used to inoculate a 5 mL culture of 
LB media. The culture was shaken for 4 hr at 225 rpm at 37°C. The 5 mL culture was then 
inoculated into 1 L of autoinduction media (1% tryptone, 0.5% yeast extract, 25 mM Na2HPO4, 
25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 0.5% glycerol, 0.05% glucose, 
0.2% α-D-lactose, and 100 µg/mL ampicillin). The culture was shaken for 24 hr at 225 rpm at 
28°C. Following growth, bacteria were harvested by centrifugation (6000 x g, 15 min) and the 
supernatant removed. Four 1 mL bacterial pellets were also prepared from the larger culture. One 
of the 1 mL bacterial pellets was resuspended in BPER lysis reagent (Thermo Scientific, 150 
μL), vortexed on high for 1 min, and cell debris was removed by centrifugation (15,000 x g, 5 
min). A second 1 mL bacterial pellet was resuspended in 3XSB (Thermo Scientific, 50 μL), 
heated at 95 °C for 5 min, and cell debris was removed by centrifugation (15,000 x g, 5 min). 
Protein in the resulting supernatant were then analyzed 12% acrylamide gel electrophoresis and 
Coomassie staining.  
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2.4.7 IPTG induction growth conditions. Plasmid of pET23a+GThPH or pET23a+GThCgH 
was transformed into Z-competent BL21 (DE3) E. coli cells. Plasmids (100 ng) were 
transformed into a 50 μL aliquot of chemically competent Z-competent BL21 (DE3) E. coli cells 
(Zymo Research) followed by incubation on ice for 30 min. Transformed bacteria were spread 
on LB-ampicillin plates (100 μg/mL) and incubated at 37 ᵒC overnight.  
Following overnight incubation, single colony was used to inoculate a 5 mL culture of 
LB media. The culture was shaken for 4 hr at 225 rpm at 37 °C. The 5 mL culture was then 
inoculated into 1 L of IPTG base media (20 g/L tryptone, 10 g/L yeast extract, 5 g/L NaCl, 1% 
glucose, 100 μg/mL ampicillin) and shaken at 37 ᵒC 225 rpm until the culture reached an optical 
density at 600 nm of 0.6 then induced by addition of IPTG (0.4 mM), shake at 225 rpm (25 ⁰ C 
for GThPH, 16 °C for GThCgH) overnight (~16 hr). Following growth, bacteria were harvested 
by centrifugation (6000 x g, 15 min) and the supernatant removed. Four 1 mL bacterial pellets 
were also prepared from the larger culture. One of the 1 mL bacterial pellets was resuspended in 
B-PER lysis reagent (Thermo Scientific, 100 μL), vortexed on high for 1 min, and cell debris 
was removed by centrifugation (15,000 x g, 5 min). A second 1 mL bacterial pellet was 
resuspended in 3XSB (Thermo Scientific, 50 μL), heated at 95 °C for 5 min, and cell debris was 
removed by centrifugation (15,000 x g, 5 mins) Protein in the resulting supernatant were then 
analyzed 12% acrylamide gel electrophoresis and Coomassie staining.  
2.4.8 GThGgH IPTG induction using LEMO-21 E. coli cells growth conditions. Plasmid of 
pET23a GThCgH was transformed into LEMO 21 E. coli cells. Plasmids (100 ng) were 
transformed into a 50 μL aliquot of chemically competent Z-competent LEMO 21 E. coli cells 
(Zymo Research) followed by incubation on ice for 30 min. Transformed bacteria were spread 
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on LB-ampicillin/chloramphenicol plates (100 μg/mL, 30 μg/mL respectively) and incubated at 
37 ᵒC overnight.  
Following overnight incubation, single colony was used to inoculate a 5 mL culture of 
LB media. The culture was shaken for 16-18 hr at 225 rpm at 37 °C. The 5 mL culture was then 
inoculated into 300 mL of media Terrific broth (Bio Basic) containing 100 μg/mL ampicillin, 34 
μg/mL chloramphenicol and shaken at 37 ⁰ C 225 rpm until the culture reached an optical 
density at 600 nm of 0.6 then induced by addition of IPTG (0.4 mM) and rhamnose (1 mM), 
shake at 16 °C overnight (~17 hr). Following growth, bacteria were harvested by centrifugation 
(6000 x g, 15 min) and the supernatant removed. Four 1 mL bacterial pellets were also prepared 
from the larger culture. One of the 1 mL bacterial pellets was resuspended in B-PER lysis 
reagent (Thermo Scientific, 100 μL), vortexed on high for 1 min, and cell debris was removed by 
centrifugation (15,000 x g, 5 min). A second 1 mL bacterial pellet was resuspended in 3XSB 
(Thermo Scientific, 50 μL), heated at 95 °C for 5 min, and cell debris was removed by 
centrifugation (15,000 x g, 5 min) Protein in the resulting supernatant were then analyzed 12% 
polyacrylamide gel electrophoresis and Coomassie staining.  
2.4.9 SDS-PAGE analysis. 3XSB lysis was performed by using cell lysate (50 μL) was mixed 
with 25 μL of 3X SDS sample buffer and heated to 95 ⁰ C for 5 min, followed by centrifugation 
(10,000 x g, 5 min) to pellet insoluble material. B-PER lysis was performed using BPER lysis 
reagent (Thermo Scientific, 150 μL), vortexed on high for 1 min, and cell debris was removed by 
centrifugation (15,000 x g, 5 mins). 25 μL of 3XSB was added and heated to 95 ᵒC for 5 min, 
followed by centrifugation (10,000 x g, 5 min) to pellet insoluble material. Protein standards 
ladder (Thermo Scientific) and samples were loaded onto a 12% polyacrylamide gel and run at 
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150 V for 1 hr 30 min, until the dye band had migrated to the bottom of the gel. Total protein in 
cell lysate samples was visualized by staining with Coomassie Blue stain and imaged on a 
ChemiDoc XRS+ BioRad gel imager.  
2.4.10 Coomassie Blue staining procedure. Each 12% polyacrylamide gel was rinsed with ultra 
pure water and covered in approximately 50 mL of destain solution (stock: 2 L water, 1.6 L 
methanol, 0.4 L acetic acid). The gel was microwaved for 18 sec, at which point the destain 
solution was removed and approximately 50 mL of Coomassie blue stain was added (stock: 0.25 
g Coomassie Blue dye, 500 mL methanol, 75 mL acetic acid). The gel was microwaved for 30 
sec and rocked for 5 min. The stain solution was removed, destain solution was added and 
rocked for 15 min, followed by another round of destain addition and rocking for 15 min. The 
gel was then placed into ultra pure water rocked overnight. Protein gels were then imaged using 
BioRad XRS+ gel imager.  
2.4.11 Western blot procedure. Cell lysates were run on a 12% polyacrylamide gel as described 
above. A polyvinylidene fluoride (PVDF) membrane was activated by immersion in methanol 
for 30 seconds, followed by equilibration in transfer buffer (20% v/v methanol, 48 mM Tris 
Base, 39 mM glycine and 0.034% v/v SDS) for 10 min. Filter papers and sponges were also 
soaked in transfer buffer. The gel was assembled into a transfer cassette and proteins were 
transferred to the PVDF membrane for 20 min at 350 mA, using a BioRad TransBlot Turbo RTA 
Transfer kit per manufacturer’s instructions.  
Following electroblotting, the PVDF membrane was washed in tris buffered saline (TBS, 
0.05 M Tris and 0.14 M NaCl), TBST (TBS with 0.1% v/v Tween 20) and blocked for 4 hr in 
10% v/v nonfat milk in TBST. The membrane was then probed with an HRP-α-antiHis primary 
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antibody (1:500 dilution, Rockland) or HRP--α-antiGST primary antibody (1:500 dilution, 
Rockland) in 10% milk TBST under parafilm overnight. Following washing in TBST, the 
membrane was treated with the West Pico Chemiluminescent substrate imaging reagent (Thermo 
Scientific) and imaged on a ChemiDoc XRS+ BioRad gel documentation system. 
2.4.12 TEV digestion. TEV-His6 protease was expressed and purified using the pMHT238 –
TEV gp1 plasmid following a published procedure.
32
 For TEV cleavage of the GThPH fusion 
protein, initial reaction conditions were GThPH fusion protein (100 μg), TEV protease (10 µg) in 
120 uL total reaction volume at room temperature for 18 hr. The cleavage reaction was analyzed 
using SDS-PAGE, Coomassie staining and Western blotting (described above). A reaction time 
course was conducted using the same conditions using various time points (5min, 30 min, 1hr, 2 
hr, 3 hr, 4 hr, and 18 hr). Following time course analysis, new reaction conditions were 
investigated: 3hr at room temperature, 3hr at 34 ᵒC, 24 hr at room temperature, and 18 hr at 34 
ᵒC. Reaction analysis revealed that cleavage at 34 ᵒC for 24 hr as the optimal conditions. The 
reaction scale was increased to 11 mL for 48 mg GThPH protein, using the same conditions 
stated above. The reaction was then purified using FPLC purification. Following incorporation of 
GST-TEV-His6, TEV digestions proceeded using a 200:1 ratio of GThPH and TEV protease in 
300 mM NaCl, 50 mM Tris-HCl, 10 mM glutathione (GSTrap elution buffer) for 8-10 hr at 34 
ᵒC. After digestion the mixture was then purified using a HisTrap FF column (GE).  
2.4.13 TEV protease ratio reaction. The ratio of GThPH and TEV protease were varied per the 
following: A 193 mg TEV protease digest of GThPH fusion protein 100:1 ratio was performed 
using the following conditions: GThPH fusion protein (193 mg), TEV protease (1930 μg), DTT 
(1mM), and EDTA (0.5 mM, pH 7.8) in 2.2 mL reaction volume at 34 ᵒC for 18 hr. The 
115 
 
digestion reaction purified using FPLC gradient elution purification as described in 2.4.17 and 
analyzed using SDS-PAGE and Anti-His western. The fractions were combined, concentrated to 
a volume of 5mL and desalted using Tris-HCl (pH 7.3). A series of ratio reactions were 
performed using 200:1, 400:1, 600:1, 1000:1, 2000:1 ratios of GThPH to TEV protease. TEV 
protease digest of GThPH fusion protein 200:1 ratio using the following conditions: GThPH 
fusion protein (6 mg), TEV protease (30 μg), DTT (1 mM), and EDTA (0.5 mM, pH 7.8) in 1.12 
mL reaction volume at 34 ᵒC for 18 hr; 400:1 ratio using the following conditions: GThPH 
fusion protein (6 mg), TEV protease (15 μg), DTT (1 mM), and EDTA (0.5 mM, pH 7.8) in 1.12 
mL reaction volume at 34 ᵒC for 18 hr; 600:1 ratio using the following conditions: GThPH 
fusion protein (6 mg), TEV protease (10 μg), DTT (1 mM), and EDTA (0.5 mM, pH 7.8) in 1.12 
mL reaction volume at 34 ᵒC for 18 hr; 1000:1 ratio using the following conditions: GThPH 
fusion protein (6 mg), TEV protease (6 μg), DTT (1 mM), and EDTA (0.5 mM, pH 7.8) in 1.12 
mL reaction volume at 34 ᵒC for 18 hr; 2000:1 ratio using the following conditions: GThPH 
fusion protein (6 mg), TEV protease (3 μg), DTT (1 mM), and EDTA (0.5 mM, pH 7.8) in 1.12 
mL reaction volume at 34 ᵒC for 18 hr. Reactions were then analyzed by SDS-PAGE and 
Coomassie staining. The series of ratio reactions (200:1, 400:1, 600:1, 1000:1, and 2000:1) were 
repeated, however, a reaction time course was conducted using the same conditions using 
various time points (24, 48, and 72 hr). The longer reaction time was concluded to make no 
visible difference in the digest. 
2.4.14 Circular dichroism. Size- exclusion purified samples were pooled and then buffer 
exchanged into 25 mM Na2HPO4/NaH2PO4 or 25 mM Tris-HCl using 5 kDa molecular weight 
cutoff concentrators (SpinX UF, Corning, Corning, NY). Fractions were concentrated to ¼ of 
their initial volume, supplemented with buffer to original volume, spun down (2,500 x g, 4ᵒ C) to 
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¼ of the volume, repeated until three volumes worth of buffer have been added. After buffer 
exchanging an A280 was taken (ε=12490 M-1cm-1). CD solutions contained proghrelin-His6 (40 
μM or 20 μM). Spectra were collected using 1mm Suprasil High Resolution Quartz cuvet 
(Hellma Analytics, Müllheim, Germany). Three accumulations were used for each spectra 
collection. There were five minute incubations after addition of detergents, before a spectrum 
was collected.  
2.4.15 
15
N labeling of proghrelin-His6. pET23a GThPH was transformed into Z-competent 
BL21 (DE3) E. coli cells. Plasmids (100 ng) were transformed into a 50 μL aliquot of chemically 
competent Z-competent BL21 (DE3) E. coli cells (Zymo Research) followed by incubation on 
ice for 30 min. Transformed bacteria were spread on LB-ampicillin plates (100 μg/mL) and 
incubated at 37 ᵒC overnight.  
Following overnight incubation, single colony was used to inoculate a 5 mL culture of 
LB media. The culture was shaken for 4 hr at 225 rpm at 37 °C. The 5 mL culture was then 
inoculated into 1 L of autoinduction media (section 2.4.6). Initially 2.5 mM FeCl3 was added to 
the autoinduction media; however, it was not included after first initial growths because of 
degradation it caused. The culture was shaken for 24 hr at 225 rpm at 28 °C. Following growth, 
bacteria were harvested by centrifugation (6,000 x g, 15 min) and the supernatant removed. Four 
1 mL bacterial pellets were also prepared from the larger culture. One of the 1 mL bacterial 
pellets was resuspended in B-PER lysis reagent (Thermo Scientific, 100 μL), vortexed on high 
for 1 min, and cell debris was removed by centrifugation (10,000 x g, 5 min). A second 1 mL 
bacterial pellet was resuspended in 3X sample buffer (Thermo Scientific, 50 μL), heated at 95ᵒC 
for 5 min, and cell debris was removed by centrifugation (10,000 x g, 5 min). Protein in the 
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resulting supernatant were then analyzed 12% acrylamide gel electrophoresis and Coomassie 
staining. 
 The protein was then purified using standard GThPH protocol, concentrated to as high of 
a concentration as possible (ideally 100-300 µM) and NMR studies were conducted by Carlos A 
Castañeda.  
2.4.16 GThCgH cloning. A HINDIII restriction site was inserted after the TEV cleavage site in 
pET23a GThPH – primers were synthesized by Integrated DNA Technologies. 
Primers: Forward 5’ CTGTACTTCCAGGGTAAGCTTTTTCTGAGTCCG 3’ 
                Reverse 3’ CGGACTCAGAAAAAGCTTACCCTGGAAGTACAG 5’ 
Primers were dissolved in purified water and concentrations were determined by UV absorbance 
at 260 nm. PCR mutagenesis reactions (50 μL) contained the following components: 1x Pfu 
reaction buffer; 10 ng pET23a GST-TEV-proghrelin-His6; 125 ng forward primer; 125 ng 
reverse primer, 20 μM dNTPs, and 1 μL Pfu Turbo DNA polymerase (Agilent). The 
thermocycler program for PCR mutagenesis proceeded as follows: initial denaturation (94 °C, 5 
min); 30 cycles of denaturation (94 °C, 30 sec), annealing (56 °C, 1 min), and extension (68 °C, 
2 min); final extension (68 °C, 5 min). DpnI (1 μL, 20,000 units/mL) was added and reactions 
were incubated at 37 °C for 1 hr. After DpnI digestion, 5 μL of the PCR reaction mixture was 
transformed into 50 μL of Z-competent DH5α cells (Zymo Research) followed by incubation on 
ice for 30 min. Transformed bacteria were spread on LB-ampicillin (100 μg/mL) plates and 
incubated at 37 °C overnight. Single colonies were then inoculated into 5 ml LB media 
containing 100 μg/mL ampicillin in sterile culture tubes, which were incubated at 37°C overnight 
with shaking (225 rpm). Following overnight growth, plasmids were purified from cultures using 
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EZ-10 Spin Column Plasmid DNA kit (BioBasic) per manufacturer’s instructions. The product 
was verified by DNA sequencing (Genewiz). 
PCR mutagenesis was also performed to insert a 5’ HINDIII, C-terminal His6 tag and a 3’ 
NotI restriction site in c-ghrelin.  
Primers: Forward 5’ TATAGCAAAACTGCAAAAGCTTGCACTGGCCGGTTGG 3’ 
              Reverse 3’ CTCGAGTGCGGCCGCTTAATGGTGGTGATGGTGATGTATA 5’ 
Primers were synthesized by Integrated DNA Technologies. Primers were dissolved in purified 
water and concentrations were determined by UV absorbance at 260 nm. PCR mutagenesis 
reactions (50 μL) contained the following components: 1x One Taq standard reaction buffer; 40 
ng pET23a GST-TEV-proghrelin-His6 template; 125 ng forward primer; 125 ng reverse primer, 
20 μM dNTPs, and One Taq DNA polymerase (1 μL, 5,000 units/mL) (Agilent). The 
thermocycler program for PCR mutagenesis proceeded as follows: initial denaturation (94 °C, 1 
min); 33 cycles of denaturation (94°C, 30 sec), annealing (59°C, 1 min), and extension (68 °C, 2 
min); final extension (68 °C, 5 min). Following PCR mutagenesis the PCR product was run on a 
0.8% agarose gel at 110 V for ~1.5 hr, then DNA was gel extracted using EZ-10 Gel Extraction 
kit (BioBasic) per manufacturer’s instructions, and concentrations were measured by UV 
absorbance at 260 nm. The c-ghrelin gene was ligated into pET23a GST-TEV-X-His6. 3 μg 
pET23a GST-TEV proghrelin-His6 and C-ghrelin insert DNA was digested with HINDIII (1 μL, 
20,000 units/mL), NotI (1 μL, 20,000 units/mL), 3 μl cutsmart buffer (30 μlL total volume), and 
incubated at 37°C for 2 hr. Samples were then run on a 0.8% agarose gel at 110 V for ~1 hr. The 
bands for the pET23a vector and the C-ghrelin insert were each cut out and DNA was purified 
using EZ-10 Gel Extraction kit (BioBasic) per manufacturer’s instructions, and concentrations 
were measured by UV absorbance at 260 nm. 
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Ligations were performed with 50 ng of vector DNA, 40 ng insert DNA, 10 μL 
quick ligase buffer, and 1 μL Quick Ligase (total volume 10 μL) and incubated on ice for 5 
m. 5 μL of ligation reaction was added to 100 μL Z-competent DH5α cells, followed by 30 min 
incubation on ice. Cells were spread on LB- ampicillin (100 μg/mL) plates and incubated at 37 
°C overnight. Single colonies were inoculated into 5 ml LB cultures containing 100 μg/ml 
ampicillin and grown overnight at 37°C with shaking (225 rpm). Following overnight growth, 
plasmids were purified from cultures using EZ-10 Spin Column Plasmid DNA kit (BioBasic) per 
manufacturer’s instructions and successful ligation was confirmed by DNA sequencing 
(Genewiz). 
2.4.17 GThPH Purification. The resuspended cell pellet was stored at 4 ⁰ C overnight.  Cells 
were placed on ice, and a protease cocktail was added to the resuspended pellet before 
sonication, composed of PMSF (10 μg /mL) in 15mL of lysis buffer. Bacteria were lysed using a 
sonicator per the following protocol: power setting of 12; 8 cycles of sonication for 30 sec 
followed by 30 sec rest. The lysis solution was centrifuged (20, 000 x g, 30 min) at 4 ⁰ C, with 
the resulting supernatant removed and filtered using a 10 mL syringe and 0.45 micron syringe tip 
filter. The supernatant was then volume up to 250 mL in lysis buffer and purified using a 
GSTrap FF GST sepharose High Performance column. Buffers for GSTrap FPLC were 
prepared as follows: lysis (300 mM NaCl, 50 mM Tris, 10% glycerol); elution buffer (300 mM 
NaCl, 50 mM Tris, 10 % glycerol, and 10 mM glutathione).  A gradient elution was performed 
using GSTrap column (0.5 mL/min) with  the following method: 250 mL of lysis buffer 
containing 0 mM glutathione followed by load of the filtered bacterial lysate, 50 mL wash with 
lysis buffer and a gradient elution over 100 mL,  0-100% of elution buffer containing 10 mM 
glutathione. The desired fractions (2 mL) containing the GThPH fusion protein were combined 
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to final volume of 45 mL.  Protein content was determined via Bradford assay in μg/mL then the 
corresponding amount of TEV protease was added (1:50-1:200) to the combined fractions in a 50 
mL conical tube and was placed in a 34 ᵒC water bath for 8-10 hr. Following the TEV digestion 
the sample was then loaded onto a primed a HisTrap FF Ni
2+
 Sepharose High Performance 
column (2 x 5 mL) column using a step-wise elution.  The following method: 15 mL of lysis 
buffer, 45 mL of TEV digestion mixture, 25 mL of wash buffer and a step-wise elution over 75 
mL of elution buffer. After HisTrap column proghrelin- His6 selected fractions were buffer 
exchanged by two cycles of adding an equal volume of 20 mM NaH2PO4, 50 mM NaCl or 100 
mM NaCl, 50 mM Tris-HCl, (pH 7.3) to sample and concentration, yielding a final volume of 2 
mL.  The 2 mL concentrate was then run on HiLoad 16/60 Superdex 75 pg size exclusion 
column (GE) or HiPrep 16/60 Sephacryl S-100 High Resolution size exclusion column (GE). 
Buffer for size exclusion column was prepared as follows: lysis buffer (20 mM NaH2PO4, 50 
mM NaCl or 100 mM NaCl, 50 mM Tris-HCl, pH 7.3). Buffer was continuously run through the 
column for 120 mL (1 column volume) after injection of 2 mL of sample and an elution profile 
was obtained.  Fractions (1 mL each) were then analyzed by SDS-PAGE and Coomassie 
staining.  Fractions containing a homogenous product were combined and concentrated, stored at 
-80 ⁰C. 
2.4.18 GST-TEV-His6 protease preparation. Transform Z-competent Rosetta 2 E. coli cells 
with 100 ng of GST-TEV-His6 and plate onto an LB ampicillin/chloramphenicol (100 µg/mL, 34 
µg/mL) selection plate. Grow at 37 ᵒC overnight. One colony was used to inoculate a 50 mL 
culture of Terrific broth (Thermo Fischer) containing 50 μg/mL ampicillin and 34 μg/mL 
chloramphenicol. Grow overnight at 30 ᵒC shaking at 210 rpm. Inoculate 1L Terrific broth with 
15 mL each of the seed 50 mL culture. Grow cultures at 37ᵒC, shaking at 210 rpm until OD600 = 
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1.0 (check every ½ hour). Once optical density reached 1.0, cool cultures for 1 hr at 4 ᵒC. After 
OD has been met turn the shaking incubator down 16 ᵒC. After 1 hr, add 1 mL of 1M IPTG to 
each culture and grow cultures for 20-26 hr at 16 ᵒC, shaking 210 rpm. 
Purification of GST-TEV-His6 utilizes the GSTrap FF column purification from section 2.4.17. 
2.4.19 GThCgH resin purification. The resuspended cell pellet was thawed at 4 ᵒC overnight. 
Cells were cooled on ice, followed by addition a protease cocktail composed of PMSF (10 μg 
/mL) in 15 mL of lysis buffer. (For denaturing conditions the pellet was resuspneded in 
resuspension buffer (20 mL) and lysed using a sonicator per the following protocol: power 
setting of 12; 8 cycles of sonication for 30 sec followed by 30 sec rest. The lysis solution was 
centrifuged (20, 000 x g, 20 min) at 4 ᵒC, the supernatant was poured off and the pellet was 
resuspended in resuspension buffer again and centrifuged, the supernatant was poured off and 
finally resuspended in binding buffer which was filtered using a 10 mL syringe and 0.45 micron 
syringe tip filter). The pellet was lysed using using a sonicator per the following protocol: power 
setting of 12; 8 cycles of sonication for 30 sec followed by 30 sec rest. The lysis solution was 
centrifuged (20, 000 x g, 20 min) at 4 ᵒC, the supernatant was poured off filtered using a 10 mL 
syringe and 0.45 micron syringe tip filter. His60 Ni
2+
 resin was equilibrated with 2 column 
volumes of lysis buffer, spun down 700 x g, 10 min, 4 °C, bacterial lysate was added to resin 
rocked 18 hr spun down 700 x g, 10 min, 4 °C, 3 column volumes of wash buffer 1 then 2 were 
added to resin in three increments with resin spun down 700 x g, 10 min, 4 °C between each 
addition, 1.5 column volumes of elution buffer was then added rocked 1 hr at 4 °C, then spun 
down 700 x g, 10 min, 4 °C. At each step the supernatant was collected. Buffers (pH 7.3) for 
His60 Ni
2+
 resin (Clonetech) were prepared as follows: resuspension buffer (20 mM Tris-HCl, 
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500 mM NaCl, 2 M GuHCl, 2% Triton-100), binding buffer (20 mM Tris-HCl, 500 mM NaCl, 6 
M GuHCl, 5mM imidazole), wash buffer 1 (20 mM Tris-HCl, 500 mM NaCl, 6 M Urea, 10 mM 
imidazole); wash buffer 2 (20 mM Tris-HCl, 500 mM NaCl, 3 M Urea, 100mM imidazole); 
refolding buffer (20 mM Tris-HCl, 500 mM NaCl, 20 mM imidazole), elution buffer (20 mM 
Tris-HCl, 500 mM NaCl, 500 mM imidazole).  
For non-denaturing purification of GThCgH, the resin conditions were the same as 
described above with a change in buffers. The buffers (pH 7.3) were prepared as follows: lysis 
buffer (20 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole), wash buffer 1 (20 mM NaH2PO4, 
300 mM NaCl, 20 mM imidazole), wash buffer 2 (20 mM NaH2PO4, 300 mM NaCl, 50 mM 
imidazole) and elution buffer (20 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole). 
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Chapter 3: Processing behavior of proghrelin and C-ghrelin 
 
 
The work in this chapter is unpublished. In this chapter, there was an experimental contribution 
from Casey L. Cabrinha (Syracuse University summer REU undergraduate) who assisted with 
construction and expression of proghrelin variants containing alanine mutations and Terry Watt 
and Tasha Toro (Xavier University of Louisiana) who performed mass spectrometry analysis of 
proghrelin cleavage products.  
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3.1 Introduction 
 
As mentioned in Chapter 1, there are multiple products derived from proghrelin after 
acylation by GOAT. The two major products are ghrelin and C-ghrelin, which is then further 
processed to obestatin (Figure 3.1).
1-6
 Ghrelin processing from proghrelin is well characterized, 
and knockout studies targeting prohormone convertases/furins show an absence of mature 
ghrelin in those cells indicating a loss of processing of proghrelin to ghrelin.
4-5, 7-9
 However, C-
ghrelin processing leading to the peptide hormone obestatin has not been characterized to the 
same extent. There is a general consensus based upon sequence and gene splicing that obestatin 
is a processing product from proghrelin, specifically C-ghrelin.
10-12
 The exact enzymes or 
mechanism in which obestatin is cleaved from C-ghrelin is unknown. Similarly the processing 
pathway for  a newly identified splicing variant produced from obestatin (1-23), obestatin (11-
23),  is also undefined (Figure 3.1).
13
 With obestatin determined to contain an amidated C-
terminus, the processing of the C-terminus of obestatin is presumed to proceed through 
carboxypeptidase which cleaves the C-terminal lysine followed by modification by peptidyl 
glycine α-amidating monooxygenase (PAM) to yield C-terminal amidation.1, 5, 9-10, 14 The lack of 
information surrounding the obestatin processing pathway from C-ghrelin, leading to production 
of two independent hormones from the same proghrelin prehormone, marks this pathway as a 
system worthy of investigation.  
Throughout both the expression and purification of proghrelin described in Chapter 2, 
loss of the parent protein and concurrent observation of small protein bands indicate that 
cleavage of the proghrelin construct was occurring. The cleavage behavior which results in an 
observed heterogeneity was also observed throughout protein purification and in homogeneous 
proghrelin samples verified by silver staining and mass spectrometry. Cleavage of homogeneous 
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proghrelin-His6 is consistent with proghrelin cleaving itself, rather than another protein being 
responsible for the observed cleavage behavior. This systematic and continuous cleavage of 
proghrelin-His6 was challenging to avoid and has been consistent since proghrelin was first 
expressed. In order to further understand the protein and determine how best to avoid this 
cleavage during purification, the processing behavior was characterized and explored. In this 
chapter the cleavage of proghrelin is analyzed and this role in C-ghrelin processing is assessed. 
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Figure 3.1. The proghrelin processing pathway. Portions of this figure are adapted and 
reprinted with permission from Reference 6 (Appendix II). © 2016 Taylor and Francis. 
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3.2 Results 
3.2.1 Proghrelin cleavage behavior in bacterial lysate 
 
The first observation of the cleavage of proghrelin and C-ghrelin followed bacterial cell 
lysis during protein expression. This behavior was observed in lysis conditions using a mild non-
denaturing detergent (BPER (Thermo scientific), bacterial protein extraction reagent) compared 
to harsher denaturing lysis using sample buffer including SDS (3XSB, 3X sample buffer) 
(Chapter 2). The lower molecular weight bands contain a GST-tag as verified by Western 
blotting but appear to lack the C-terminal His6-tag (Chapter 2, Figure 2.2). To attempt to block 
GThPH cleavage by endogenous proteases, bacterial lysis buffers were treated with protease 
inhibitor cocktails including phenylmethylsulfonyl fluoride (PMSF, serine protease inhibitor), 
benzamidine (trypsin-like enzymes, serine protease inhibitor), pepstatin A (aspartyl protease 
inhibitor), and leupeptin (cysteine, serine and threonine protease inhibitor). However, protease 
inhibitor addition did not eliminate the cleavage of GThPH during bacterial lysis with a non-
denaturing detergent based reagent such as BPER reagent or during sonication (Figure 3.2). The 
same cleavage behavior was observed plus or minus a protease cocktail. 
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Figure 3.2. Addition of a protease cocktail during bacterial lysis and purification does not 
inhibit cleavage. A 300 mL bacterial pellet of GThPH was sonicated in the presence of a 
protease cocktail (10 μg/mL PMSF, 50 μg/mL benzamidine, 10 μg/mL leupeptin, and 0.7 μg/mL 
peptstatin A) and was loaded onto a HisTrap FF column using a step-wise elution method. 
Fractions were collected from under the A280 peak. No difference in cleavage was observed 
with a protease cocktail present. The gel is 12% polyacrylamide. Lane 1, protein ladder (Thermo 
scientific); Lane 2, post-sonicated GThPH (in the presence of protease cocktail); Lane 3, column 
flow-through; Lane 4, column wash; Lane 6, fraction 1; Lane 7 fraction 2; Lane 8, fraction 3; 
Lane 9, fraction 5; Lane 10, fraction 7; Lane 11, fraction 9; Lane 12, fraction 12; Lane 13, 
fraction 15; Lane 14, fraction 18; Lane 15, fraction 20.  
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The observed cleavage of proghrelin occurs within a short time scale during bacterial 
lysis using non-denaturing conditions. The time frame of GThPH cleavage is approximately 6-15 
minutes after the initial bacterial pellet is lysed before the addition of denaturing sample loading 
buffer for polyacrylamide gel analysis. The lower molecular weight proteins including GST-
tagged proteins were not present during bacterial lysis when bacterial pellets were lysed using 
denaturing conditions (3XSB). The loss of GThPH cleavage under denaturing conditions 
indicates that a folded protein structure is likely important for cleavage behavior and/or the 
presence of the denaturant blocks GThPH from interacting with lipids or other proteins in the 
bacterial cytosol that enhance cleavage.  
In light of the reproducible cleavage of GThPH in bacterial lysate on relatively short time 
scales (<10-20 minutes), we investigated this behavior to determine the solution conditions 
accelerate or inhibit GThPH cleavage. The first avenue was to ascertain if this cleavage can 
either be halted or enhanced by addition of metal ions into the bacterial lysate and the metal 
dependency of GThPH cleavage in lysate. However, the behavior observed during multiple 
studies with metal ion addition was unclear and not reproducible from experiment to experiment. 
Since bacterial lysate contains many molecular species including unidentified E. coli proteins 
and lipids, studies in lysate were limited and instead the focus switched to study proghrelin’s 
cleavage behavior in its purified form. In future studies of proghrelin cleavage, incubation with 
fractionated bacterial lysates may be pursued to explore the impact (if any) of bacterially derived 
proteins or small molecules.                                                                                                             
 
To inhibit the cleavage behavior observed in bacterial lysate and purified samples, a 
denaturing purification protocol was utilized since addition of a denaturing bacterial lysis limited 
GThPH cleavage. As bacterial lysis by denaturing gel loading sample buffer including SDS 
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completely inhibited cleavage of GThPH, we reasoned GThPH purification under denaturing 
conditions may have allowed for proghrelin purification without cleavage. Supporting this 
approach was the denaturing purification protocol that was used for C-ghrelin (Chapter 2) with 
some success. For the GThPH purification under denaturing conditions, guanidine hydrochloride 
(GuHCl, 6 M) was included in all buffers from bacterial pellet resuspension, sonication and resin 
purification. In the presence of GuHCl, the GThPH fusion protein did not exhibit cleavage as 
reflected by a single predominant band by SDS-PAGE analysis, compared to the three 
predominant bands observed in the absence of GuHCl (Figure 3.3). The suppression of GThPH 
cleavage upon bacterial lysis in the presence of 6 M GuHCl was encouraging. After elution 
during buffer exchange decreasing the concentration of GuHCl there was aggregation of the 
fusion protein, this same behavior was observed using both dialysis and a gradient elution to 
lower the concentration of GuHCl over a greater period of time. This aggregation behavior was 
also observed with C-ghrelin’s denaturing purification. While the suppression of proghrelin 
cleavage under denaturing conditions supports the requirement for a folded protein or an 
unidentified protein-protein interaction for the cleavage behavior observed with this protein, the 
aggregation observed upon removal of GuHCl precluded further development of a denaturing 
protocol for proghrelin purification.  
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Figure 3.3. Bacterial pellet lysis in the presence of 6 M GuHCl. 1 mL bacterial pellets were 
resuspended in buffer containing either 0 or 6 M GuHCl then lysed using FastBreak cell lysis 
reagent (Promega), a non-denaturing cell lysis reagent. Lane 7 is the result of growth of a 300 
mL bacterial pellet which was lysed in 6 M GuHCl. The red box indicates GThPH which appears 
as a single band. The gel is 12% polyacrylamide. Lane 1 protein ladder (Thermo scientific) Lane 
3, 1 mL bacterial pellet lysed using FastBreak; Lane 5, 1 mL bacterial pellet lysed using 
FastBreak in presence of 6 M GuHCl; Lane 7, A sample from a 300 mL bacterial pellet 
resuspended and sonicated in presence of 6 M GuHCl.  
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3.2.2 Proghrelin cleavage in purified samples 
 
The cleavage behavior observed in bacterial lysate was also observed in purified 
proghrelin-His6 samples, which was discussed briefly in Chapter 2. Homogeneous proghrelin-
His6 purified by size exclusion chromatography was stored at 4 ⁰ C and over a time span of 24 
hours lower molecular weight cleavage products were observed. Upon further examination, it 
became apparent that purified proghrelin-His6 would degrade when stored in solution, with 
protein remaining intact only if frozen or lyophilized. Freeze-thaw cycles in solution added to the 
appearance of cleavage of proghrelin, so these cycles were avoided as much as possible. There 
was also an observable increase in lower molecular weight cleavage products as a result of 
centrifugation during protein concentration and buffer exchanging with centrifugation. This was 
demonstrated in a side-by-side comparison of a sample in which half was either concentrated or 
left dilute and then analyzed by gel electrophoresis (Figure 3.4). This behavior may suggest a 
potential for protein-protein interactions between proghrelin molecules to contribute to the 
observed cleavage of proghrelin since a higher concentration would increase the relative number 
of these interactions occurring. 
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Figure 3.4. Increased proghrelin-His6 cleavage observed following protein concentration. 
After purification using size exclusion chromatography, fractions were pooled, half were left 
unconcentrated and the other half were concentrated to a tenth of their original volume. The 
concentrated sample was corrected for protein concentration before gel loading. The gel is 15% 
polyacrylamide. Lane 1, protein ladder (Thermo scientific); Lane 3, unconcentrated purified 
proghrelin-His6 sample; Lane 5, concentrated purified proghrelin-His6 sample.  
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In an attempt to stabilize purified proghrelin, ethylenediaminetetraacetic acid (EDTA) 
was added to purified samples to chelate any metals that may contribute to proghrelin cleavage 
(Figure 3.5). The rationale for EDTA addition was the behavior with metal addition to bacterial 
lysate having some effect but not reproducibly increasing proghrelin cleavage. While proghrelin 
cleavage was observed in samples that were EDTA-free, addition of EDTA (1 or 5 mM) appears 
to suppress proghrelin degradation over the time course monitored (Figure 3.5). Moving forward, 
this finding supported that inclusion of EDTA in proghrelin storage buffers would stabilize 
proghrelin against cleavage.  
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Figure 3.5. Addition of EDTA stabilized proghrelin-His6 against cleavage. Purified 
proghrelin-His6 was incubated at room temperature for up to 96 hours with varying concentration 
of EDTA added. Red boxes indicate proghrelin-His6 at each time point (0, 24, 48, 96 hours) in 
the absence of EDTA (0 mM). The gel is 15% polyacrylamide. Lane 1, protein ladder (Thermo 
scientific); Lane 2, 0mM EDTA/0 hrs; Lane 3, 1 mM EDTA/ 0 hrs; Lane 4, 5 mM EDTA/ 0 hrs; 
Lane 6 0 mM EDTA / 24 hrs; Lane 7, 1 mM EDTA/ 24 hrs; Lane 8, 5 mM EDTA/ 24 hrs; Lane 
10, 0 mM EDTA/ 48 hrs; Lane 11, 1 mM EDTA/48 hrs; Lane 12, 5 mM EDTA/ 48 hrs; Lane 14, 
0 mM EDTA/96 hrs.  
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3.2.3 Mass spectrometry analysis of proghrelin cleavage 
 
To determine the location of the cleavage site(s) within purified proghrelin, the 
proghrelin cleavage products were analyzed by our collaborator Prof. Terry Watt at Xavier 
University of Louisiana using MALDI-TOF (matrix-assisted laser desorption/ionization-time of 
flight) mass spectrometry (Figure 3.6, Table 3.1). To generate samples for MALDI-TOF 
analysis, purified proghrelin was incubated at room temperature in 50 mM Tris-HCl, pH 7.3 for a 
series of time points over a span of six days. Following this incubation, the proghrelin-derived 
peptides were analyzed and cleavage sites assigned based on the mass of the peptide products. 
Proghrelin cleavages were observed at several sites in a short stretch of sequence, with this 
fragmentation occurring over time in an ordered process (Table 3.1, Figure 3.7). The cleavages 
occur at a high concentration towards the C-terminus of obestatin (proghrelin amino acid 
residues 53-77 and the obestatin splice variant amino acids 63-77), with the first observable 
cleavages at Q73 and K77 by 48hrs, following longer incubation cuts at A74, Y68, and H71 
were also detected. The C-terminal fragments with their corresponding N-terminal fragments for 
the cleavage sites listed above (1-68 and 69-100, 1-71 and 72-100, 1-73 and 74-100, 1-74 and 
75-100, 1-77 and 78-100) were detected (Table 3.1, Figure 3.7). This analysis confirms that 
purified proghrelin cleaves itself at a small set of potential sites in a time-dependent manner.  
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Figure 3.6. MALDI-TOF mass spectrometry analysis of time-dependent proghrelin-His6 
cleavage. The amount of uncleaved proghrelin (11,322 Da) gradually decreases consistent with 
cleavage of the protein over 144 hours. Proghrelin was prepared in 50 mM Tris-HCl, pH 8.0 and 
allowed to sit at room temperature. Each panel is indicated by the hour the sample was taken, the 
parental protein is indicated with a black arrow at the top right of the figure, small peptides 
derived from cleavage are under the black bracket at the top left of the figure.  
0 hrs 
72 hrs 
144 hrs 
48 hrs 
24 hrs 
Proghrelin-His6 Cleaved Proghrelin-His6 
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Table 3.1. Fragmentation analysis of proghrelin-His6 cleavage. The table displays fragment 
sizes (m/z) and their corresponding sequence from the cleavage of proghrelin-His6. The time 
points at which each fragment at detected are indicated by an “x”.  
Mass (m/z) 
observed 
Time fragment occurred (hrs) 
Sequence fragment (proghrelin-His6 length 
1-100) 
 
0hrs 24hrs 48hrs 72hrs 144hrs N-terminal fragment 
11322 x x x x x 1 - 100 
8514     x x x 1 - 77 
8216       x x 1 - 74 
8144   x x x x 1 - 73 
8016         x 1 - 72 
7929       x x 1 - 71 
7664       x x 1 - 69 
7535       x x 1 - 68 
7144         x 1 - 65 
7088         x 1 - 64 
6887         x 1 - 62 
 
0hrs 24hrs 48hrs 72hrs 144hrs C-terminal fragment 
3803.1       x x 69 - 100 
3410.1         x 72 - 100 
3194.8   x   x x 74 - 100 
3123.8       x x 75 - 100 
2825.6       x x 78 - 100 
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Figure 3.7. Proghrelin-derived peptides observed by mass spectrometry analysis of a 144 
hour time course. Fragments of proghrelin-His6’s sequence observed during the 144 hour time 
course in Figure 3.6 and Table 3.1. The m/z values were analyzed and the fragmentation was 
plotted onto proghrelin-His6’s sequence. The boxes correspond with the size of the sequence 
displayed and the time the fragments started to occur T= x hours.  
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3.2.4 Alanine mutagenesis studies towards inhibition of proghrelin cleavage 
 
The mass spectrometry analysis of proghrelin indicated a small set of cleavage sites in the 
C-terminal portion of the protein. There was a two-fold effort to inhibit the cleavage behavior 
informed by the mass spectrometry; the first was to mutate amino acids at the cut sites near C-
terminal obestatin. This was done in order to try to block proghrelin’s cleavage by mutating the 
cleavage site. This approach is under the assumption that the individual amino acids at the 
cleavage sites and their distinct functionalities are important for a motif recognition or 
mechanistically for cleavage to occur. If this is so, mutating the required residue(s) should inhibit 
or slow the cleavage. The second approach was to mutate a series of amino acids near the 
beginning of obestatin (N-terminal C-ghrelin) where there is a high concentration of amino acids 
that can serve to chelate metal ions or act as general bases, generally associated with a catalytic 
core in proteases such as chymotrypsin (Figure 3.9A). 
15-16
 This approach takes a mechanistic 
route in trying to eliminate the residues that contribute to or are responsible for cleavage. Each 
amino acid in this two-pronged approach was mutated to alanine to remove side chain 
functionality which may contribute to residue recognition or catalysis of protein cleavage (a 
representative alanine mutant expression analysis shown Figure 3.8). The amino acids at the 
cleavage sites identified by mass spectrometry (Q73, K77, and F78) were individually mutated to 
alanine without an observable change in cleavage behavior. Double and triple alanine mutants 
were also examined (Q73A-K77A, Q73A-F78A, and Q73A-K77A-F78A) but their behavior was 
similarly unchanged relative to non-mutated proghrelin (wild-type proghrelin). Focusing on 
potential catalytic residues (specifically, glutamic acid (E) and aspartic acid (D)), amino acids 
from E37 to E50 were mutated to alanine but no difference in the cleavage pattern with the 
alanine mutants compared to non-mutated proghrelin (E43A expression shown in Figure 3.8).  
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Figure 3.8. Alanine mutations of GThPH lead to no change in protein cleavage. This is 
representative data for all alanine mutations made in proghrelin’s sequence. 1 mL bacterial 
pellets from E37A, E46A or wild-type (WT) growths of GThPH were lysed using either BPER 
reagent or 3XSB then analyzed by SDS-PAGE and Coomassie staining. There is no discernable 
difference between the alanine mutants and WT GThPH cleavage pattern. The gel is 12% 
polyacrylamide. Lane 1, protein ladder (Thermo scientific); Lane 2, E37A BPER lysis; Lane 3, 
E37A 3XSB lysis; Lane 5, WT GThPH BPER lysis; Lane 6, WT GThPH 3XSB lysis; Lane 8, 
E46A BPER lysis; Lane 9, E46A 3XSB.  
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The residues that were targeted for mutation in the stretch from 30-50 are highly 
conserved across all mammalian species in which proghrelin has been found and sequenced 
(Figure 3.9B). This conservation suggests these residues may be important for proghrelin 
interactions with GOAT, the ghrelin receptor GHS-R1a and/or that this cleavage behavior is also 
present in proghrelin across species. Since, none of the individual alanine mutations resulted in 
delayed or inhibited cleavage there is the possibility that multiple residues are involved or the 
residues targeted for mutation play no role in proghrelin’s cleavage behavior. 
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G1SSFLSPEHQRVQQRKESKKPPAKLQPRALAGWLRPEDGGQAEGAEDELEVRFNAPFD
VGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK94  
 
G1SSFLSPEHQRVQQRKESKKPPAKLQPR28-----------------Ghrelin 1-28 
F53NAPFDVGIKLSGVQYQQHSQALG76--------------------Obestatin 53-76 
L63SGVQYQQHSQALG76--------------------------------------- Splice variant 63-76 
 
 
 
 
 
 
Figure 3.9. Hormone products from proghrelin processing. A) Cleavage sites from MALDI-
TOF fragmentation analysis. Cut sites are indicated with black dotted lines in proghrelin’s 
sequence, amino acid residues that were mutated to alanine indicated in red. The individual 
products from biological hormone processing are indicated (ghrelin, obestatin and obestatin’s 
splicing variant) and their lengths are in terms of proghrelin’s sequence. Ghrelin is in green text, 
obestatin in bold text in proghrelin’s sequence. B) Homology alignment of amino acid 
probability for proghrelin residues 30-50. This is the range which contains the necessary 
residues for cleavage. The figure is a result of all known mammalian proghrelin sequences input 
into WebLogo. Residues that are more conserved are larger at their position.  
 
 
 
 
Hormone processing 
 
A 
B 
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3.2.5 Development of a fluorescence-based system to investigate proghrelin cleavage 
 
The cleavage of proghrelin, both in bacterial lysate and purified samples, has been 
observed continuously throughout expression and purification of proghrelin. Proghrelin 
cleavages had been detected using SDS-PAGE followed by either Coomassie staining and /or 
Western blotting. Mass spectrometry was also used but only indicated the sites of cleavage not 
the sequence or residues needed for it to occur. With these methods not conducive to a complete 
characterization of proghrelin cleavage behavior, another analytical technique was needed to 
analyze proghrelin cleavage. 
 Work done by Brian Callahan and coworkers created a system that utilized cyan 
fluorescent protein (CFP) and yellow fluorescent protein (YFP) in a Förester resonance energy 
transfer (FRET) system to study the intein splicing. 
17-19
 Callahan then modified this system to 
monitor cleavage of the protein Hedgehog which is induced by cholesterol (Figure 3.10).
17-21
 
Since, this FRET system has been previously used to study protein splicing, it could be 
potentially used to study proghrelin’s unique cleavage behavior. A fluorescent protein construct 
was created to substitute proghrelin into CFP-X-YFP (CXY, where X is a small linker sequence) 
FRET construct yielding CFP-proghrelin-YFP (CpgY) (Figure 3.11).  
149 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. Schematic of hedgehog cholesterolysis and the FRET construct used to study 
it, developed by Brian Callahan. This figure is reproduced with permission of reference 21 
(Appendix IV). © 2015 Elsevier.   
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Figure 3.11. Cloning schematic of obtaining CpgY from the GST-based GThPH.  
151 
 
The CpgY construct allows investigation of proghrelin self-cleavage by both gel analysis 
and fluorescence-based measurements. The CpgY fusion construct was created by inserting 
restriction sites on either end of the proghrelin sequence in the GThPH vector by PCR. The 
proghrelin sequence was then ligated into the pBAD33 CXY vector. After ligation into the 
pBAD33 plasmid was complete it was then subcloned in a pET23a plasmid since previous work 
with proghrelin in its GST-fusion construct high expression and was easily inducible (Figure 
3.11).
22
 The design of this plasmid provided the opportunity to study proghrelin cleavage 
utilizing fluorescence/FRET measurements and places proghrelin in another fusion protein 
construct to ascertain if the cleavage observed in GThPH occurs in another structural/sequence 
context.  
CpgY was expressed utilizing the standard autoinduction protocol.
22
 The expression was 
analyzed via Coomassie staining and Anti-His Western blotting to confirm that the presence of 
CpgY which has a C-terminal His6-tag (Figure 3.12). Following gel analysis using non-reducing 
conditions (no dithiothreitol or heating), CpgY lysate was fluorescently analyzed and initial 
FRET readings were compared to CXY and CY (CFP-YFP, with no X linker region) in bacterial 
lysate (Figure 3.13).  CpgY had a similar FRET signature to that observed for CXY and CY, 
indicating that FRET was occurring in the protein.  
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Figure 3.12. Expression of bacterially expressed pET23a CpgY. 1 mL bacterial pellets, either 
CpgY or pET23a (empty vector), were lysed with BPER cell extraction reagent or 3XSB then 
loaded onto an SDS-PAGE gel. CpgY parental protein is a 63 kDa and runs closer to 70 kDa 
than 55 kDa. The gel is 12% polyacrylamide.  Lane 1, protein ladder (Thermo scientific); Lane 3, 
purified proghrelin-His6; Lane 5, CpgY BPER bacterial pellet lysis; Lane 6, CpgY 3XSB 
bacterial pellet lysis; Lane 8, pET23a BPER bacterial pellet lysis; Lane 9, pET23a 3XSB 
bacterial pellet lysis.  
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Figure 3.13. Initial FRET readings of CpgY in bacterial lysate. Bacterial pellets were lysed 
using BPER reagent and diluted into 50 mM Tris-HCl, pH 7.3 in a 96-well polystyrene black 
coated microplate (Thermo fischer). Fluorescence readings were taken for YFPexcitationYFPemission 
(488, 580 nm), CFPexcitationCFPemission (400, 485 nm), CFPexcitationYFPemission (400, 540 nm). The 
corrected FRET ratio is CFPexcitationYFPemission/CFPexcitationCFPemission. Readings were taken every 
1:41 minutes (101 seconds) for each CpgY, CXY, and CY.  
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CpgY was purified utilizing the His6 tag on the C-terminal YFP using Ni
2+
-IMAC resin 
and a batch method purification, such as in Chapter 2 for C-ghrelin.
23
 This sample was 
concentrated and stored under foil at 4 ᵒC. The purified sample was visualized both using 
Coomassie staining and fluorescence monitoring using the FRET signal as a result of 
CFPexcitationYFPemission. If proghrelin cleaves itself there should be a loss of FRET signal due to 
the lack of transfer of energy from CFP to YFP (Figure 3.14). The time course demonstrated that 
there is indeed a loss of FRET due to cleavage of the CpgY construct in a purified sample over 
the time course (Figure 3.15A). There was also support of this using gel analysis of the cleavage 
samples (Figure 3.15B).  
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Figure 3.14. Proghrelin cleavage using FRET signal. Schematic displaying the expected 
results from the CpgY FRET construct in the case that there is (right) or if cleavage does not 
occur (left). 
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 Figure 3.15. Cleavage of purified CpgY. The purified FRET construct CpgY was incubated at 
4 ᵒC under foil for the allotted times (0, 24, 48, 72, 96, 120, 144, and 168 hours). A sample from 
the incubation was taken for fluorescence reading and gel analysis. A) FRET readings for 
CpgY cleavage time course. The fluorescence readings were at λexcitation 400 nm λemission 540 nm, 
exciting CFP and emitting YFP. Samples were diluted into 50 mM Tris-HCl pH 7.3 in a 96-well 
polystyrene black coated microplate (Thermo fischer). The FRET signal decreases over the 
allotted time due to the cleavage of proghrelin and the loss of energy transfer from CFP to YFP, 
shown in bar chart. B) Gel analysis of CpgY cleavage. CpgY was purified using Ni
2+
-IMAC 
resin and concentrated yielding Lane 1. Samples taken from the same time points used for 
fluorescence readings were analyzed by SDS-PAGE and Coomassie staining. The gel is 12% 
polyacrylamide. Lane 1, protein ladder (Thermo scientific); Lane 2, 0 hrs incubation of CpgY; 
Lane 3, 24 hrs incubation; Lane 4, 48 hrs incubation; Lane 5, 72 hrs incubation; Lane 6, 96 hrs 
incubation; Lane 7, 120 hrs incubation; Lane 8, 144 hrs incubation; Lane 9, 168 hrs incubation.  
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With the cleavage observed in the CpgY construct, proghrelin has been shown to cleave 
in two different protein fusion constructs and as purified proghrelin-His6. In addition to enabling 
detection of proghrelin cleavage by FRET, the CpgY construct provides the ability to detect 
CpgY protein cleavage by in-gel fluorescent imaging of crude bacterial lysates or purified 
samples. To leverage this capability, a series of CpgY constructs containing truncations of 
proghrelin were designed to determine which parts of proghrelin are either required for cleavage 
or susceptible to cleavage. In these constructs, successive 15 amino acid deletions were 
introduced proceeding both from the N- to C-terminus and the C- to N-terminus to yield a total 
10 proghrelin truncations (Figure 3.16).  
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Figure 3.16. Proghrelin N- and C-terminal truncation constructs. A) Proghrelin truncation 
sequence from N- or C-terminal CpgY. The lines in the figure are to indicate the missing 
sequence; there is no linker region in each fluorescent fusion protein. B) The sequence of 
proghrelin in each of the FRET constructs shown in A. Actual amino acid composition of 
proghrelin in each fusion construct. Ghrelin indicated in green text and obestatin in bold.  
B 
A 
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The CpgY truncation constructs were expressed in Z-competent BL21 (DE3) E. coli, with all 
constructs producing soluble proteins and Anti-His Western blotting confirming the correct size 
for the intact protein. FRET readings were taken both demonstrated that the protein is the correct 
size and that they all have FRET signals. To try and identify if cleavages were occurring and in 
which direction N to C or C to N-terminal the constructs were fluorescently imaged using in-gel 
fluorescence using both CFPexcitationYFPemission and YFPexcitationYFPemission (Figure 3.17 and 3.18, 
both the result of YFPexcitationYFPemission imaging). In comparison to the control constructs CXY 
and YFP, there were distinct banding patterns for each of the CpgY constructs (Figure 3.17).  
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Figure 3.17. Fluorescent imaging of CpgY proghrelin truncation constructs. 1 mL bacterial 
pellets were lysed using BPER bacterial extraction reagent, non-reducing sample buffer (does 
not contain dithiothreitol and no boiling of the sample) and loaded onto a 12% polyacrylamide 
gel. The gel was imaged λexcitation 488 nm λemission 580 nm for YFPexcitationYFPemission. Red arrows 
indicate the parent protein in the fluorescent protein construct. The constructs are indicated by 
CpgY to indicate the construct and then the length of the truncation 1-X or X-94. Bands not 
present in either CXY or YFP are likely the result of construct cleavage. Lane 1, CXY; Lane 2, 
CpgY 1-94; Lane 3, CpgY 16-94; Lane 4, CpgY 31-94; Lane 5, CpgY 46-94; Lane 6, CpgY 61-
94; Lane 7, CpgY 76-94; Lane 8, CpgY 1-19; Lane 9, CpgY 1-34; Lane 10, CpgY 1-49; Lane 
11, CpgY 1-64; Lane 12, CpgY 1-79; Lane 13, YFP. 
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Comparison of the patterns for the truncation constructs supports that the cleavage 
behavior requires specific portions of the proghrelin sequence. From these observations it was 
determined that constructs 1-49, 16-94, 31-94, 1-64, and 1-79 show distinct proghrelin cleavage. 
The stable sequences were 1-34, 1-19, 46-94, 61-94 and 76-49 in which there was no observable 
proghrelin cleavage. Analysis of the FRET constructs indicated that the core sequence required 
for cleavage was the sequence from 30-49, since those lacking that sequence do not cleave. The 
fluorescent gel imaging used the YFP fluorescent signal of CpgY so it is likely that the C-
terminal fragments from any cleavages were being observed. However, it was unclear from the 
in-gel imaging whether the cleavages were occurring N to C or C to N-terminally.  
The constructs with the most prominent cleavage patterns were CpgY 1-49 and 16-94 
which showed multiple distinct cleavage products. Specifically, the sequence from 16-49 was a 
highly unstable region based upon fluorescence gel imaging of the N- and C-terminal FRET 
constructs. This indicates that 16-49 is the minimal sequence required for protein construct 
cleavage (Figure 3.17 and 3.18, lane 8), and so, a FRET protein containing this sequence was 
also constructed and imaged and it showed a similar banding pattern to the 1-49 construct 
(Figure 3.18) which indicates that this region is essential for FRET protein cleavage to be 
observed.  
The relative time scale of cleavage in the FRET construct was much slower than that of 
the GST construct, GThPH, possibly due to the fact that CFP and YFP are relatively large 
molecules compared to small molecule fluorophores which lead to stabilization of the proghrelin 
fusion protein. The observed relative time scale of cleavage in purified and in lysate of CpgY 
demonstrates that having CFP and YFP on either end of proghrelin increases stability and 
lifetime of the protein. In the GST-construct there is only one large protein bound to proghrelin 
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which leaves the C-terminus unbound and available to fold and interact with itself or other 
adjacent proteins.  To determine whether proghrelin was being stabilized by the presence of both 
CFP and YFP a two-fold approach was taken the first being a series of X-94-YFP protein 
constructs. This approach will indicate whether incorporation of two large fluorophores are 
necessary for protein stability, as well as, to determine if the position of the large protein (N- or 
C-terminal) is important for proghrelin stability. The second approach was to generate a number 
of the truncated proghrelin sequences in the GST-TEV-X-His6 fusion protein construct. 
Truncations were chosen for either their instability or the opposite; their sequence did not cleave 
in the FRET construct. Based upon the behavior observed with GThPH, ideally the truncated 
sequences will cleave on a faster time scale and could be purified using established methods 
(Chapter 2).  
The CFP portion of CpgY was excised from the protein leaving pgY in a series of 
constructs containing the following N-terminal proghrelin sequence: 16-94, 31-94, 46-94, 61-94, 
and 76-94. When these YFP constructs were expressed and analyzed there was a greater losses of 
parental protein and the appearance of a greater number of distinct protein cleavage products 
compared to their observed behavior during their CpgY fluorescence imaging (Figure 3.18). All 
of the constructs except for 16-94 and 31-94 were completely stable in CpgY but in the pgY this 
behavior changed as did all of the five constructs. All of the pgY constructs were observed to 
have protein cleavage. This reaffirms that the presence of both CFP and YFP stabilized the 
parental protein and the proghrelin sequence.  
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Figure 3.18. Fluorescent imaging of proghrelin fluorescent protein constructs. 1 mL 
bacterial pellets were lysed using BPER bacterial extraction reagent, non-reducing sample buffer 
(does not contain dithiothreitol and no boiling of the sample) and loaded onto a 12% 
polyacrylamide gel. The gel was imaged λexcitation 488 nm λemission 580 nm for 
YFPexcitaionYFPemission. Red arrows indicate the parental protein in each of the fluorescent protein 
constructs. For comparison of CFP contribution look to Lane 3 compared to Lane 9 and Lane 4 
compared to Lane 10. The constructs are indicated by CpgY to indicate the construct and then 
the length of the truncation 1-X or X-94. Lane 1, CXY; Lane 2, CpgY 1-94; Lane 3, CpgY 16-
94; Lane 4, CpgY 31-94; Lane 5, CpgY 1-49; Lane 6, CpgY 1-64; Lane 7, CpgY 1-79; Lane 8, 
CpgY 16-49; Lane 9, 16-94-YFP; Lane 10, 31-94-YFP; Lane 11, CpgY 46-94-YFP; Lane 12, 
61-94-YFP; Lane 13, 76-94-YFP; Lane 14, YFP.  
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Figure 3.19. GST-based proghrelin truncation expression analysis. A) Anti-GST Western 
blot of the BPER lysed expression pellets in Figure 3.19B. The protein ladder is indicated to the 
left of Lane 1. The gel is 12% polyacrylamide. Lane 1, GThPH; Lane 3, GThPH 1-94; Lane 5, 
GThPH 1-49; Lane 7, GThPH 16-49; Lane 9, GThPH 46-94; Lane 11, GThPH 61-94; Lane 12, 
pET23a (empty vector). B) Expression analysis of GST-truncated proghrelin fusion proteins. 
1 mL bacterial pellets were either lysed using BPER reagent or 3XSB and Coomassie stained. 
The red boxes correspond to the GST-tagged cleavage products in A. Parental GST-fusion 
proteins are indicated with red arrows. The gel is 12% polyacrylamide. Lane 1, protein ladder 
(Thermo scientific); Lane 2, GThPH BPER lysed; Lane 3, GThPH 3XSB; Lane 4, GThPH 1-94 
BPER lysed; Lane 5, GThPH 1-94 3XSB; Lane 6, GThPH 1-49 BPER lysed; Lane 7, GThPH 1-
49 3XSB; Lane 8, GThPH 16-49 BPER lysed; Lane 9, GThPH 16-49 3XSB; Lane 10, GThPH 
46-94 BPER lysed; Lane 11, GThPH 46-94 3XSB; Lane 12, GThPH 61-94 BPER lysed; Lane 
13, GThPH 61-94 3XSB; Lane 14, GThCgH BPER lysed; Lane 15, pET23 (empty vector) BPER 
lysed.  
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The GST-based proghrelin truncations and allow investigation of proghrelin cleavage 
sequence dependency in a context in which has been characterized in full-length proghrelin, 
analysis by both N- and C-terminal Western blotting, time scale comparison (full length already 
studied to new truncated constructs) and investigate C-terminal stability. The sequences chosen 
in this study were from both sequences that lead to protein cleavage: 1-94, 1-49, and 16-49 or 
were stable in their FRET constructs: 46-94 and 61-94 (Figure 3.17). The trend was the same as 
in the FRET constructs in which constructs that were more prone to protein cleavage were 
observed to have more cleavage products in their GST-based constructs (Figure 3.19).  The time 
scale of protein cleavage and overall lower molecular weight cleavage products from this GST-
based study did not provide any additional information about the sequences, their contribution to 
proghrelin cleavage, or the individual residues responsible for cleavage and are overall 
inconclusive.  
The proghrelin cleavage behavior in the proghrelin fusion proteins GThPH and CpgY 
constructs were observed as a result of expression in bacteria. To determine if the same behavior 
is observed in proteins expressed in mammalian cells, the CpgY construct was transferred into a 
mammalian plasmid containing a CMV promoter,
24
 a pCAF vector, and transfected into HEK 
293FT cells. Following transfection and fluorescent imaging, comparison to CpgY expressed in 
bacteria showed a similar banding pattern (Figure 3.20). The lower signal in mammalian samples 
is likely due to lower overall protein content and low transfection efficiency. These data are 
consistent with cleavage of proghrelin reflecting an intrinsic property of the protein rather than 
an artifact arising from expression in and purification from bacteria.  
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Figure 3.20. Fluorescent imaging of CpgY transfected in HEK 293FT cells. pCAF CpgY was 
transfected into 1 x 10
6
 cells/well in a 6-well plate using Lipofectamine 2000 transfection reagent 
(Thermo fischer), cells were harvested and lysed using RIPA buffer (containing a mini Roche 
tablet). Lane 11 is CpgY expressed in E. coli, a 1 mL pellet was lysed using BPER reagent. Non-
reducing sample buffer (does not contain dithiothreitol and no boiling of the sample) was added 
to samples and loaded onto a 12% polyacrylamide gel. The gel was imaged λexcitation 488 nm 
λemission 580 nm for YFPexcitationYFPemission. The black arrow indicates the parental CpgY protein 
and the black bracket indicates the cleavage products observed. Lane 1, 9 μL Liopofectamine 
2000 + 4 µg CpgY DNA; Lane 2, 10 μL Liopofectamine 2000 + 4 µg  CpgY DNA; Lane 3, 12 
μL Liopofectamine 2000 + 4 µg CpgY DNA; Lane 4, 15 μL Liopofectamine 2000 + 4 µg CpgY 
DNA; Lane 6, 9 μL Liopofectamine 2000; Lane 7, 10 μL Liopofectamine 2000; Lane 8, 12 μL 
Liopofectamine 2000; Lane 9, 15 μL Liopofectamine 2000; Lane 11, CpgY grown in from E. 
coli. and lysed using BPER .
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3.2.6 Cleavage behavior of GST-C-ghrelin fusion protein  
 
The studies above show proghrelin cleaves into discrete products, with the required 
residues and cleavage site both located within the C-ghrelin portion of proghrelin (Figure 3.9 and 
3.21). Following bacterial expression, GThPH and GThCgH were analyzed for cleavage 
behavior. The C-ghrelin fusion expressed as a soluble protein under optimized conditions 
(Chapter 2), although less efficiently than the proghrelin construct. When bacterial pellets were 
lysed and analyzed by gel electrophoresis, a similar banding pattern appeared in both the 
proghrelin and C-ghrelin constructs and Anti-GST Western confirmed that as previously shown 
these bands are GST-tagged (Chapter 2, Figure 2.3 and 2.4). The bacterial lysis demonstrates that 
the GST-C-ghrelin fusion cleaves in a similar fashion to GST-proghrelin. 
To further characterize C-ghrelin cleavage, mass spectrometry studies were pursued to 
identify the cleavage sites within the C-ghrelin sequence. Due to an inability of TEV protease to 
cleave C-ghrelin from GST, MALDI-TOF mass spectrometry was performed on purified GST-
TEV-human C-ghrelin-His6 samples. The same time course was repeated using the same 
conditions as the analysis for proghrelin-His6 and resulted in mass spectra with a definitive 
cleavage pattern similar to proghrelin and similar fragmentation and cut sites as reflected by the 
C-terminal peptides detected (Figure 3.21).  
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GThCgH sequence 
MSPILGYWKI KGLVQPTRLL LEYLEEKYEE HLYERDEGDK WRNKKFELGL EFPNLPYYID  
GDVKLTQSMA IIRYIADKHN MLGGCPKERA EISMLEGAVL DIRYGVSRIA YSKDFETLKV  
DFLSKLPEML KMFEDRLCHK TYLNGDHVTH PDFMLYDALD VVLYMDPMCL DAFPKLVCFK  
KRIEAIPQID KYLKSSKYIA WPLQGWQATF GGGDHPPKID TTENLYFQGKLA29LAG  
WLRPEDGGQA EGAEDELEVR FNAPFDVGIK LSGVQYQQHS QALGKFLQDI  
LWEEAKEAPADKHHHHHH  
 
C-ghrelin fragment 
sequence (in terms of 
proghrelin 1-100) 
Amino acid sequence of fragment 
Mass (m/z) 
observed 
72-100 S QALGKFLQDI LWEEAKEAPA DKHHHHHH 3409.6936 
80-100 QDI LWEEAKEAPA DKHHHHHH 2565.2130 
76-100 GKFLQDILWE EAKEAPADKH HHHHH 3010.4818 
65-100 GVQYQQHSQA LGKFLQDILW EEAKEAPADK HHHHHH 4250.0815 
 
Figure 3.21. Fragments from MALDI-TOF analysis of GThCgH fusion protein. A) The 
amino acid of the fusion protein GST-TEV-C-ghrelin-His6 (GThCgH). TEV site is 
highlighted in blue, C-ghrelin sequence is in bold text. The first amino acid of C-ghrelin is 
indicated as A29 (proghrelin residue 29). B) Mass spectrometry analysis of GThCgH cleavage. 
The m/z values observed were analyzed and compared to C-ghrelin’s sequence for sequence 
identification. All of the fragments observed using MALDI-TOF are C-terminal. 
A 
B 
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3.3 Conclusions  
 
The behavior of proghrelin during bacterial expression and purification, followed by 
studies of purified proghrelin, are consistent with proghrelin exhibiting self-cleaving proteolytic 
activity. This self-cleavage is initially observed following non-denaturing lysis of bacterial cells 
and continues throughout the purification and after purification. Characterization in both 
bacterial lysate and purified samples has helped to identify behaviors that accelerate it, such as 
increased concentration of the protein sample. The unique cleavage behavior seen with 
proghrelin both purified and in its fusion protein construct (GThPH) has been characterized by 
SDS-PAGE using Coomassie staining and Western blotting.  
The fluorescent proghrelin constructs (FRET, CpgY) were created and used in order to 
determine the residues that are required for proghrelin cleavage. This also provided another 
avenue to observe the cleavage in full-length proghrelin using fluorescence detection and 
fluorescent gel imaging. The FRET construct results further support that the cleavage observed is 
a property of proghrelin and not due to external interference from another protein or small 
molecule, since the same behavior was not seen with the control construct CXY. The cleavage 
behavior of proghrelin was also observed in different species (HEK 293FT mammalian cells and 
BL21 (DE3) E. coli.). The truncation constructs indicate that there is a region of proghrelin from 
amino acid residues 30-50 that is required for cleavage. This specific sequence was based upon 
the protein cleavage behavior of the N- and C-terminal sequence fluorescent gel imaging. To 
slow or completely inhibit proghrelin’s cleavage behavior, amino acids within this range were 
mutated to alanine. The amino acids targeted for mutagenesis were those that can chelate metals 
or are commonly apart of a catalytic triad which could be responsible for proghrelin cleavage. 
The alanine mutants behaved exactly like the parent protein; possibly due to the fact that 
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multiple residues are responsible for this behavior and that if one residue is mutated another will 
take its place. This mutagenesis was not very informative and did not aid in identifying specific 
essential residues.   
Amongst the CpgY proghrelin truncation constructs, the 1-49 and 16-49 sequences 
exhibited the most prominent cleavage of all constructs tested. This behavior was unexpected 
because, while these constructs contain the X-49 residues implicated for proghrelin cleavage 
activity by truncation analysis, they do not contain the downstream sequence region of 
proghrelin that has been identified as the cleavage site(s) within proghrelin by mass 
spectrometry. This could be the result of cleavage occurring within the N-terminal portion of 
YFP in a length-dependent cleavage site model instead of a model where specific amino acid 
residues are necessary for cleavage. This approach to identifying the necessary residues for 
proghrelin cleavage was informative and allowed comparison of residues between multiple 
different constructs. This methodology and analytical technique is useful for proteins that show 
splicing or unique processing behavior and should be pursued to probe for necessary residues or 
sequence.  
Informed only by the sequence, FRET behavior and alanine mutations it was unclear 
where the exact cut sites are occurring. To determine the location of the cleavage sites within 
proghrelin, mass spectrometry was employed to unambiguously determine the identities of the 
fragments from these cleavages. The FRET constructs and conservation analysis indicated what 
region is necessary for cleavage to occur which then leads to the residues identified during mass 
spectrometry fragmentation analysis.  
C-ghrelin cleavage was also characterized using mass spectrometry; C-ghrelin by itself 
has cleavage behavior as well as similar fragmentation as full-length proghrelin which indicates 
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that C-ghrelin’s sequence is responsible for the cleavage behavior. This was interesting since 
there is no known mechanism/enzyme/actor that is responsible for the cleavage of obestatin,
 10
 
suggesting that proghrelin and C-ghrelin could be self-processing. It is still unclear to the exact 
nature of the cleavage of proghrelin and whether structure or a multi-partner system is needed for 
cleavage, but the data indicates that ghrelin (1-28) is not needed for cleavage to occur and that 
the cuts are occurring near the cleavage sites of obestatin. The proximity to the cleavage sites of 
obestatin could just be coincidental or could provide the missing step in C-ghrelin processing.  
The future of the research within this chapter is to further characterize proghrelin 
cleavage by identifying the residues/mechanism in which this process occurs. This will help to 
define whether the behavior that was observed during work with human proghrelin is 
biologically relevant and an intrinsic property of this small protein. It would also be 
advantageous to compare other species’ full-length proghrelin to define if the cleavage behavior 
occurs solely in humans or in multiple species as the conservation analysis suggests.  
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3.4 Materials and Methods 
 
3.4.1 Cloning of proghrelin into pBAD33. PCR mutagenesis was performed to insert a 5’ XhoI 
and a 3’ PstI restriction cut site on either end of proghrelin. Primers were synthesized by 
Integrated DNA Technologies. Primers were dissolved in purified water and concentrations were 
determined by UV absorbance at 260 nm.  
Primer to insert XhoI site at the 5’end of proghrelin:   
5’TATAGGCTCGAGCAAATTTGCGGAATATGGTAGCAGCTTTCTG 3’ 
Primer to insert PstI site at 3’ end of proghrelin: 
5’GCACCGGCCGATAAATGCTTTAACCTGCAGTATA 3’ 
PCR mutagenesis reactions (50 μL) contained the following components: 1x One Taq standard 
reaction buffer; 40 ng pET23a GST-TEV-human proghrelin-His6 template; 125 ng forward 
primer; 125 ng reverse primer, 20 μM dNTPs, and  One Taq DNA polymerase (1 μL , 5,000 
units/mL)  (Agilent). The PCR thermocycler program proceeded as follows: initial denaturation 
(94 °C, 1 min); 33 cycles of denaturation (94 °C, 30 sec), annealing (59 °C, 1 min), and 
extension (68 °C, 2 min); final extension (68 °C, 5 min). The PCR product was run on a 0.8% 
agarose gel at 110 V for ~1.5 hr, then DNA was gel extracted using EZ-10 Gel Extraction kit 
(BioBasic) per manufacturer’s instructions, and concentrations were measured by UV 
absorbance at 260 nm.  
The proghrelin gene was ligated into pBAD33 CXY vector. 3 μg pBAD33 CXY and the 
proghrelin PCR product DNA was digested with XhoI (1 μL, 20,000 units/mL), PstI (1 μL, 
20,000 units/mL), 3 μL Cutsmart buffer (30 μL total volume), and incubated at 37 °C for 2 hr. 
Samples were then run on a 0.8% agarose gel at 110 V for ~1 hr. The bands for the pBAD33 
vector and the proghrelin insert were each cut out and DNA was purified using EZ-10 Gel 
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Extraction kit (BioBasic) per manufacturer’s instructions, and concentrations were measured by 
UV absorbance at 260 nm.  
Ligations were performed with 250 ng of vector DNA, 12 ng insert DNA, 10 μL quick 
ligase buffer, and 1 μL Quick Ligase (total volume 20 μL) and incubated on ice for 5 min. 5 μL 
of ligation reaction was added to 100 μL Z-competent DH5α E. coli. cells followed by 30 min 
incubation on ice. Cells were spread on LB-chloramphenicol (34 μg/mL) plates and incubated at 
37 °C overnight. Single colonies were inoculated into 5 mL LB cultures containing 34 μg/mL 
chloramphenicol and grown overnight at 37 °C with shaking (225 rpm).  
Following overnight growth, plasmids were purified from cultures using EZ-10 Spin 
Column Plasmid DNA kit (BioBasic) per manufacturer’s instructions. Sequencing of the gene 
was done by utilizing internal sequencing primers which were synthesized by Integrated DNA 
Technologies. Primers were dissolved in purified water and concentrations were determined by 
UV absorbance at 260 nm. The sequencing samples sent to Genewiz contained 1,000 ng of 
ligated DNA, 25 pmol of sequencing primer and H20 (10 μL total volume).  
Forward sequencing primer: 5’ GCTAACTTCAAAGCCAGACACAAC 3’  
Reverse sequencing primer: 5’ GGTAAATTGACCTTAAAATTACTCTGTACT 3’. 
 
3.4.2 Cloning CpgY into pET23a.  The CFP-proghrelin-YFP gene was ligated into pET23a. 3 
μg pBAD33 CpgY and pET23a DNA was digested with SacI (1 μL, 20,000 units/mL), HindIII 
(1 μL, 20,000 units/mL), 3 μL Cutsmart buffer (30 μL total volume), and incubated at 37 °C for 
2 hr. Samples were then run on a 0.8% agarose gel at 110 V for ~1 hr. The bands for the pET23a 
vector and the proghrelin insert were each cut out and DNA was purified using EZ-10 Gel 
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Extraction kit (BioBasic) per manufacturer’s instructions, and concentrations were measured by 
UV absorbance at 260 nm. 
Ligations were performed with 30 ng of vector DNA, 42 ng insert DNA, 10 μL quick 
ligase buffer, and 1 μL Quick Ligase (total volume 10 μL) and incubated on ice for 5 min. 5 μL 
of ligation reaction was added to 100 μL Z-competent DH5α E. coli cells, followed by 30 min 
incubation on ice. Cells were spread on LB- ampicillin (100 μg/mL) plates and incubated at 37 
°C overnight. Single colonies were inoculated into 5 mL LB cultures containing 100 μg/mL 
ampicillin and grown overnight at 37 °C with shaking (225 rpm). Following overnight growth, 
plasmids were purified from cultures using EZ-10 Spin Column Plasmid DNA kit (BioBasic) per 
manufacturer’s instructions and successful ligation was confirmed by DNA sequencing 
(Genewiz). 
 
3.4.3 Removal of duplicate restriction site. There were two SacI and XhoI sites in order to 
successfully clone the truncations each additional site was mutated (forward primers located 
below, their reverse complement were also ordered). PCR mutagenesis primers were designed to 
mutate out either an extra XhoI or PstI restriction site in pET23a CpgY and were synthesized by 
Integrated DNA Technologies. Primers were dissolved in purified water and concentrations were 
determined by UV absorbance at 260 nm. 
PstI knockout 5’ GACACCACGATGCCTGCTGCAATGGCAACAACG 3' 
XhoI knockout 5’ CACTAAAAGCTTGCGGCCGCACAGGAGCACCACCAC 3’  
PCR mutagenesis reactions (50 μL) contained the following components: 1x Pfu reaction buffer; 
10 ng pET23a CpgY; 125 ng forward primer; 125 ng reverse primer, 20 μM dNTPs, and 1 μL 
Pfu Turbo DNA polymerase (Agilent). The thermocycler program for PCR mutagenesis 
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proceeded as follows: initial denaturation (94 °C, 5 min); 30 cycles of denaturation (94 °C, 30 
sec), annealing (56 °C, 1 min), and extension (68 °C, 2 min); final extension (68 °C, 5 min). 
DpnI (1 μL, 20,000 units/mL) was added and reactions were incubated at 37 °C for 1 hr. After 
DpnI digestion, 5 μL of the PCR reaction mixture was transformed into 50 μL of Z-competent 
DH5α E. coli  cells (Zymo Research) followed by incubation on ice for 30 min. Transformed 
bacteria were spread on LB-ampicillin (100 μg/mL) plates and incubated at 37 °C overnight. 
Single colonies were then inoculated into 5 mL LB media containing 100 μg/mL 
ampicillin in sterile culture tubes, which were incubated at 37 °C overnight with shaking 
(225 rpm). Following overnight growth, plasmids were purified from cultures using EZ- 
10 Spin Column Plasmid DNA kit (BioBasic) per manufacturer’s instructions. The product was 
verified by DNA sequencing (Genewiz). 
 
3.4.4 Proghrelin truncation cloning. PCR reactions was also performed to create proghrelin 
truncations 1-19, 1-34,1-49,1-64, 1-79, 16-94,31-94,46-94,61-94, and 76-94. Primers were 
synthesized by Integrated DNA Technologies. Primers were dissolved in purified water and 
concentrations were determined by UV absorbance at 260 nm.  
The primer sequences were as follows (forward sequences are listed below, the reverse 
compliment was ordered for 1-X constructs): 
1-79 5’ GCACTGGGCAAGTTCCTGTGCTTTAACCTGCAGTATA 3’ 
1-64 5’ GTGGGCATCAAGCTGAGTTGCTTTAACCTGCAGTATA 3’ 
1-49 5’ GCCGAAGACGAGCTGTGCTTTAAGCTGCAGTATA 3’ 
1-34 5’ GCACTGGCCGGTTGGTTATGCTTTAAGCTGCAGTATA 3’ 
1-19 5’ GTTCAGCAGCGCAAGGAAAGTAAGTGCTTTAAGCTGCAGTATA 3’ 
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16-94 5’ TATAGGCTCGAGCAAATTTGCGGAATATAAGGAAAGTAAG 3’ 
31-94 5’ TATAGGCTCGAGCAAATTTGCGGAATATGCCGGTTGGTTACGT 3’ 
46-94 5’ TATAGGCTCGAGCAAATTTGCGGAATATGAAGACGAGCTGGAG 3’ 
61-94 5’ TATAGGCTCGAGCAAATTTGCGGAATATATCAAGCTGAGT 5’ 
76-94 5’ TATAGGCTCGAGCAAATTTGCGGAATATGGCAAGTTCCTG 3’ 
XhoI site at the 5’ end 
5’TATAGGCTCGAGCAAATTTGCGGAATATGGTAGCAGCTTTCTG3’ 
PstI site at 3’ end 
5’GCACCGGCCGATAAATGCTTTAACCTGCAGTATA3’ 
For construct 16-49 the forward primer 16-94 and reverse 1-49 were used in PCR mutagenesis 
reaction. 
PCR reactions (50 μL) contained the following components: 1x One Taq standard 
reaction buffer; 40 ng pET23a CpgY (with corresponding SacI or XhoI knockout) template; 125 
ng forward primer; 125 ng reverse primer, 20 μM dNTPs, and One Taq DNA polymerase (1 μL, 
5,000 units/mL)  (Agilent). The thermocycler program for PCR mutagenesis proceeded as 
follows: initial denaturation (94 °C, 1 min); 33 cycles of denaturation (94 °C, 30 sec), annealing 
(59 °C, 1 min), and extension (68 °C, 2 min); final extension (68 °C, 5 min). Following PCR 
mutagenesis the PCR product was run on a 0.8% agarose gel at 110 V for ~1.5 hr, then DNA was 
gel extracted using EZ-10 Gel Extraction kit (BioBasic) per manufacturer’s instructions, and 
concentrations were measured by UV absorbance at 260 nm. 
The proghrelin truncated genes were ligated into pET23a CFP-proghrelin-YFP. 3 μg 
pET23a CFP-proghrelin-YFP-His6 and proghrelin truncation insert DNA was digested with SacI 
(1 μL, 20,000 units/mL), PstI (1 μL, 20,000 units/mL), 3 μL cutsmart buffer (30 μL total 
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volume), or digested with XhoI (1 μL, 20,000 units/mL), HindIII (1 μL, 20,000 units/mL), 3 μL 
cutsmart buffer (30 μL total volume) and incubated at 37 °C for 2 hr. Samples were then run on a 
0.8% agarose gel at 110 V for ~1 hr. The bands for the pET23a vector and the insert were each 
cut out and DNA was purified using EZ-10 Gel Extraction kit (BioBasic) per manufacturer’s 
instructions, and concentrations were measured by UV absorbance at 260 nm.  
Ligations were performed with 50 ng of vector DNA, 40 ng insert DNA, 10 μL quick 
ligase buffer, and 1 μL Quick Ligase (total volume 10 μL) and incubated on ice for 5 min. 5 μL 
of ligation reaction was added to 100 μL Z-competent DH5α E. coli cells, followed by 30 min 
incubation on ice. Cells were spread on LB- ampicillin (100 μg/mL) plates and incubated at 37 
°C overnight. Single colonies were inoculated into 5 mL LB cultures containing 100 μg/mL 
ampicillin and grown overnight at 37 °C with shaking (225 rpm). Following overnight growth, 
plasmids were purified from cultures using EZ-10 Spin Column Plasmid DNA kit (BioBasic) per 
manufacturer’s instructions and successful ligation was confirmed by DNA sequencing 
(Genewiz). 
 
3.4.5 C-ghrelin GST-fusion cloning. PCR primers were designed to insert a HindIII restriction 
site at the beginning of proghrelin’s sequence and were synthesized by Integrated DNA 
Technologies. 
PCR primers: 
5’ CTGTACTTCCAGGGTAAGCTTTTTCTGAGTCCG 3’ 
3’ GACATGAAGGTCCCATTCGAAAAAGACTCAGGC 5’ 
Primers were dissolved in purified water and concentrations were determined by UV 
absorbance at 260 nm. PCR mutagenesis reactions (50 μL) contained the following components: 
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1x Pfu reaction buffer; 10 ng pET23a GST-TEV-human proghrelin-His6; 125 ng forward primer; 
125 ng reverse primer, 20 μM dNTPs, and 1 μL Pfu Turbo DNA polymerase (Agilent). The 
thermocycler program for PCR mutagenesis proceeded as follows: initial denaturation (94 °C, 5 
min); 30 cycles of denaturation (94 °C, 30 sec), annealing (56 °C, 1 min), and extension (68 °C, 
2 min); final extension (68 °C, 5 min). DpnI (1 μL, 20,000 units/mL) was added and reactions 
were incubated at 37 °C for 1 hr. After DpnI digestion, 5 μL of the PCR reaction mixture was 
transformed into 50 μL of Z-competent DH5α E. coli cells (Zymo Research) followed by 
incubation on ice for 30 min. Transformed bacteria were spread on LB-ampicillin (100 μg/mL) 
plates and incubated at 37 °C overnight. 
Single colonies were then inoculated into 5 ml LB media containing 100 μg/mL 
ampicillin in sterile culture tubes, which were incubated at 37 °C overnight with shaking 
(225 rpm). Following overnight growth, plasmids were purified from cultures using EZ- 
10 Spin Column Plasmid DNA kit (BioBasic) per manufacturer’s instructions and verified by 
DNA sequencing (Genewiz). 
PCR reactions was also performed to insert a 5’ HindIII, C-terminal His6 tag and a 3’ 
NotI restriction site in C-ghrelin.  
PCR mutagenesis primers for C-ghrelin construct construction: 
Forward 5’ TATACGAAAACTGGAAAAGCTTGCACTGGCCGGTTGG 3’ 
Reverse 5’ CTCGAGTGCGGCCGCTTAATGGTGGTGATGGTGATGTATA 3’ 
Primers were synthesized by Integrated DNA Technologies. Primers were dissolved in 
purified water and concentrations were determined by UV absorbance at 260 nm. PCR 
mutagenesis reactions (50 μL) contained the following components: 1x One Taq standard 
reaction buffer; 40 ng pET23a GST-TEV-proghrelin-His6 template; 125 ng forward primer; 125 
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ng reverse primer, 20 μM dNTPs, and One Taq DNA polymerase (1 μL, 5,000 units/mL)  
(Agilent). The thermocycler program for PCR mutagenesis proceeded as follows: initial 
denaturation (94 °C, 1 min); 33 cycles of denaturation (94 °C, 30 sec), annealing (59 °C, 1 min), 
and extension (68 °C, 2 min); final extension (68 °C, 5 min). Following PCR mutagenesis the 
PCR product was run on a 0.8% agarose gel at 110 V for ~1.5 hr, then DNA was gel extracted 
using EZ-10 Gel Extraction kit (BioBasic) per manufacturer’s instructions, and concentrations 
were measured by UV absorbance at 260 nm. 
The C-ghrelin gene was ligated into pET23a GST-TEV (HindIII)-X-His6. 3 μg pET23a 
GST-TEV(HindIII)-proghrelin-His6 and C-ghrelin insert DNA was digested with HindIII (1 μL, 
20,000 units/mL),  NotI (1 μL, 20,000 units/mL), 3 μL cutsmart buffer (30 μL total volume), and 
incubated at 37 °C for 2 hr. Samples were then run on a 0.8% agarose gel at 110 V for ~1 hr. The 
bands for the pET23a vector and the C-ghrelin insert were each cut out and DNA was purified 
using EZ-10 Gel Extraction kit (BioBasic) per manufacturer’s instructions, and concentrations 
were measured by UV absorbance at 260 nm. 
Ligations were performed with 50 ng of vector DNA, 40 ng insert DNA, 10 μL 
quick ligase buffer, and 1 μL Quick Ligase (total volume 10 μL) and incubated on ice for 5 
min. 5 μL of ligation reaction was added to 100 μL Z-competent DH5α E. coli cells, followed by 
30 min incubation on ice. Cells were spread on LB- ampicillin (100 μg/mL) plates and incubated 
at 37 °C overnight. Single colonies were inoculated into 5 ml LB cultures containing 100 μg/mL 
ampicillin and grown overnight at 37 °C with shaking (225 rpm). Following overnight growth, 
plasmids were purified from cultures using EZ-10 Spin Column Plasmid DNA kit (BioBasic) per 
manufacturer’s instructions and successful ligation was confirmed by DNA sequencing 
(Genewiz). 
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3.4.6 CpgY FRET assay. Purified CpgY (purified same manner as Materials and Methods 
Chapter 2, section 2.4.19 non-denaturing conditions), CFP-X-YFP in a buffered solution (200 
mM NaCl, 20 mM Tris-HCl, pH 7.3 or 50 mM Tris-HCl, pH 7.3) or bacterial lysate (10 μL) 
were added to either 20 mM Tris-HCl, 10 mM EDTA or to the same buffer the sample was in to 
a total volume of 100 μL. This protein sample was added to a black polystyrene 96-well plate 
(Costar) in the dark and kept under foil until it was read. The wavelength for excitation and 
emission were 488, 555 nm for YFPexcitationYFPemission, 400, 485 nm for CFPexcitationCFPemission, 
and 400, 540 nm for CFPexcitationYFPemission. The plate was read three times, with the reads 10 min 
apart unless otherwise stated. 
 
3.4.7 Fluorescent gel imaging. Protein constructs, either in bacterial lysate or purified protein 
were loaded onto a 12% SDS-PAGE gel using non-reducing sample buffer (no dithiothreitol 
present) immediately (no boiling of the sample). After the gel was finished running it was 
transferred to a blotting container filled with ultrapure H2O. The gel was then imaged using a 
Typhoon 9410 fluorescent gel imager (GE) (Upstate Medical School in Dr. Thomas Duncan’s 
laboratory). The gel was scanned using λex 457 nm, λem 526 nm for CFPexcitationYFPemission and λex 
488 nm, λem 580 nm for YFPexcitationYFPemission, each wavelength reading had a 20 nm bandpass, 
PMT no more than 600V, scan resolution 50 dots/cm, and pixel size 200. All images were 
analyzed using ImageQuant 5.1 software (GE).   
 
3.4.8 SDS-PAGE analysis. 3XSB lysis was performed by using cell lysate (50 μL) was mixed 
with 25 μL of 3x SDS sample buffer and heated to 95 ᵒC for 5 min, followed 
by centrifugation (10,000 x g, 5 min) to pellet insoluble material. B-PER lysis was 
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performed using B-PER lysis reagent (Thermo Scientific, 150 μL), vortexed on high for 1 
min, and cell debris was removed by centrifugation (10,000 x g, 5 min). 25 μL of 3X SDS 
sample buffer was added and heated to 95ᵒC for 5 min, followed by centrifugation 
(10,000 x g, 5 min) to pellet insoluble material. Samples and a protein standards ladder 
(Precision Plus Dual Color Standards, Bio Basic) were loaded onto a 12% polyacrylamide 
gel and run at 150V for 1 hr 30 min or until the dye band had migrated to the bottom of 
the gel. Total protein in cell lysate samples was visualized by staining with Coomassie Blue 
stain and imaged on a ChemiDoc XRS+ BioRad gel imager. 
 
3.4.9 Coommasie Blue staining procedure. Each acrylamide gel was rinsed with ultra pure 
water and covered in approximately 50 mL of destain solution (stock: 2 L water, 1.6 L methanol, 
.4 L acetic acid). The gel was microwaved for 18 sec, at which point the destain solution was 
removed and approximately 50 mL of Coomassie blue stain was added (stock: 0.25 g Coomassie 
Blue dye, 500 mL methanol, 75 mL acetic acid). The gel was microwaved for 30 sec and rocked 
for 5 min. The stain solution was removed, destain solution was added and rocked for 15 min, 
followed by another round of destain addition and rocking for 15 min. The gel was then placed 
into ultra pure water and rocked overnight. Protein gels were then imaged using BioRad XRS+ 
gel imager. 
 
3.4.10 Western blot procedure. Cell lysates or purified protein samples were run on a 
polyacrylamide gel as described above. A polyvinylidene fluoride (PVDF) membrane was 
activated by immersion in methanol for 30 sec, followed by equilibration in transfer buffer (20% 
v/v methanol, 48 mM Tris Base, 39 mM glycine and 0.034% v/v SDS) for 10 min. Filter papers 
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and sponges were also soaked in transfer buffer. The gel was assembled into a transfer cassette 
and proteins were transferred to the PVDF membrane for 20 min at 350 mA, using a BioRad 
TransBlot Turbo RTA Transfer kit per manufacturer’s instructions. 
Following electroblotting, the PVDF membrane was washed in Tris-buffered saline 
(TBS, 0.05 M Tris and 0.14 M NaCl), TBST (TBS with 0.1% v/v Tween 20) and blocked for 4 
hr in 10% v/v nonfat milk in TBST. The membrane was then probed with an HRP-α- 
antiHis primary antibody (1:500 dilution, Rockland) or HRP-α-antiGST primary antibody 
(1:500 dilution, Rockland) in 10% milk TBST overnight under parafilm. Following washing in 
TBST, the membrane was treated with the West Pico Chemiluminescent substrate imaging 
reagent (Thermo Scientific) and imaged on a ChemiDoc XRS+ BioRad gel documentation 
system. 
 
3.4.11 Mass spectrometry of proghrelin and C-ghrelin cleavage. Proghrelin was purified 
using its purification protocol (Chapter 2). Fractions were pooled; buffer exchanged into 50 mM 
Tris-HCL, pH 8.0 and concentrated to 28 μM. A time course was conducted over 144 hr, a time 
point (20 μL for mass spectrometry, 24 μL for gel analysis) was taken from the stock every 24 hr 
and frozen at -80ᵒC. After completion of the time course an SDS-PAGE gel was run and the 
mass spectrometry samples were sent on dry ice to Xavier University in New Orelans, LA.  
 
3.4.12 Alanine mutations of proghrelin-His6. All primers were synthesized by Integrated DNA 
Technologies. Primers were dissolved in purified water and concentrations were determined by 
UV absorbance at 260 nm.  
Forward primers (reverse compliment sequences were also ordered):  
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Q73A 5’ CAGCAGCACAGTGCGGCACTGGGCAAGTTC 3’ 
K77A 5’ CACAGTCAGGCACTGGGCGCGTTCCTGCAAGACATC 3’ 
F78A 5’ CAGGCACTGGGCAAGGCCCTGCAAGACATCCTG 3’ 
Q73AK77A 5’ CAGTATCAGCAGCACAGTGCGGCACTGGGCGCGTTCCTGCAAGAC 3’ 
Q73AF78A 5’ CAGCAGCACAGTGCGGCACTGGGCAAGGCCGTGCAAGACATC 3’  
S18A 5’ CAGCGCAAGGAAGCCAAGAAGCCGCCG 3’ 
D38A 5’ TTAGGTCCGGAAGCTGGCGGCCCAAGC 3’ 
D47A 5’ GGCGCCGAAGCCGAGCTGGAG 3’ 
E43A 5’ GGCCAAGCAGCAGGCGCCGAAGAC 3’ 
E48A 5’ GCCGAAGACGCGCTGGAGGTTCGC 3’ 
E50A 5’ GCCGAAGACGAGCTGGCCGTTCGCTTCAAC 3’ 
E37A 5’ TGGTTACGTCCGGCAGATGGCGGCCCA 3’ 
E46A 5’ GAAGGCGCCGCAGACGAGCTGGAG 3’  
PCR mutagenesis reactions (50 μL) contained the following components: 1x Pfu reaction buffer; 
10 ng pET23a GST-TEV-human proghrelin-His6; 125 ng forward primer; 125 ng reverse primer, 
20 μM dNTPs, and 1 μl Pfu Turbo DNA polymerase (Agilent). For double mutants the GThPH 
Q73A sequence was used as the template. The thermocycler program for PCR mutagenesis 
proceeded as follows: initial denaturation (94 °C, 5 min); 30 cycles of denaturation (94 °C, 30 
sec), annealing (56 °C, 1 min), and extension (68 °C, 2 min); final extension (68 °C, 5 min). 
DpnI (1 μL, 20,000 units/mL) was added and reactions were incubated at 37 °C for 1 hr. After 
DpnI digestion, 5 μL of the PCR reaction mixture was transformed into 50 μL of Z-competent 
DH5α E. coli cells (Zymo Research) followed by incubation on ice for 30 min. Transformed 
bacteria were spread on LB-ampicillin (100 μg/mL) plates and incubated at 37 °C overnight. 
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Single colonies were then inoculated into 5 ml LB media containing 100 μg/mL 
ampicillin in sterile culture tubes, which were incubated at 37 °C overnight with shaking 
(225 rpm). Following overnight growth, plasmids were purified from cultures using EZ- 
10 Spin Column Plasmid DNA kit (BioBasic) per manufacturer’s instructions. The product was 
verified by DNA sequencing (Genewiz). 
 
3.4.13 GST-TEV-X-His6 constructs. Primers were synthesized by Integrated DNA 
Technologies. Primers were dissolved in purified water and concentrations were determined by 
UV absorbance at 260 nm. 
1-X 5’ TATACTGTACTTCCAGGGTAAGCTTGGTAGCAGCTTTCTG 3’ 
16-49 5’ TATACTGTACTTCCAGGGTAAGCTTAAGGAAAGTAAGAAGCCG 3’ 
46-94 5’ TATACTGTACTTCCAGGGTAAGCTTGAAGACGAGCTGGAG 3’ 
61-94 5’ TATACTGTACTTCCAGGGTAAGCTTATCAAGCTGAGTGGTGTG 3’ 
X-94 5’ GCGAAGGAAGCACCGGCCGATAAAGCGGCCGCACTATATA 5’ 
X-49 5’ CAAGCAGAAGGCGCCGAAGACGAGCTGGCGGCCGC 3’  
PCR mutagenesis reactions (50 μL) contained the following components: 1x One Taq 
standard reaction buffer; 40 ng pET23a CpgY template; 125 ng forward primer; 125 ng reverse 
primer, 20 μM dNTPs, and One Taq DNA polymerase (1 μL, 5,000 units/mL) (Agilent). The 
thermocycler program for PCR mutagenesis proceeded as follows: initial denaturation (94 °C, 1 
min); 33 cycles of denaturation (94 °C, 30 sec), annealing (59 °C, 1 min), and extension (68 °C, 
2 min); final extension (68 °C, 5 min). Following PCR mutagenesis the PCR product was run on 
a 0.8% agarose gel at 110 V for ~1.5 hr, then DNA was gel extracted using EZ-10 Gel Extraction 
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kit (BioBasic) per manufacturer’s instructions, and concentrations were measured by UV 
absorbance at 260 nm. 
The proghrelin truncated genes were ligated into pET23a GST-TEV-X-His6. 3 μg 
pET23a GST-TEV-proghrelin-His6 and proghrelin truncation insert DNA was digested with SacI 
(1 μL, 20,000 units/mL), PstI (1 μL, 20,000 units/mL), 3 μL cutsmart buffer (30 μL total 
volume), or digested with NotI (1 μL, 20,000 units/mL), HindIII (1 μL, 20,000 units/mL), 3 μL 
cutsmart buffer (30 μL total volume) and incubated at 37 °C for 2 hr. Samples were then run on a 
0.8% agarose gel at 110 V for ~1 hr. The bands for the pET23a vector and the insert were each 
cut out and DNA was purified using EZ-10 Gel Extraction kit (BioBasic) per manufacturer’s 
instructions, and concentrations were measured by UV absorbance at 260 nm.  
Ligations were performed with 50 ng of vector DNA, 40 ng insert DNA, 10 μL quick 
ligase buffer, and 1 μL Quick Ligase (total volume 10 μL) and incubated on ice for 5 min. 5 μL 
of ligation reaction was added to 100 μL Z-competent DH5α E. coli cells, followed by 30 min 
incubation on ice. Cells were spread on LB- ampicillin (100 μg/mL) plates and incubated at 37 
°C overnight.  
Single colonies were inoculated into 5 ml LB cultures containing 100 μg/mL ampicillin 
and grown overnight at 37 °C with shaking (225 rpm). Following overnight growth, plasmids 
were purified from cultures using EZ-10 Spin Column Plasmid DNA kit (BioBasic) per 
manufacturer’s instructions and successful ligation was confirmed by DNA sequencing 
(Genewiz). 
 
3.4.14 Oligo annealing for construction of X-YFP proghrelin truncations. DNA oligomers 
were constructed by Integrated DNA Technologies. Oligomers were dissolved in purified water 
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and concentrations were determined by UV absorbance at 260 nm. They utilized SacI, XhoI 
restriction sites.  
Oligomers:  
1. CGGCCACGAAGGCCAGGAGTGAAT GGGC  
2. TCGAGCCCATTCACTCCTGGCCTTCGTGGCCGA 
Anneal the oligomers together (200 μM of each) using PCR protocol: 1 cycle (94°C, 5 
min), 2 cycles (94°C, 30 sec), 2 cycles (94°C, 5 min), 2 cycles (80°C, 5 min), 1 cycle (72°C, 7 
min), 1 cycle (66°C, 7 min), 5 cycles (60°C, 3 min), 6 cycles (52°C, 3 min), 7 cycles (46°C, 3 
min), and finally 8 cycles (37°C, 20 min). 
Ligations were performed with 100 ng of parent plasmid DNA either pET23a CpgY 16-
94, 31-94, 46-94, 61-94, and 76-94 (already digested using SacI and XhoI to cut out CFP, gel 
extracted and purified), 1 μL of the annealed oligomers from the PCR reaction, 2 μL quick ligase 
buffer, and 1 μL Quick Ligase (total volume 20 μL) and incubated on ice for 5 min. 5 μL of 
ligation reaction was added to 100 μL Z-competent DH5α E. coli cells, followed by 30 min 
incubation on ice. Cells were spread on LB- ampicillin (100 μg/mL) plates and incubated at 37 
°C overnight. Single colonies were inoculated into 5 mL LB cultures containing 100 μg/mL 
ampicillin and grown overnight at 37 °C with shaking (225 rpm). Following overnight growth, 
plasmids were purified from cultures using EZ-10 Spin Column Plasmid DNA kit (BioBasic) per 
manufacturer’s instructions and successful ligation was confirmed by DNA sequencing 
(Genewiz). 
The only positive result was 16-94-YFP so this construct was used for the remaining 
constructs. This construct was then digested alongside CpgY 31-94, 46-94, 61-94, 76-94. 3 μg 
pET23a 16-64-YFP and proghrelin truncation insert DNA was digested with HINDIII (1 μL, 
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20,000 units/mL), XhoI (1 μL, 20,000 units/mL), 3 μL cutsmart buffer (30 μL total volume) and 
incubated at 37 °C for 2 hr. Samples were then run on a 0.8% agarose gel at 110 V for ~1 hr. The 
bands for the pET23a vector and the insert were each cut out and DNA was purified using EZ-10 
Gel Extraction kit (BioBasic) per manufacturer’s instructions, and concentrations were measured 
by UV absorbance at 260 nm.  
Ligations were performed with 50 ng of vector DNA, 40 ng insert DNA, 10 μL quick 
ligase buffer, and 1 μL Quick Ligase (total volume 10 μL) and incubated on ice for 5 min. 5 μL 
of ligation reaction was added to 100 μL Z-competent DH5α E. coli cells, followed by 30 min 
incubation on ice. Cells were spread on LB- ampicillin (100 μg/mL) plates and incubated at 37°C 
overnight. Single colonies were inoculated into 5 mL LB cultures containing 100 μg/mL 
ampicillin and grown overnight at 37°C with shaking (225 rpm). Following overnight growth, 
plasmids were purified from cultures using EZ-10 Spin Column Plasmid DNA kit (BioBasic) per 
manufacturer’s instructions and successful ligation was confirmed by DNA sequencing 
(Genewiz). 
 
3.4.15 Cloning CpgY into pCAF. The CpgY gene was ligated into pCAF. 3 μg pET23a CpgY 
and pCAF DNA was digested with NotI (1 μL, 10,000 units/mL), EcoRI (1 μL, 20,000 
units/mL), 3 μL Cutsmart buffer (30 μL total volume), and incubated at 37 °C for 2 hr. Samples 
were then run on a 0.8% agarose gel at 110 V for ~1 hr. The bands for the pCAF vector and the 
CpgY insert were each cut out and DNA was purified using EZ-10 Gel Extraction kit (BioBasic) 
per manufacturer’s instructions, and concentrations were measured by UV absorbance at 260 nm. 
Ligations were performed with 50 ng of vector DNA, 51 ng insert DNA, 10 μL quick 
ligase buffer, and 1 μL Quick Ligase (total volume 10 μL) and incubated on ice for 5 min. 5 μL 
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of ligation reaction was added to 100 μL Z-competent DH5α E. coli cells, followed by 30 min 
incubation on ice. Cells were spread on LB- ampicillin (100 μg/mL) plates and incubated at 37 
°C overnight. Single colonies were inoculated into 5 mL LB cultures containing 100 μg/mL 
ampicillin and grown overnight at 37 °C with shaking (225 rpm). Following overnight growth, 
plasmids were purified from cultures using EZ-10 Spin Column Plasmid DNA kit (BioBasic) per 
manufacturer’s instructions and successful ligation was confirmed by DNA sequencing 
(Genewiz). 
 
3.4.16 pCAF CpgY transfection. Following confirmation of CpgY insertion the pCAF CpgY 
plasmid was then transfected into HEK 293FT cells. 1 x 10
6
 cells/well were plated in DMEM 
((Dulbecco's Modified Eagle's Medium, Corning) containing 10% FBS and 1% 
penicillin/streptomycin) in a 6-well clear bottom plate. Cells were allowed to incubate 16-18 hr 
at 37 ᵒC 5% CO2 before transfection. Transfections used DMEM in the absence of FBS, 4 μg 
pCAF CpgY DNA, and a range of Lipofectamine 2000 transfection reagent (Thermo fischer) 
transfection reagent (9, 10, 12, 15 μL). After overnight incubation, DMEM (containing no FBS), 
DNA and transfection reagent were allowed to incubate together for 5 min at room temperature 
then were added to the plated cells. After the transfection mixture was added, cells were allowed 
to incubate for 48 hours at 37 ᵒC 5% CO2. Cells were collected, washed in PBS, and lysed using 
RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 10% v/v NP40, 0.1% v/v 
SDS) containing a mini Roche tablet (Sigma). 
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Chapter 4: Structure-activity relationship determination of ghrelin 
O-acyltransferase substrate binding utilizing unnatural amino acid 
incorporated peptides 
 
Portions of this chapter, including figures and experimental, have been previously published and 
reproduced with permission from the publisher, Reference 57, Cleverdon, E. R.; Davis, T. R.; 
Hougland, J. L., Functional group and stereochemical requirements for substrate binding by 
ghrelin O-acyltransferase revealed by unnatural amino acid incorporation. Bioorg Chem 2018, 
79, 98-106. Copyright © 2018 Elsevier Inc.  
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4.1 Introduction 
 
Ghrelin octanoylation is catalyzed by the ER membrane-bound enzyme, ghrelin O-
acyltransferase (GOAT),
1-2
 which is a member of the membrane-bound O-acyltransferase 
(MBOAT) family.
3
 GOAT is one of three MBOATs, along with Porcupine (PORCN) and 
Hedgehog acyltransferase (Hhat), which acylate protein substrates with the other family 
members modifying small molecules.
3-5
 These enzymes are topologically complex integral 
membrane proteins, which has limited studies towards understanding of the structures and 
catalytic mechanisms of these proteins. Since these enzymes modify substrates that play 
important roles in cell function and biological signaling, there is substantial interest in inhibitor 
development targeting them.
3, 6-16
 A complete understanding of the substrate recognition 
elements necessary for acylation of ghrelin by GOAT is crucial for exploiting the therapeutic 
potential provided by this enzyme and other MBOAT family members.  
As discussed in Chapter 1, ghrelin receptor activation and signaling has been linked to 
diseases including diabetes and obesity.
17-19
 Ghrelin is involved in many biological functions as 
well as disease states all of which are a result of GHS-R1a activation.
20-23 
Since GOAT acylation 
is the first step in this signaling cascade, the ghrelin-GOAT system presents a unique and largely 
unexploited target for inhibition as a therapeutic avenue.
4, 24-27
 Previous studies have shown short 
peptides containing the first five amino acids of the ghrelin N-terminal sequence (GSSFL) can 
serve as substrates for GOAT-catalyzed serine octanoylation. 
10, 28-31
 Since the N-terminal region 
of ghrelin has been determined to be important for GOAT recognition, ghrelin mimetic peptides 
have the potential for high selectivity for GOAT and reduced off-target effects from binding to 
other protein targets. The design of ghrelin mimetic inhibitors increases our understanding of 
ghrelin binding and recognition by GOAT.
9-10, 28-29, 31-32
 Through the use of small N-terminal 
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ghrelin peptides with amino acid substitutions and/or chemical addition/deletions, it was 
concluded that GOAT utilizes distinct functional group contacts with multiple positions within 
ghrelin for acylation to occur. 
28-29
 
In studies focused solely on ghrelin binding to GOAT, unlike studies which are based 
upon reactivity that includes both binding and octanoylation of the peptide, 
28-29, 33
 acylated 
ghrelin mimetics have been demonstrated to be efficient inhibitors of GOAT. In the first reported 
GOAT inhibitors, Yang and coworkers showed acylated pentapeptides inhibit GOAT-catalyzed 
ghrelin acylation.
10
 These octanoylated peptides utilized the serine ester motif in ghrelin but 
instead use a more stable amide linkage.
10
 Using the reported inhibitor by Yang and coworkers 
as a template, Darling and coworkers designed acylated ghrelin-mimetic peptides to demonstrate 
GOAT has a preference for acyl chains with a length of seven or eight carbons.
29
 Ghrelin 
mimetic inhibitors continued to incorporate acyl chains attachments into their design which has 
resulted in enhanced binding from the attachment of the hydrophobic moiety.
9, 34
 The acylated 
ghrelin mimetics have shown potency against GOAT. However, there are issues with their ability 
to cross the cell membrane without the presence of a cell-penetrating peptide sequence, 
biostability, as well as, the possibility of GHS-R1a receptor activation. All of these negative 
attributes have hindered their further therapeutic development 
20
.  
More recently, a longer ghrelin-mimetic peptide incorporating 2,3-diaminopropanoic acid 
(Dap), a serine analog that replaces the hydroxyl with an amine (same starting residue as used in 
the acylated inhibitors described above), at the third position was reported by Taylor and 
coworkers to serve as an inefficient substrate for GOAT-catalyzed acylation.
31
 To further 
investigate the importance of the amino side chain of the non-acylated Dap residue, we have 
designed a series of small N-terminal ghrelin mimetics to probe binding affinity and acylation 
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efficiency by hGOAT (Figure 4.1). This approach fully defined the necessary residues for GOAT 
recognition and binding which complements previous investigations of GOAT reactivity with 
ghrelin mimetic peptides.  
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Figure 4.1. Structure of GSSLFCAcDan and GSDapFLCAcDan peptides. Both peptides were 
probed for their acylation efficiency by human GOAT (hGOAT) by fluorescent detection using 
RP-HPLC analysis. Serine is indicated by Ser and a hydroxyl, Dap is indicated by Dap and an 
amine.  
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4.2. Results  
4.2.1 A 2, 3-diaminopropanoic acid (Dap) substituted ghrelin peptide acts as an inefficient 
hGOAT substrate.  
 
Based on the reported data mentioned above that showed longer ghrelin-mimetic peptides 
with Dap substitution at the serine 3 (S3) position act as weak substrates for the mouse ortholog 
of GOAT (mGOAT), 
31
 we investigated if human GOAT (hGOAT) was able to acylate a short 
fluorescently labeled peptide with a Dap residue at the third position (GSDapFLCAcDan) (Figure 
4.1).  Since GSDapFLCAcDan acylation with octanoyl-CoA has a very similar structure to the first 
reported inhibitor of GOAT,
 10
 octanoylation of this peptide could lead to product inhibition. To 
reduce the chance of product inhibition, we explored acylation of GSDapFLCAcDan using a less 
active acyl donor co-substrate, decanoyl-CoA, which would yield an acylated product with lower 
potency as an inhibitor.
29
 Incubation of GSDapFLCAcDan in the presence of decanoyl-CoA and 
hGOAT-containing microsomal fraction reproducibly produced two peaks, both of which are 
consistent with attachment of the longer CoA donor based on their retention time on RP-HPLC 
(Figure 4.2A and 4.2B). Integration of peak fluorescence showed that acylation of 
GSDapFLCAcDan is not as efficient as GSSFLCAcDan, which is consistent with the report from 
Taylor and coworkers in reactions using longer Dap-containing peptides and mGOAT (Figure 
4.2C).
31
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Figure 4.2. Analysis of acylation of a ghrelin mimetic peptide substrate incorporating a 
Dap residue. A) HPLC chromatograms showing product formation. A single acylation 
product is detected upon incubation of GSSFLCAcDan in the presence of hGOAT and decanoyl-
CoA and two product peaks for GSDapFLCAcDan under analogous reaction conditions; red trace, 
GSSFLCAcDan; blue trace, GSDapFLCAcDan. B) Full chromatograms for analysis of acylation 
of ghrelin mimetic peptide substrates. Expanded view of peaks for decanoylated products 
observed with GSSFLCAcDan (red) and GSDapFLCAcDan (blue) from A. HPLC chromatograms 
from hGOAT reactions with GSSFLCAcDan (in red) and GSDapFLCAcDan (in blue) and decanoyl-
CoA under analogous conditions. C) Normalized integrated product fluorescence (product / 
product+substrate) for GSSFLCAcDan and GSDapFLCAcDan acylation. D) Acylation of 
GSSFLCAcDan and GSDapFLCAcDan in the presence of multiple reaction conditions. hGOAT 
inhibitor (+ NEM), absence of esterase inhibitor (-MAFP), absence of hGOAT in membrane 
protein fraction (-hGOAT), and absence of membrane protein fraction (no membrane) compared 
to acylation under standard reaction conditions. All reported activities represent the average of a 
minimum of three independent trials, with error bars representing one standard deviation. The 
figure is reproduced with permission from Reference 57 (Appendix V). © 2018 Elsevier Inc. 
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In order to determine if the two acylation products observed with GSDapFLCAcDan 
require hGOAT enzymatic activity, N-ethylmaleimide (NEM) was introduced to the reaction. 
NEM has been shown to irreversibly inhibit hGOAT enzymatic activity.
7
 Production of the 
longer eluting GSDapFLCAcDan product peak (peak 2) was susceptible to NEM treatment (Figure 
4.2D), which indicated hGOAT activity was required for efficient acylation leading to that 
product. In contrast, the first GSDapFLCAcDan product peak (peak 1) was minimally affected by 
NEM treatment indicating that hGOAT was not or minimally required for product formation. 
Both product peaks were also observed when GSDapFLCAcDan was incubated with decanoyl-
CoA without the presence of membrane fraction containing hGOAT or in buffer alone. Peak 2 is 
not as prevalent as in the presence of hGOAT in either of those conditions.  This demonstrated 
that the acylation reaction with the GSDapFLCAcDan peptide occurred through both enzymatic 
(peak 2) and non-enzymatic routes (peak 1 and peak 2). 
The presence of esterases in microsomal fractions provides an avenue for probing ester 
linkages as a result of hGOAT catalysis.
36
 Treatment with the esterase inhibitor methyl 
arachidonyl fluorophosphonate (MAFP) inhibited esterase hydrolysis activity the microsomal 
fractions, while untreated microsomal fraction hydrolyzes an ester linkage such as those in S3 
acylated ghrelin peptides.
36
 When hGOAT reactions were performed without MAFP 
pretreatment to inactivate esterases, the first peak in the GSDapFLCAcDan
 
reaction had a smaller 
integrated fluorescence value in a similar manner as the acylated product peak for the 
GSSFLCAcDan substrate (Figure 4.2D). The second product peak in the GSDapFLCAcDan reaction 
was not affected by the presence/absence of MAFP, consistent with this peak representing 
GSDapFLCAcDan acylation of the amino group which resulted in an esterase-resistant amide 
linkage.  In summary, the data indicates that acylation likely occurred at both S2 (ester linkage) 
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and Dap3 (amide linkage) positions of the GSDapFLCAcDan substrate. The Dap3 modification 
was catalyzed by hGOAT, with a small minority occurring non-enzymatically, and acylation of 
S2 was occurring solely through a non-enzymatic pathway. This is consistent with the inability 
of GOAT to acylate S2 reported by other research groups.
1-2, 37
 In either case, acylation of the 
Dap-containing ghrelin mimetic peptide is much less efficient than for a substrate with serine at 
the canonical acylation site. 
Given that GSDapFLCAcDan can act as a substrate for hGOAT, enzymatic acylation of the 
peptide should be subject to loss of activity upon removal of residues within GOAT required for 
acylation of the wildtype sequence with serine at the acylation site. A number of hGOAT 
mutants including H338A, D234A and C235A were evaluated
38
 and found to be catalytically 
inactive and were not able to catalyze the acylation of GSSFLCAcDan. If GSDapFLCAcDan is 
acting as an hGOAT substrate then the catalytic machinery should be necessary for this substrate 
as well. When GSDapFLCAcDan was under its standard reaction conditions (1 mM decanoyl-CoA, 
5 µM peptide) the catalytically inactive hGOAT mutants (H338A, D234A, and C235A) led to no 
observable product in comparison to wild type hGOAT. This behavior was also observed with 
conservative mutations of these sites H338F, D234N and C235S. It was previously proposed that 
H338 is not the catalytic base because the amine in the Dap’s sidechain has a moderate pKa, 31, 39 
and GOAT is able to acylate a Dap-incorporated peptide in its absence. This conclusion is not 
supported by examples of similar systems, as demonstrated in histone acetylation wherein lysine 
residues are modified using a catalytic base
40
 or by the behavior observed during these studies. 
There is enhancement of product formation for the GSDapFLCAcDan substrate (peak 2) in the 
presence of H338 compared to when it is knocked out (as well as at C235 and D234) using an 
alanine or phenylalanine mutant, implying that this residue is important for enzymatic catalysis. 
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4.2.2 A Dap-substituted peptide acts as a potent hGOAT inhibitor.  
 
To determine if Dap incorporation at the S3 position affected peptide binding to hGOAT, 
ghrelin mimetic peptides with alanine (GSAFL), serine (GSSFL), or Dap (GSDapFL) were 
assayed as unlabeled competitive inhibitors of hGOAT acylation using GSSFLCAcDan as a 
substrate (Figure 4.3). No inhibition of GSSFLCAcDan octanoylation was observed with GSAFL 
up to 10 M.2, 29, 41 The serine-containing GSSFL peptide exhibited an IC50 value of 53 ± 4 μM, 
but S3 substitution with the amine (Dap) increases peptide potency as an hGOAT inhibitor ~380-
fold (GSDapFL IC50 = 140 ± 20 nM). The potency this unnatural amino acid incorporation 
indicated the free amine at the acylation site enhanced peptide binding to the hGOAT active site 
and provided an opportunity to explore many facets of peptide binding to GOAT. 
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Figure 4.3. Inhibition of hGOAT-catalyzed octanoylation of GSSFLCAcDan by GSSFL and 
GSDapFL. IC50 values for unlabeled GSSFL (R = OH) and GSDapFL (R = NH2) peptides were 
calculated from percent activity as described in the experimental section, with error bars 
indicating the standard deviation from a minimum of three independent measurements. The inset 
displays the inhibition data for GSDapFL with a logarithmic concentration scale. The figure is 
reproduced with permission from Reference 57 (Appendix V). © 2018 Elsevier Inc. 
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4.2.3 Length dependence of GOAT inhibition by Dap-containing peptides.  
Using Dap-containing ghrelin peptides mimetics, we examined the impact of both N-
terminal and C-terminal truncations on peptide binding to hGOAT (Figure 4.4). Deletion of the 
N-terminal glycine residue yielded the peptide SDapFL and led to a complete loss of inhibition 
of GOAT (IC50 > 100 μM). Acetylation of the SDapFL peptide also led to no detectible binding 
to hGOAT (IC50 > 100 μM), reflected at minimum of a 700-fold loss in peptide binding affinity 
compared to the GSDapFL parent upon removal of the N-terminal amino group.  Length changes 
to the C-terminal sequence also affected peptide binding, although not as severely as the N-
terminal truncations.  To determine if a longer peptide with more N-terminal sequence would 
increase its binding affinity for the enzyme, we examined inhibition using a six amino acid 
ghrelin mimetic sequence (GSDapFLS). There was enhanced binding with the longer sequence 
but with less than a 2-fold change in IC50 value.  Removal of L5 residue from GSDapFL 
(GSDapF) increased the IC50 ~10-fold relative to GSDapFL. An additional C-terminal truncation 
to GSDap resulted in complete loss of inhibition (IC50 > 100 μM). The truncation analysis 
highlighted two important groups within the ghrelin sequence that are essential in peptide 
binding to hGOAT, the N-terminal amino group on G1 and the F4 position. 
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Figure 4.4. Defining the N- and C-terminal length dependence of Dap-containing ghrelin 
mimetic peptide GOAT inhibitors. The GSDapFLS peptide was truncated from the N- and C-
termini as shown above, with IC50 values calculated for each truncated derivative as described in 
the experimental section. The figure is reproduced with permission from Reference 57 
(Appendix V). © 2018 Elsevier Inc. 
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4.2.4 Sequence dependence of GOAT inhibition by Dap-containing peptides  
 
The truncation analysis of the GSDapFL peptide inhibitor highlighted the importance of 
the F4 residue for peptide binding to hGOAT. To probe the importance of F4’s benzyl group, a 
series of amino acid changes were analyzed at the F4 position in the context of peptides 
containing either five amino acids in GSDapFL or with four amino acids in GSDapF. In the 
GSDapFL peptide, the phenylalanine was changed to alanine, threonine (smaller amino acids) 
and then tryptophan (a large amino acid, which is also hydrophobic and aromatic).
29
 
Incorporation of either alanine or threonine in the peptide led to a complete loss of binding 
reflected by lack of inhibition up to 100 μM (Table 4.1).  In contrast, mutation to tryptophan only 
reduced inhibitor potency by approximately 2-fold (GSDapWL IC50 = 0.30 ± 0.04 μM). In the 
shorter GSDapF peptide, the phenylalanine was substituted with either alanine or glycine to 
determine the importance of the benzyl sidechain of F4 to peptide binding in a shorter context. In 
both cases, no inhibition of hGOAT activity was observed up to 100 μM which indicates the 
phenylalanine side chain is crucial for peptide binding which is consistent with the studies of the 
longer GSDapFL peptide. 
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Mutation Peptide Sequence IC50 (μM) 
wildtype GSDapFL 0.14 ± 0.02 
S2A GADapFL 0.23 ± 0.03 
F4A GSDapAL >100 
F4T GSDapTL >100 
F4W GSDapWL 0.3 ± 0.04 
L5A GSDapFA 11 ± 2  
   
wildtype GSDapF 1.2 ± 0.1 
F4A GSDapA >100 
F4G GSDapG >100 
 
Table 4.1. Impact on mutations within GSDapFL and GSDapF peptides on inhibitor 
potency against hGOAT. IC50 measurements utilized the unlabeled Dap peptides as competitive 
inhibitors using GSSLFCAcDan as the substrate for hGOAT acylation. Based upon the decrease in 
integrated fluorescence value and inhibitor concentration the IC50 was calculated, as described in 
the experimental section. The figure is reproduced with permission from Reference 57 
(Appendix V). © 2018 Elsevier Inc. 
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Alanine amino acid incorporation at other positions in the GSDapFL peptide was used to 
investigate whether the importance of the functionality at F4 is unique to that position. When S2 
was changed to alanine (GADapFL) the peptide was an effective inhibitor of hGOAT with an 
IC50 within 2-fold of the GSDapFL parent, while substitution of L5 to alanine decreased inhibitor 
potency 78.5 fold with an IC50 = 11 ± 2 μM compared to the parent, IC50 = 0.14 ± 0.02 μM. 
These studies of alanine incorporation throughout the GSDapFL peptide further demonstrate that 
the F4 side chain provides a necessary recognition element for ghrelin binding by hGOAT. 
4.2.5 D-amino acid substitution at S3 and F4 impedes ghrelin octanoylation by hGOAT.  
 
To investigate the stereoselectivity of substrate recognition by hGOAT, two peptides 
containing a D-amino acid at either the S3 or F4 position, GS(D-S)FLCAcDan and GSS(D-
F)LCAcDan, were evaluated for activity as GOAT substrates since the stereoselectivity of GOAT 
at or near the ghrelin acylation site had not been previously reported. In enzymatic 
characterization studies in the 1970s, chymotrypsin was observed to proteolyze peptide 
substrates bearing D-amino acids slower than ones containing L-amino acids using identical 
peptide sequences (Figure 4.5).
42-44
 Using this information about the relative rate of digestion 
between D- and L-substrates, chymotrypsin digestion was used to confirm the presence of D-F4 
in the GSSFLCAcDan peptide (Figure 4.5). Using the chymotrypsin digestion as evidence of D-
amino acid incorporation, we examined both the D-S3 and D-F4 peptides for their reactivity. 
When measured under standard reaction conditions (1.5 µM peptide, 500 µM octanoyl-CoA), 
incorporation of a D-S3 residue at the acylation site resulted in a small (<2-fold) reduction in 
acylation activity relative to the analogous L-GSSFLCAcDan (Figure 4.6). However, the peptide 
with the D-F4 substitution exhibited a more noticeable effect with peptide substrate reactivity 
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exhibiting ~20% of the activity of the L-wildtype substrate.  This apparent loss of peptide 
substrate reactivity is comparable to previously reported alanine substitution at this same position 
in a ghrelin-mimetic substrate peptide.
29
 These findings reinforce the data collected so far that 
the F4 position is playing a crucial role in ghrelin recognition by GOAT but more surprising is 
that the enzyme active site will acylate a substrate containing a stereochemical inversion at the 
acylation site.  
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Figure 4.5. Protection from chymotryptic digestion confirmed presence of D-phenylalanine 
residue in GSSFLCAcDan substrate. GSSFLCAcDan and GSS(D-F)LCAcDan peptides were 
subjected to digestion by chymotrypsin. Following digestion for time points given, reactions 
were analyzed by HPLC to determine the amount of undigested peptide remaining. All time 
points are normalized to the peptide integration at the zero time point. Each data point represents 
the average of three independent trials, with error bars reflecting one standard deviation. The 
figure is reproduced with permission from Reference 57 (Appendix V). © 2018 Elsevier Inc. 
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Figure 4.6. The impact of D-amino acid substitution on peptide acylation by hGOAT. 
hGOAT exhibits distinct amino acid stereoselectivity at the S3 and F4 positions. Product 
formation for peptide substrates with D-amino acid mutations at the S3 and F4 positions of the 
GSSFLCAcDan substrate peptide, shown as % peptide conversion to octanoylated product 
normalized to the wildtype substrate peptide containing all L-amino acids. The figure is 
reproduced with permission from Reference 57 (Appendix V). © 2018 Elsevier Inc. 
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4.2.6 hGOAT tolerates backbone methylation within ghrelin peptides 
 
In addition to amino acid side chains, the GSDapFL peptide contains the N-terminal 
amino group and backbone amides which could be important recognition elements for hGOAT 
within ghrelin.  The removal of the N-terminal amine had been shown to eliminate ghrelin 
peptide binding and reactivity, 
29
 but the backbone amide groups had not been investigated in the 
same manner.  To probe possible ghrelin-hGOAT interactions, the N-terminal amine of G1 and 
the peptide backbone amides at each position, excluding Dap3, were methylated. These 
methylated peptides were evaluated for their ability to inhibit hGOAT acylation of the ghrelin 
mimetic GSSFLCAcDan peptide substrate (Table 4.2). G1 amino group methylation with sarcosine 
resulted in a small improvement in binding affinity as reflected by an IC50 value of 0.088 ± .001 
μM, consistent with the reactivity of a peptide substrate with an N-terminal sarcosine 
modification in a previous study.
29
 Backbone amide N-methylation was similarly tolerated at two 
of the three sites examined, methylation at F4 and L5 resulted in increased binding affinity to the 
enzyme compared to the non-methylated peptides by a small amount. However, N-methylation 
of the S2 backbone amide led to complete loss of inhibition at concentrations up to 100 μM.  The 
loss of enzyme binding affinity with N-methylation at the backbone amide of S2 indicated a 
possible binding contact between ghrelin and GOAT at this position, possibly involving a 
hydrogen bond involving the amide hydrogen group or binding disruption upon incorporation of 
the larger methyl group.  
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Table 4.2. Impact of peptide backbone methylation on Dap peptide inhibitor potency 
against hGOAT. IC50 measurements utilized the unlabeled Dap peptides as competitive 
inhibitors using GSSLFCAcDan as the substrate for hGOAT acylation. Based upon the decrease in 
integrated fluorescence value and inhibitor concentration the IC50 was calculated, as described in 
the experimental section. The figure is reproduced with permission from Reference 57 
(Appendix V). © 2018 Elsevier Inc. 
Methylation Site(s) Peptide Sequence IC50 (μM) 
none GSDapFL 0.14 ± 0.02 
G1 SarSDapFL 0.088 ± .001  
S2 GN-MeSDapFL >100 
F4 GSDapN-MeFL 0.097 ± 0.013  
L5 GSDapFN-MeL 0.062 ± 0.009  
   
G1, F4 SarSDapN-MeF 1.5 ± 0.1 
G1, F4, L5 SarSDapN-MeFN-MeL 6 ± 1 
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With all of the single-site methylations except for the S2 position within the GSDapFL 
peptide yielding small but detectible improvements in peptide binding to hGOAT, the next 
approach was to investigate the impact of multiple simultaneous methylations in the sequence.  
Methylation at G1 (sarcosine), F4, and L5 led to the design of two methylated analogs of the 
GSDapF and GSDapFL peptides, SarSDapN-MeF and SarSDapN-MeFN-MeLeu (Table 4.2).  Each of 
those methylated peptides served as hGOAT inhibitors, with the IC50 value for the shorter 
peptide comparable to its unmethylated counterpart within 11-fold. This result indicates that the 
simultaneous methylations in the peptides did not prove to be additive since SarSDapN-MeF and 
SarSDapN-MeFN-MeLeu had IC50 higher than their unmethylated parent peptides, although they are 
hypothetically more cell permeable than their parent peptides.
45-46
 The cell permeability affects 
their potency since in order to bind to GOAT they will need to cross the cell membrane. 
Although, cell-based studies of GOAT inhibition suggested that these peptides do not exhibit 
sufficient cell permeability to target GOAT within the cell (Section 4.2.7). The SarSDapN-MeF 
peptide exhibited sufficient potency against hGOAT in enzyme-based studies to support further 
development of ghrelin-derived substrate mimetics as GOAT inhibitors. 
4.2.7 Cell studies into Dap-peptide permeability 
 
SarSDapN-MeF was chosen to pursue cell studies since it is shorter, has a smaller IC50 
value than the SarSDapN-MeFN-MeLeu peptide and is compliant with some of Lipinski’s rules for 
orally available drug molecules.
47-48
  The effect on cell viability of this peptide was determined 
using an Alamar blue assay
49
 in two different human cell lines, HEK 293FT and PC3 cell lines. 
Both of these cell lines were modified to stably produce the cellular machinery for ghrelin 
acylation to occur (proghrelin and GOAT are both present). In both cases, there was no loss of 
cell viability observed up to 100 μM (Figure 4.7A) using Alamar blue (described in detail, 
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materials and methods section 4.4.7).
49
 Other Dap peptides described previously were also 
measured on PC3 cells up to 100 μM and there was no loss of cell viability was observed (Figure 
4.7B).  
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Figure 4.7 Cell viability of Dap-incorporated peptides in PC3 or HEK 293FT cells. Cell 
viability is expressed relative to the cells treated with DMSO which show no cell death at 1% 
v/v. A lower cell viability percentage means more cell death. A) Cell viability of SarSDapN-
MeF) in HEK 293FT cells expressing mGOAT. The inhibitor was dissolved in DMSO with 1% 
DMSO to total cell volume. The peptide was incubated with 10% v/v Alamar blue for 24 hours 
with 100 µL of 2 X 10
5
 cells/mL to each well in a 96-well clear bottom plate.  Absorbance 
readings at 500 and 670 nm was read for analysis. B) Cell viability of multiple Dap-
incorporated peptides in PC3 cells expressing hGOAT. The inhibitors were dissolved in 
DMSO with 1% DMSO to total cell volume. The peptides were incubated with 10% v/v Alamar 
blue for 24 hours with 100 µL of 2 X 10
5
 cells/mL to each well in a 96-well clear bottom plate. 
Absorbance at 500 and 670 nm was read for analysis. The peptides were at a concentration of 
100 μM as well as the steroid CDDO-Me which is a positive control for cell death.  
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The lack of cytotoxicity observed for these peptides may suggest these inhibitors are 
incapable of permeating the cell membrane, which would block binding to and inhibiting GOAT 
localized in the ER membrane.
50
 To determine whether these peptides were inhibiting GOAT 
within cells, an ELISA (enzyme-linked immunosorbent assay) was used to determine the 
production of acylated ghrelin by GOAT in HEK 293FT cells in the presence and absence of 
Dap-containing ghrelin mimetic peptides. Using the SarSDapN-MeF peptide inhibitor, a small 
decrease in acyl ghrelin was observed at 30 μM peptide concentration. However, due to the 
detection limit of the ELISA antibodies and the cell line we were unable to measure total 
(unacylated and acylated) ghrelin levels. Consequently, were unable to conclusively analyze the 
efficacy of SarSDapN-MeF inhibition of acyl ghrelin levels in the mGOAT expressing HEK 
293FT cell line. Following up on unsuccessful ELISA measurements, the Dap-containing 
peptides were probed for their cell permeability; since the reason that there was no measurable 
effect on acylation was a result of low permeability. Cells were incubated with Dap-containing 
peptides then lysed and the lysate labeled with fluorescamine. Fluorescamine specifically labels 
primary amines, such as a Dap residue which is present in SarSDapN-MeF (Figure 4.8).
51-52
 This 
cell lysate was then analyzed using RP-HPLC to detect the presence of Dap-containing peptides 
(Figure 4.9). In comparison to the control lysate (no peptide added, black trace in Figure 4.9) or 
the peptide alone (purple trace in Figure 4.9) there was no evidence that peptides were present in 
the cell lysate. The HPLC chromatograms are unclear as to the presence of the peptide in the cell 
due to background from cellular proteins or peptides.  
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Figure 4.8. Schematic of fluorescamine labeling. Fluorescamine was used in cell studies to 
determine the cell permeability of Dap containing peptides. Initially in the absence of a primary 
amine, fluorescamine is non-fluorescent then is derivatized to its fluorescent counterpoint. Figure 
is reproduced with permission from Reference 52 (Appendix VI) © 1972 American Chemical 
Society. 
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Figure 4.9. Fluorescamine labeling of SarSDapN-MeF-treated HEK 293FT cells. Cells 
treated with SarSDapN-MePhe (dissolved in DMSO) or DMSO (vehicle) were pelleted, lysed 
using RIPA buffer containing a Roche protease inhibitor tablet, fluorescamine labeled, protein 
precipitated with ammonium sulfate, and supernatants were analyzed via RP-HPLC. Blue trace 
100 μM SarSDapN-MePhe-treated cells, red trace RIPA buffer (buffer control), purple trace 25 
μM SarSDapN-MePhe without cell lysate present (peptide control), black trace DMSO treated 
cells. The peak at 4.5 minutes is elution of fluorescamine-labeled SarSDapN-MePhe indicated in 
the inset with a black arrow. 
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4.3 Conclusions 
 
 A number of N-terminal ghrelin peptides containing a Dap substitution were screened to 
study the binding to hGOAT and hGOAT’s ability to catalyze acylation of amino groups. 
Incorporation of a Dap residue at S3 (the acylation site) led to a noticeable decrease in the 
efficiency of hGOAT-catalyzed peptide acylation and the appearance of an increased amount of 
non-enzymatic acylation. GSDapFLCAcDan in the presence of hGOAT and decanoyl-CoA led to 
two distinct products with one consistent with acylation that occurred at the serine hydroxyl 
group at the S2 position and the other acylation that occurred at the Dap side chain amino group. 
The appearance of two distinct product peaks with acylation of GSDapFLCAcDan did not occur 
with a substrate containing two serine residues, GSSFLCAcDan. The behavior seen with 
GSDapFLCAcDan suggested that the adjacent serine and Dap residues resulted in an increased 
non-enzymatic catalysis of side chain acylation of these amino acids. While Dap incorporated 
peptides with longer sequences had been used to investigate GOAT’s acylation reaction as 
mechanistic probes, 
31
 the non-enzymatic acylation observed with the short peptides used in our 
experimental analysis and the overall limited reactivity reduces the ability of these Dap-based 
peptides as tools for investigating ghrelin acylation by GOAT. 
One of the more unexpected results from these studies is that replacement of the S3 
(hydroxyl) position with Dap3 (amine) significantly enhance peptide binding to hGOAT. 
GSDapFL and GSDapFLS peptides are the first examples of non-acylated peptide “substrate-
mimetic” inhibitors of hGOAT with sub-micromolar IC50 values. It is clear that the incorporation 
of Dap in ghrelin mimetic peptides enhanced binding to hGOAT; however, the exact chemical 
interactions/mechanism occurring which led to this result is unknown. There is a possibility that 
the amine side chain is involved in an electrostatic or hydrogen-bond within the hGOAT active 
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site. If these chemical interactions are occurring we can look to serine proteases or hydrolases as 
examples for acylation of S3 in GSSFLCAcDan by hGOAT, in which, the serine hydroxyl acts as a 
nucleophile in a transition-state interaction. When an amine is present such as in GSDapFL, the 
transition-state interaction mentioned above is converted to a ground-state interaction which 
could greatly contribute to the increase in binding to GOAT.
53-55
 Regardless of the molecular 
basis for the binding to GOAT seen with Dap-incorporated peptides, these small ghrelin 
mimetics provide a scaffold which can be easily modified in order to study ghrelin binding and 
the necessary recognition elements by GOAT. Structure-activity relationship of Dap-
incorporated peptides binding to GOAT described has led to the identification of critical aspects 
of a pharmacophore which defines a new class of GOAT inhibitors (Figure 4.10).  There were 
key findings regarding ghrelin recognition elements by GOAT like the importance of the N-
terminal amino group and the finding that the minimum length for the peptide is a four amino 
acid, “GSSF”, sequence for binding to GOAT.10, 28-30 Methylation at G1’s N-terminal amine, 
sarcosine, shown in this study and others to be tolerated in both activity- and inhibition-based 
studies, these studies also provided evidence that GOAT is tolerant of backbone amide 
methylation at multiple distinct sites within the ghrelin peptide scaffold. This does not 
necessarily mean they acted in an additive manner since peptides containing methylations at 
multiple positions led to a decreased IC50 values. Methylation of peptides has been shown to 
improve peptide stability and cell permeability, 
45-46, 56
 so determining GOAT’s tolerance for 
peptide methylation provides a possible new avenue to increase activity in biological systems. 
There was also another important finding in which there was a distinction between the binding-
based studies described throughout this chapter and the previously published activity-based 
studies into ghrelin’s recognition by GOAT,28-29 since substitution or deletion at the F4 position 
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lead to a loss of binding. This indicated that the F4 position is central for ghrelin binding to 
hGOAT which was not identified using activity-based screenings. One such example that shows 
this discrepancy is GOAT’s tolerance for alanine mutations at this site in GOAT activity-based 
acylation assays. 
10, 29
 The result observed with the importance of F4 for ghrelin binding in this 
study may be reflected in ghrelin species conservation since phenylalanine is highly conserved at 
the fourth position within ghrelin sequences across vertebrates (99.5% identity, 100% similar)
57
 
(Figure 4.11). These studies have completed the characterization of elements needed for GOAT 
recognition within the N-terminal ghrelin sequence, and the avenue is to study the downstream 
elements in ghrelin and proghrelin which might play a role in the interaction of ghrelin and 
GOAT leading to acylation of ghrelin at S3.
29, 31
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Figure 4.10. Functional groups composing the pharmacophore for GOAT substrate-
mimetic inhibitors, as defined by Dap-containing peptide inhibitor structure-activity 
analysis. Chemical groups implicated in ghrelin binding to GOAT are highlighted in orange. The 
figure is reproduced with permission from Reference 57 (Appendix V). © 2018 Elsevier Inc. 
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Figure 4.11. Conservation analysis indicates the F4 position is conserved. The first five 
amino acids of all known ghrelin sequences,185, across vertebrate classes were aligned and their 
% similarity and % conservation were calculated using Clustal W protein sequence alignment. 
The figure is adapted with permission from Reference 57 (Appendix V). © 2018 Elsevier Inc. 
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The potency of the Dap-incorporated peptides provides a way to target the 
ghrelin/GOAT/GHS-R1a endocrine signaling pathway. As previously mentioned, the small 
peptides evaluated during the studies in this chapter constitute a new class of inhibitors since all 
of the previously characterized ghrelin-mimetic GOAT inhibitors have contained either an acyl 
or acyl-mimetic group at the third position.
9-10, 29, 34, 58
 Since the acyl group is a major recognition 
element for the GHS-R1a receptor, there is a high probability that there will be unintended 
interaction of acylated ghrelin mimetics with the GHS-R1a receptor.
20
 This cross-reactivity is 
less likely to be an issue with a peptide like GSDapFL which does not contain a hydrophobic 
moiety at the Dap residue. The GSDapFL-based peptides should not have the same receptor 
activation issues that other product mimetic peptides have had, but the commonality between 
them is that there are problems with cell permeability.
10, 34
 There have been two recent reports 
indicating that GOAT exists exposed in the plasma membrane of cells instead of the canonical 
ER; the first study used mouse tibial bone marrow adipocytes and the second used mouse and rat 
hippocampal neurons.
59-60
 It is possible that Dap-containing ghrelin mimetic peptides could be 
potentially used as imaging agents to detect extracellular-facing GOAT without the possibility of 
GHS-R1a receptor labeling.
59-60
 This hypothesis is supported by the fluorescamine-labeling data 
in this chapter indicating that Dap-containing peptides are not cell permeable or at least not 
detectable in cell lysate. Another important finding from this work is the tolerance of GOAT for 
D-amino acids and backbone amide methylations in distinct positions, which could increase the 
biostability of these molecules against proteolytic degradation in the bloodstream.
45, 61
  
The issues seen with the low cell permeability of the ghrelin mimetic Dap-incorporated 
peptides is one of the most omnipresent challenges with peptide-based GOAT inhibitors. There 
have been attempts to increase cell permeability using cell-penetrating sequences since none 
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have been successful in the absence of such a motif.
34, 41
 However, there are other approaches 
such as using established peptidomimetic medicinal chemistry.
45, 56, 61
 Substrate-mimetic 
peptides are powerful new candidates for a scaffold to develop the next generation of GOAT 
inhibitors, since they increased the specificity of binding to GOAT and are targets for attachment 
of covalent warheads to target essential residues necessary for GOAT function.
7
 We have 
designed an unnatural amino acid incorporated peptide scaffold which is useful to establish the 
binding and necessary recognition elements within GOAT’s active site which can be used for 
rational inhibitor design targeting this intriguing and therapeutically unexploited system. 
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4.4 Materials and Methods 
 
4.4.1 General methods. All data were plotted and analyzed using Kaleidagraph (Synergy 
Software, Reading, PA, USA). Octanoyl and decanoyl coenzyme A (octanoyl-CoA and 
decanoyl-CoA) were solubilized at a concentration of 5 mM in 10 mM Tris-HCl (pH 7.0), 
aliquoted into low-adhesion microcentrifuge tubes, and stored at -80 
o
C. Methyl arachidonyl 
fluorophosphonate (MAFP) was purchased from Cayman Chemical (Ann Arbor, MI) as a stock 
in methyl acetate and diluted into DMSO prior to use. Acrylodan (Anaspec) was solubilized in 
acetonitrile, with the stock concentration determined by absorbance at 393 nm on dilution into 
methanol ( = 18,483 M-1 cm-1 per manufacturer’s data sheet). Dap-containing peptides were 
purchased from Pepmic (Suzhou, China) with >90% purity verified by reverse phase high-
pressure liquid chromatography (HPLC) and peptide mass confirmed by matrix-assisted laser 
desorption/ionization time-of-flight (MALDI–TOF) mass spectrometry (Table 4.3).  
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Peptide 
sequence 
Purity 
(%) 
Calculated mass 
for (M+H)
+ 
Observed mass 
for (M+H)
+
 
GSDapFLS 98% 594.93 595.35 
GSDapFL 99% 507.96 508.55 
GSDapWL 98% 546.88 547.35 
GSDapTL 98% 461.78 462.30 
GSDapAL 98% 431.75 432.25 
GSDapFA 98% 465.77 466.25 
GADapFL 98% 491.85 492.30 
GSDapF 98% 394.80 395.35 
GSDapA 99% 317.70 319.35 
GSDapG 99% 303.67 305.30 
GSDap 96% 247.62 248.20 
SDapFL 99% 449.90 451.40 
[Ac]SDapFL 97% 492.83 493.30 
SarSDapFL 98% 522.09 522.35 
GN-MeSDapFL 97% 521.85 522.35 
GSDapFN-MeL 97% 521.85 522.35 
GSDapN-MeFL 96% 521.85 522.35 
SarSDapN-MeFN-MeL 96% 550.09 550.40 
SarSDapN-MeF 95% 422.94 423.30 
 
Table 4.3 Analytical data of Dap-containing peptides. Peptides were analyzed by RP-HPLC 
and MALDI-TOF mass spectrometry, percent purity and m/z values were provided by Pepmic 
(Suzhou, China). The figure is reproduced with permission from Reference 57 (Appendix V). © 
2018 Elsevier Inc. 
 228 
 
The GSSFLCNH2 peptide for fluorescent labeling with acrylodan was synthesized by Sigma–
Genosys (The Woodlands, TX, USA) in the Pepscreen format. Peptides containing D-amino 
acids were synthesized by BioBasic (Amherst, NY), with the presence of D-phenylalanine in the 
GSS
62
LCAcDan peptide verified by chymotryptic digestion as described below. Peptides were 
solubilized in a 1:1 mixture of water and acetonitrile and stored at -80 
o
C. Concentrations for 
peptides containing cysteine residues, such as GSSLFC and GSDapFLC, were determined 
spectrophotometrically at 412 nm by reaction of the cysteine thiol with 5,5′-dithiobis(2-
nitrobenzoic acid) using ε412= 14,150 M
-1 
cm
-1
.
63
 Concentrations for peptides containing Dap 
residues were determined using fluorescamine labeling and fluorescence relative to a 
GSDapFLC peptide external standard with correction for the numbers of primary amine 
groups.
64-65
 
4.4.2 Peptide fluorescent labeling.  Peptide substrates with C-terminal cysteine residue 
sidechains were labeled with an acrylodan fluorophore and HPLC purified per our previously 
reported protocol.
28-29
. Acrylodan labeling was verified by MALDI–TOF mass spectrometry 
(Table 4.4) and acrylodan labeled peptide concentrations were determined by UV absorbance 
measurement at 360 nm.
66
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Table 4.4. MALDI-TOF mass spectrometry (m/z) characterization of acrylodan labeled 
hGOAT peptide substrates. The figure is reproduced with permission from Reference 57 
(Appendix V). © 2018 Elsevier Inc. 
 
Sequence 
Calculated exact mass  
(Daltons) 
Experimental mass 
(Daltons) 
GSSFLCAcdan 837.40 (M+H) 875.153 (M+K) 
GSDapFLCAcdan 836.41 (M+H) 874.417 (M+K) 
GS(D-S)FLCAcdan 837.40 (M+H) 877.022 (M+ K) 
GSS(D-F)LCAcdan 837.40 (M+H) 877.035 (M+ K) 
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4.4.3 hGOAT activity assays. Assays were performed using previously reported protocols.
7, 29
 
For each assay, membrane fraction from Sf9 cells expressing hGOAT was thawed on ice and 
homogenized by passage through an 18-gauge needle 10 times. Assays were performed with 
~10-50 μg of membrane protein, as determined by Bradford assay. Unless noted otherwise, 
membrane fraction was preincubated with 1 μM methyl arachidonyl fluorophosphonate (MAFP) 
and inhibitor or vehicle as indicated in 50 mM HEPES pH 7.0 for 30 min at room temperature 
prior to reaction initiation.
7, 36
 All reactions were initiated by the addition of fluorescently-
labeled GSSFLCAcDan or GSDapFLCAcDan peptide substrate and acyl-CoA donor. Assays 
comparing the reactivity of the GSDapFLCAcDan to GSSFLCAcDan were initiated with 5 µM 
GSDapFLCAcDan or 1.5 µM GSSFLCAcDan and 1mM decanoyl-CoA in a total volume of 50 µL, 
followed by incubation at room temperature under foil for 3 hr. Assays investigating inhibition 
by unlabeled ghrelin-mimetic peptides Dap peptide were pretreated with the inhibitor for 30 min, 
followed by reaction initiation with the addition of 1.5 µM GSSFLCAcDan and 500µM octanoyl- 
CoA. Reactions were incubated for 3 hr at room temperature under foil. Reactions investigating 
the reactivity of ghrelin-mimetic peptides incorporating D-amino acids were performed in a 
similar manner with acrylodan-labeled D-amino acid containing substrate peptide in place of the 
GSSFLCAcDan peptide. All assays were stopped with the addition of 50 µL of 20% acetic acid in 
isopropanol
trichloroacetic acid, followed by centrifugation (1,000 x g, 1 min). The supernatant was then 
analyzed using reverse-phase HPLC with fluorescence detection as previously described.
7, 29
 
Peak integrations for both substrate and product peaks were calculated using Chemstation for LC 
(Agilent Technologies). Data reported is the average of three independent determinations, with 
error bars representing one standard deviation. 
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4.4.4 IC50 determination. For determination of IC50 values, reactions were performed and 
analyzed as described in the presence of either inhibitor or vehicle as appropriate. The percent 
activity at each inhibitor concentration was calculated from HPLC integration data using 
equations 1 and 2: To determine an IC50 value for a given inhibitor, the plot of % activity versus 
[inhibitor] was fit to equation 3, with % activity0 denoting hGOAT activity in the presence of the 
vehicle alone. All reported IC50 values represent the average of a minimum of three independent 
trials. 
 
 
 
 
 
 
 
4.4.5 Verification of D-F in GSS(D-F)LCAcDan by chymotryptic digestion. To verify the 
presence of D-phenylalanine in the acrylodan labeled GSS(D-F)LCAcDan peptide, the peptide was 
subjected to digestion by chymotrypsin in parallel with the wildtype GSSFLCAcDan peptide 
substrate peptide. Chymotrypsin exhibits stereoselectivity for L-phenylalanine,
42-44
 with 
incorporation of D-phenylalanine providing protection against chymotryptic cleavage.  
Chymotrypsin digestions (300 uL) contained: 3 μM peptide (GSSFLCAcdan or GSS(D-F)LCAcdan), 
0.1 nM chymotrypsin, 10 mM CaCl2, 100 mM Tris, pH 7.8. Reactions were initiated by the 
addition of chymotrypsin and incubated at 37 ᵒC under foil.  Time points were taken at 0, 5, 10, 
  (3) 
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20, 40, and 60 min elapsed reaction time, with reactions stopped by the addition of 50 μL 12 M 
HCl. Digestions were analyzed by reverse-phase HPLC using fluorescence detection.
28
  Peak 
integrations for the undigested peptides were calculated using Chemstation for LC (Agilent 
Technologies) and plotted versus reaction time. 
4.4.6 Fluorescamine labeling of cell lysates. A standard curve of SarSDapN-MeF in the presence 
of HEK 293FT: 50 μL total reactions contained: 5 μL SarSDapN-MeF at (50 μM, 25 μM, 12.5 μM, 
6.25 μM, 3.125 μM, 1.5 μM, 0.75 μM and 0 μM peptide), 10 μL HEK 293FT cell lysate ((3 
wells of 2 x 10
5
 cells/well in a 24-well plate were combined),cells were plated in DMEM 
((Dulbecco's Modified Eagle's Medium, Corning) containing 10% FBS, 1% v/v 
penicillin/streptomycin), and PBS containing 9 mg/mL fluorescamine. Reactions proceeded for 
15 min then cellular proteins were precipitated with 0.75 M ammonium sulfate and supernatants 
were analyzed via RP-HPLC.   
For inhibitor addition to cell lysate: 3, 6-wells per condition of HEK 293FT cells were 
plated at 2 x 10
5
 cells/well (plated in DMEM containing 10% FBS, 1% v/v 
penicillin/streptomycin) in a 24-well plate and incubated 18 hr at 37 ᵒC 5% CO2. SarSDapN-MeF 
was dissolved in DMSO, inhibitor (100 μM) or a null (DMSO) was added to wells to 1% total 
cell volume and incubated 18 hr at 37 ᵒC 5% CO2. After incubation cell media was aspirated and 
cells were trypsinzed washed with PBS and lysed using RIPA buffer (50 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 2 mM EDTA, 10% v/v NP40, 0.1% v/v SDS ) containing a mini Roche tablet 
(Sigma). Fluorescamine labeling reactions: 50 μL of cell lysate (inhibitor or DMSO treated cells) 
containing 9mg/mL fluorescamine proceeded for 15 min, cellular proteins were precipitated with 
addition of 0.75 M ammonium sulfate and supernatants were analyzed via RP-HPLC with 
Excitation = 365 nm, Emission = 470 nm.
52
 
 233 
 
4.4.7 Alamar blue assay. Detection of metabolic activity since the dye is an oxidation–reduction 
indicator. Cellular metabolism, the mitochondria, induces reduction of Alamar Blue the effect of 
the conditions (inhibitor) can be quantified based on the conversion of the blue, non-fluorescent 
resazurin to pink, fluorescent resorufin by metabolically active cells. HEK 293FT (F11) or PC3 
(hPPG #1) cells were plated using 100 μL of 2 x 105  cells/mL in a clear bottom 96-well 
microplate (Thermo scientific) containing 100 μL of DMEM ((Dulbecco's Modified Eagle's 
Medium, Corning, DMEM F-12 media was used for PC3 cells, Corning) containing 10% FBS, 
1% v/v penicillin/streptomycin). 0.01% puromycin v/v was added to HEK 293FT cells, 0.3% 
G418 (Thermo fischer) v/v was added to PC3 cells. Dap-incorporated peptides were then added 
to each well with 1% DMSO v/v at corresponding concentration based upon desired range (3-
wells per condition). Cells were incubated for 18 hr at 37 ᵒC 5% CO2 in the presence of the 
peptides, 10% v/v Alamar blue (Thermo fischer) was added to each well, excluding control wells 
and absorbance readings at 540, 5470, 600, and 630 nm were taken at 0, 18, 24, 36, and 48 hr. 
The average of 3-wells per condition was taken for 570 and 600 nm. The % cell viability was 
calculated in relationship to the DMSO-treated cells containing no peptide (Equation 4).  The 
cells were also inspected visually for morphology and cell health. 
 
    (4) 
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Chapter 5: Conclusions and future directions 
5.1 Introduction  
  
Ghrelin was initially identified to be the endogenous ligand of the GHS-R1a GPCR, 
which is one of several receptors controlling the release of growth hormone.
1
 Since its discovery 
in 1999, ghrelin has been implicated in a multitude of biological processes including most 
notably hunger signaling, metabolism, and energy balance.
2-6
 The attachment of an eight carbon 
fatty acid to an N-terminal serine of ghrelin results in recognition and activation of its receptor, 
the GHS-R1a, and thus is necessary for its biological activity.
7
 This post-translational attachment 
of an octanoyl moiety was discovered to be catalyzed by the enzyme, ghrelin O-acyltransferase 
(GOAT).
8-9
 This step in ghrelin maturation is an ideal candidate for regulating ghrelin signaling 
using inhibitors since ghrelin is the only predicted substrate for GOAT.
10
 The goals of the work 
in this dissertation were to better understand how GOAT acylates ghrelin by studying the 
biological substrate, proghrelin, and investigating the substrate binding requirements of GOAT 
for peptide inhibitor development. There has been no thorough investigation into the structure of 
proghrelin or C-terminal processing until the work presented in this document, which has 
advanced our understanding of this key intermediate in the ghrelin-GOAT pathway. The second 
goal of the work presented was to understand the binding requirements governing the formation 
of the ghrelin:GOAT complex. Analysis of unnatural amino acid incorporated peptides has 
provided both a comprehensive picture of ghrelin-GOAT functional binding requirements as 
well as a potent inhibitor scaffold. This dissertation has provided crucial information to 
unexplored areas in the ghrelin-GOAT field which enhances our understanding of how ghrelin is 
acylated by GOAT and ghrelin processing.  
244 
 
5.2 Development of a method for purification and structural analysis of proghrelin 
 
In order to pursue investigation into the structural and biological properties of proghrelin 
a bacterial expression system was developed to produce recombinant GST-TEV-human-
Proghrelin-His6 as well as GST-TEV-human-C-ghrelin-His6. The first published protocol for 
purifying recombinantly expressed proghrelin utilized a similar fusion protein construct.
11
 There 
were complications during the purification process to obtain a homogenous product. Proghrelin 
displayed a unique banding pattern in which there were consistent lower molecular weight 
protein impurities throughout the purification, from bacterial lysis to purified protein samples. In 
order to combat the low molecular weight proteins, the purification method was modified to 
decrease the total purification time and introduction of size exclusion chromatography. A 
homogenous product was obtained which was verified by silver staining, Western blot and mass 
spectrometry. Proghrelin was then subjected to structural analysis including CD and NMR which 
concluded that proghrelin contains a region of alpha helical secondary structure, although the 
majority of the protein structure is random coil. When detergents were added to the protein there 
was an increase in secondary structure, particularly with SDS.  Comparison of proghrelin to 
ghrelin in an aqueous environment indicated that the C-ghrelin region is the major contributor to 
proghrelin secondary structure. These results are somewhat consistent with the literature since 
ghrelin in an aqueous environment and in modeling studies was observed to be random coil and 
flexible and C-ghrelin, specifically obestatin, contained some elements of secondary structure.
12-
14
 The result of structural analysis suggests that proghrelin contains secondary structure and this 
structure may be enhanced by lipids and a membrane-like environment. This information is 
important when modeling or analyzing interactions between proghrelin and GOAT. GOAT is 
located in the ER membrane, and this membrane environment would likely affect proghrelin 
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structure based upon the impact of detergents observed during the studies in this dissertation and 
previously published data.
12, 15-18
  
 The aggregation and low solubility observed with the GST-fusion protein of C-ghrelin 
(GThCgH) is in juxtaposition to the behavior observed with proghrelin. The fusion construct was 
completely insoluble until expression conditions were modified (low temperature, 0.4 mM IPTG 
protein induction, and LEMO-21 E. coli), and even then a significant fraction of the fusion 
protein remained insoluble. C-ghrelin was unable to be purified from the GST fusion protein 
since the TEV digestion was unable to be completed. This is due possibly to GThCgH protein 
misfolding or availability of the TEV cleavage site to the TEV protease. When a denaturant-
based purification was introduced, GThCgH was able to be purified. However, it exhibited 
aggregation and insolubility when the protein was buffer exchanged into a non-denaturing 
buffer. The expression and purification of GST-TEV-human C-ghrelin-His6, although not 
completely successful, provided some intriguing findings supporting the possibility that ghrelin 
stabilizes C-ghrelin structure and solubility. Without ghrelin present, C-ghrelin is highly unstable 
leading to the insoluble behavior observed in this work.  
5.3 The cleavage of proghrelin 
 
 During lysis and purification of proghrelin, distinct lower molecular weight proteins were 
observed which persisted throughout and reappeared after purification to homogeneity. Initially, 
this behavior was attributed to cleavage due to a bacterial protease. However, after thorough 
addition of protease inhibitors and purification/buffer exchanges through at least three 
complementary purification steps, the observed cleavage behavior of proghrelin persisted. The 
only condition in which no proghrelin cleavage was observed was when a strong denaturant 
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(3XSB or 6 M GuHCl) was included during lysis or purification. This is consistent with folded 
protein structure being required for cleavage activity. The unique cleavage behavior of this 
protein was unable to be fully characterized using Western blotting or gel-based analysis so a 
fluorescence-based reporter system was introduced to study proghrelin cleavage. The fluorescent 
proghrelin construct reproduced the results observed with purified proghrelin, in which cleavages 
occur over time and generated a number of discrete products. After the reporter system was 
verified with the full length protein, a series of N- and C-terminal truncated constructs were 
made to study the sequence dependent behavior of cleavage. Fluorescent gel imaging provided a 
facile method for monitoring the cleavage behavior of proghrelin constructs, and a section of the 
proghrelin sequence between amino acids 30-50 was shown to be necessary for cleavage. In 
parallel analysis, the cleavage behavior of proghrelin was analyzed by mass spectrometry that 
identified the cleavage sites within purified proghrelin and showed these sites to be clustered 
near the C-terminal end of obestatin. Attempts to block proghrelin cleavage by mutating single 
amino acid residues were not successful, suggesting that this activity is robust and tolerant to a 
significant degree of sequence variation. The identified cut sites and the residues that are most 
likely responsible for cleavage are both located in C-ghrelin. There is a possibility that the 
cleavage behavior observed with proghrelin is related to C-ghrelin processing to obestatin, but 
this remains to be conclusively proven. 
5.4 Unnatural amino acid-containing peptides to study GOAT binding 
 
 A ghrelin-mimetic peptide substrate incorporating an amine (2,3-diaminopropanoic acid) 
in place of the serine hydroxyl group at the acylation site (GSDapFLCAcDan) was explored to 
determine the ability of GOAT to catalyze amide bond formation. In comparison to the wildtype 
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substrate with a serine at the acylation site, the Dap3 residue is accepted by the enzyme but not 
as well as the wiltype S3 substrate. There was also the appearance of a second ester-linked peak 
observed in the GSDapFLCAcDan reaction, suggesting acylation at the S2 position as well as at 
Dap3. The acylation at the S2 position and some at Dap3 is the result of a non-enzymatic 
acylation reaction which means that in solution the acylation will occur without hGOAT present. 
This previously unidentified non-enzymatic reaction needs to be accounted for when using Dap-
incorporated peptides as mechanistic probes so as not to over interpret binding and activity in 
relation to GOAT.  
 The inefficient acylation of GSDapFLCAcDan led to instead utilizing Dap-incorporation as 
a tool to study hGOAT binding. The incorporation of the Dap group at the third position 
dramatically increased binding to hGOAT in small unlabeled peptides. Within the context of the 
GSDapFL peptide, amino acids were truncated or mutated to evaluate the contribution of each 
amino acid side chain to the peptide’s binding of GOAT. The studies indicate that the G1 and F4 
are the most important residues for GOAT binding. The lack of peptide binding with deletion or 
acetylation at the G1 position in GSDapFL indicated that these peptides are binding into the 
active site of GOAT. Previous reactivity studies have concluded that the N-terminal G1 is a 
necessary recognition motif for GOAT.
10-11, 19 
The significance of the F4 in peptide binding is in 
contrast to published reactivity data suggesting that F4 is replaceable with minimal impact on 
substrate acylation.
10, 19
 These studies have provided a comprehensive picture of the functional 
requirements for GOAT binding. 
 Since the incorporation of Dap into small ghrelin mimetic peptides increased the binding 
affinity for hGOAT dramatically, there was an effort to increase the biostability for in vitro 
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purposes by introducing backbone methylations. After investigating the effect of cooperativity of 
methylations at multiple positions, SarSDapN-MeF which has a high nanomolar IC50, was chosen 
for cell studies to evaluate its ability to inhibit in vitro ghrelin acylation. However, there was no 
effect on ghrelin acylation in cell-based studies although subsequent characterization suggests 
this lack of activity may result from low cell permeability of the peptide. These unnatural amino 
acid- incorporated peptide studies provide a peptide scaffold that could be modified to increase 
the cell permeability, for example introduction of a HIV-Tat sequence
20
 which was shown to 
improve permeability with Go-COA-Tat.
21
 There is also another avenue to utilize the Dap-
incorporated peptides to study externally located GOAT
22-23
 as an imaging agent which would 
open a window into studying a new aspect of ghrelin signaling. 
5.5 Summary and future directions 
 
The goals of the work were to define how GOAT recognizes and modifies ghrelin by first 
investigating the structure and unique processing behavior of the biological substrate of hGOAT 
and to define the binding requirements of hGOAT to small ghrelin-mimetic peptides. The results 
through this dissertation have provided multiple approaches to efficiently express and purify both 
proghrelin and C-ghrelin. Expression of proghrelin provides the opportunity to define the 
structural characteristics of this intriguing prohormone. The studies done in this work indicated 
that the presence of a detergent or a lipid environment enhance regions of secondary structure 
within proghrelin. This is in agreement with studies focused which indicate that SDS enhances 
secondary structure in ghrelin and obestatin.
12, 14, 16-18, 24
 The results indicated that there are 
possible structural interactions occurring during ghrelin-GOAT binding and acylation that have 
not been accounted for previously. There has also been characterization of possible self-
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processing and cleavage with proghrelin, which potentially plays a role in the processing 
pathway leading to the other hormone produced from proghrelin, obestatin. This work has also 
furthered our understanding of GOAT binding by completing the full picture of what are the 
functional requirements for GOAT substrate recognition. A series of ghrelin peptide mimetics 
with Dap-incorporation focused on binding to hGOAT instead of reactivity. Evaluating substrate 
reactivity can lead to over interpretation of substrate binding since reactivity encapsulates 
binding, catalysis and release of the substrate in the enzyme. The work that has been completed 
has yielded both new conclusions about the ghrelin-GOAT system as well as a variety of new 
methods and techniques that will aide future researchers in their efforts to characterize 
interactions between ghrelin and GOAT. 
 Even though there have been large gains in our understanding of this system through the 
work presented in this dissertation, future research is required to fully define the molecular basis 
for ghrelin processing and activity. For studies of proghrelin cleavage, it is essential that the 
functionally essential residue(s) for this proteolytic activity are identified to both understand this 
biochemically intriguing chemistry and to allow inhibition of cleavage to aid in structural 
studies. The studies of alanine mutations within proghrelin demonstrate that multiple 
simultaneous mutations may be needed to block proghrelin cleavage activity. Inhibition of 
proghrelin will allow for complete structural characterization and aid in characterization of 
proghrelin bound to GOAT. Once proghrelin is completely characterized and the processing 
behavior is fully understood at the molecular level, this could support the conclusion that 
proghrelin (C-ghrelin) does in fact self-process. This form of protein cleavage would be a 
completely novel finding potentially revealing a new method of protein processing.  
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 In light of the self-cleavage behavior observed in proghrelin, purification and structural 
characterization of the peptide hormone motilin presents another opportunity to explore the 
impact of self-cleavage in hormone processing. Motilin is also a hormone found in the 
gastrointestinal tract which shares a degree of sequence similarity to ghrelin, with ghrelin 
originally named the motilin-related peptide.
25-26
 Like ghrelin, motilin is expressed as a larger 
precursor protein prepromotilin and then is subsequently proteolytically cleaved to yield a 22 
amino acid peptide.
26-28
 Motilin stimulates gastrointestinal motor activity and has been proposed 
to play a physiological role in the regulation of fasting motility patterns and gastric emptying, 
with maximum secretion of motilin during fasting and after eating.
26, 29
 Motilin also activates a 
GPCR for its biological activity, akin to the GHS-R1a.
30
 Homology, localization and 
cooperativity between ghrelin and motilin provide motivation for studying these peptide 
hormones. Ghrelin and motilin signaling are connected within the body, with ghrelin 
administration decreasing plasma levels of motilin and inhibiting intestinal propulsive 
contractions.
31
 Motilin in turn decreases plasma ghrelin levels suggesting that these gut peptides 
cooperatively control the function of gastric motor movement and contractions.
32
  Another 
similarity to the ghrelin/proghrelin/obestatin system, processing of premotilin is proposed to 
generate a second potential hormone (motilin-associated peptide) alongside motilin, although the 
biological role of motilin-associated peptide remains unclear.
33-35
 There is a possibility that 
proghrelin and promotilin have similar processing and thus cleavage behavior that was observed 
with proghrelin. There is also interest in the ability to control ghrelin/motilin signaling in the 
gastrointestinal tract,
36-39
 which includes the ability to regulate gastric emptying, feeding and 
metabolism.
29
 The possibility also exists that ghrelin mimetics can act as motilin agonists in 
gastrointestinal hypomotility disorders.
40-41
 The ability to express, purify and investigate the 
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biological activity of this molecular cousin of ghrelin could provide another opportunity to 
explore and explain the cleavage behavior observed with proghrelin. 
 The future of the structure-activity definition found with the small unnatural amino acid 
incorporated peptides is to use them as scaffold for further inhibitor design. Limitations of the 
present scaffolds include both the lack of cell permeability and potency against GOAT. To 
address the first limitation, a moiety would need to be attached that would increase cell 
permeability if intracellular GOAT was the target, such as an HIV Tat sequence, in a similar 
manner as Go-CoA-Tat.
21
 In an attempt to address potency, the scaffold could be modified with 
a small molecule such as a CDDO-derivative
42
 in which the peptide would increase the 
specificity and the small molecule would increase the potency. There have been two recently 
published reports of GOAT located in the plasma membrane and not in the ER membrane.
22, 43
 
The challenges with GOAT peptide inhibitor cell permeability would not impact targeting 
extracellular GOAT. In this case, these potent inhibitors could be used for their binding affinity 
as imaging or identification agents to identify the tissues or location of extracellular GOAT.
22-23
 
These inhibitors should also be characterized against the ghrelin receptor GHS-R1a to gain a 
better understanding of the structure-activity relationship differences between GOAT and the 
ghrelin receptor and to ensure there is no unintended receptor activation if these molecules were 
to be pursued as in vitro/in vivo GOAT inhibitor.  
 The current candidates of GOAT assays are limited and none are ideal for detecting 
ghrelin in vitro. This lack of cost-efficient and reproducible cell-based GOAT activity assays 
poses a key limitation for future drug development and in vitro testing. An in vitro ghrelin 
acylation assay would be useful not only for determining inhibitor effectiveness before going 
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into in vivo models. It would also be useful for testing GOAT mutants and acylation efficiency in 
a more biological relevant model, since currently GOAT is produced in Sf9 insect cells.
10, 19, 44-45
 
The final future direction of this project is to work further on the development of a metabolic-
labeling based cell assay for detection of ghrelin acylation. Preliminary studies into an in vitro 
ghrelin acylation assay through the introduction of an alkyne-labeled octanoic acid have been 
attempted but have not been successful. In the future, alkyne octanoic acid incorporation would 
lead to the labeling of acylated ghrelin with an alkyne and enable monitoring and detection of 
ghrelin acylation using a copper-catalyzed azide-alkyne [3+2] cycloaddition
46-47
 and gel-based 
detection. These studies have determined the cytotoxicity of octanoic acid and an optimum 
concentration for metabolic labeling
47-50
 based upon the cytotoxicity determination. The 
permeability of octanoic and octynoic acid (alkyne octanoic acid) has been tested and increased 
with the use of bovine serum albumin (BSA) to the mixture. This is still an ongoing goal and 
necessary future direction. The method of introducing an alkyne derivative or the method of 
detection could be modified but the foundation of an in vitro assay has been laid and should be 
further pursued by future researchers in this laboratory. 
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